



(51) International Patent Classification:

A61K 39/108 (2006.01) G01N 33/569 (2006.01)
C07K 14/26 (2006.01)

(21) International Application Number:

PCT/EP2016/050468

(22) International Filing Date:

12 January 2016 (12.01.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

15150819.9 12 January 2015 (12.01.2015) EP

(71) Applicant: EVAXION BIOTECH APS [DK/DK]; Ole
Maaløes Vej 3, 2200 Copenhagen N (DK).

(72) Inventors: IVERSEN MØLLER, Niels; Toldbodgade
38B, St. th., 1253 Copenhagen K (DK). HOLM MATTS-
SON, Andreas; c/o Ole Maaløes Vej 3, 2200 Copenhagen
N (DK).

(74) Agents: FREDERIKSEN, Jakob et al.; Inspicos P/S,
Kogle Allé 2, 2970 Hørsholm (DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- of inventorship (Rule 4.17(iv))

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PROTEINS AND NUCLEIC ACIDS USEFUL IN VACCINES TARGETING KLEBSIELLA PNEUMONIAE

(57) Abstract: The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.



WO 2016/113252 A2

PROTEINS AND NUCLEIC ACIDS USEFUL IN VACCINES TARGETING KLEBSIELLA
PNEUMONIAE

FIELD OF THE INVENTION

The present invention relates to the field of antimicrobial prophylaxis and therapy. In particular the present invention relates to novel proteins and polynucleotides derived from *Klebsiella pneumoniae*. The invention further relates to vectors comprising the polynucleotides, transformed host organisms expressing the polynucleotides, antibodies (mono- or polyclonal) specific for the polypeptides as well as diagnostic, prophylactic and therapeutic uses and methods. Finally, also methods of preparation are part of the invention.

10 BACKGROUND OF THE INVENTION

Bacterial infections are in most instances successfully treated by administration of antibiotics to patients in need thereof. However, due to careless or thoughtless use of powerful antibiotics, many pathological germs become resistant against antibiotics over time. One threatening example is *Klebsiella pneumoniae*.

- 15 The genus *Klebsiella* belongs to the family Enterobacteriaceae and is divided into at least 4 species. They are gram-negative, capsulated, oxidase-negative, non-motile, straight rods. They are facultative anaerobes, having both a respiratory and fermentative metabolism. Most strains can use citrate and glucose as their sole carbon source. Some strains can fix nitrogen. They are commonly found in the intestines, clinical samples, soil, water and grains.
- 20 The species *Klebsiella pneumoniae* can be divided into 3 subspecies; *pneumoniae*, *ozaenae* and *rhinoscleromatis* (Orskov, I. 1984. Genus V. *Klebsiella* Trevisan 1885, 105. Krieg and Holt (editors) In Bergey's Manual of Systematic Bacteriology, 1:461-465). *Klebsiella pneumoniae* is the most common gram-negative pathogen causing community acquired pneumonia (Carpenter, J., et al, 1990. Rev Infect. Dis. 12:672-682).
- 25 *Klebsiella* is also responsible for an estimated 8% of all nosocomial infections (Sahly, H. and Podschun, R., 1997. Clin. Diagn. Lab. Immunol. 4:393-399).

K. pneumoniae is an opportunistic pathogen that is associated with pneumonia, septicemia, meningitis, endocarditis, ventriculitis, and infections of urinary tract and wounds. These diseases are both nosocomial and community acquired. *K. pneumoniae* also plays a large role in two major nonrheumatoid arthritic diseases, Ankylosing Spondylitis and Reiter's Syndrome (Schwimmbeck, P. and Oldstone, M., 1989. Current Topics in Microbiology and Immunology. 145:45-56.). Despite available antibiotics, observed mortality rates for pneumonia are

approximately 50%, but when bacteremic *K. pneumoniae* occurs in alcoholics, the mortality rises to almost 100% (Sahly, H. and Podschun, R., 1997. Clin. Diagn. Lab. Immunol. 4:393-399). The overall mortality rate for Klebsiella bacteremia in one study was 37% and has ranged in others from 25% to 55% (Watanakunakron, C. and Jura, J., 1991. Scand. J. Infect. Dis. 23:399-405).

Incidence of *K. pneumoniae* meningitis is on the rise. A study of 3377 cases of Bacterial meningitis in 1948, found only 7 were *K. pneumoniae*. In 1957, *K. pneumonia* accounted for 1.5% of all cases of meningitis. In an eleven-year study, from 1981 to 1991, 13% of culture proven bacterial meningitis cases were *K. pneumoniae*. There was an increase occurrence of *K. pneumoniae* meningitis within this study with 7% occurrence in the first 6 years, and 16% occurrence in the last 5 years (Tang, L-M and Chen, S-T., 1994. Scand. J. Infect. Dis. 26:95-102).

In recent years, Klebsiella strains have become multi-resistant to many antibiotics. In the 1970's, the resistance was mainly to aminoglycoside antibiotics. Since 1982, some Klebsiella strains have become resistant to the extended-spectrum cephalosporins (Sahly, H. and Podschun, R., 1997. Clin. Diagn. Lab. Immunol. 4:393-399). Resistance to the extended-spectrum cephalosporins among clinical isolates of Klebsiella in France and England has been reported at 14 to 16% (Sirot, D. 1995 J. Antimicrob. Chemother. 36:19-34). Since Klebsiella is a good recipient for R factors, resistance has been gained to β -lactams, tetracycline, chloramphenicols, ceftazidime, sulfonamides and trimethoprim. Today, almost all strains of Klebsiella are resistant to ampicillin. (Orskov, I. 1984. Genus V. Klebsiella Trevisan 1885, 105. Krieg and Holt (editors) In Bergey's Manual of Systematic Bacteriology, 1:461-465).

Microbial fermentation is an important way to convert renewable resources to products of biological and industrial importance. *K. pneumoniae* has been used to convert simple sugars to the commodity chemicals 1,3-propanediol and 1,2-propanediol. These products have been made by fed-batch fermentation of glycerol by *K. pneumoniae*. (Cameron, D. et al, 1998. Biotechnol. Prog. 14:116-125). Genes from the 1,3-propanediol pathway of *K. pneumoniae* have recently been cloned and expressed into both *E. coli* and *S. cerevisiae*. Metabolic engineering of these genes can significantly improve the product yield and productivity (Cameron, D. et al, 1998. Biotechnol. Prog. 14:116-125).

With *K. pneumoniae* playing the lead role, the Klebsiella genus is becoming an increasingly important pathogen. Over the past 10 years, discovery of multi-drug resistant strains has emphasized the importance of this genus. Furthermore, Klebsiella is considered to be a model for systemic infections caused by capsulated bacteria.

Vaccination is considered to be a very effective method of preventing infectious diseases in human and veterinary health care. Vaccination is the administration of immunogenically effective amounts of antigenic material (the vaccine) to produce immunity to a disease/disease-causing pathogenic agent. Vaccines have contributed to the eradication of smallpox, the near eradication of polio, and the control of a variety of diseases, including rubella, measles, mumps, chickenpox, typhoid fever.

Before "the genomic era", vaccines were based on killed or live attenuated, microorganisms, or parts purified from them. Subunit vaccines are considered as a modern upgrade of these types of vaccine, as the subunit vaccines contain one or more protective antigens, which are more or less the weak spot of the pathogen. Hence, in order to develop subunit vaccines, it is critical to identify the proteins, which are important for inducing protection and to eliminate others.

An antigen is said to be protective if it is able to induce protection from subsequent challenge by a disease-causing infectious agent in an appropriate animal model following immunization.

The empirical approach to subunit vaccine development, which includes several steps, begins with pathogen cultivation, followed by purification into components, and then testing of antigens for protection. Apart from being time and labour consuming, this approach has several limitations that can lead to failure. It is not possible to develop vaccines using this approach for microorganisms, which cannot easily be cultured and only allows for the identification of the antigens, which can be obtained in sufficient quantities. The empirical approach has a tendency to focus on the most abundant proteins, which in some cases are not immuno-protective. In other cases, the antigen expressed during *in vivo* infection is not expressed during *in vitro* cultivation. Furthermore, antigen discovery by use of the empirical approach demands an extreme amount of proteins in order to discover the protective antigens, which are like finding needles in the haystack. This renders it a very expensive approach, and it limits the vaccine development around diseases, which is caused by pathogens with a large genome or disease areas, which perform badly in a cost-effective perspective.

OBJECT OF THE INVENTION

It is an object of embodiments of the invention to provide *K. pneumoniae* derived antigenic polypeptides that may serve as constituents in vaccines against *K. pneumoniae* infections and in diagnosis of *K. pneumoniae* infections. It is also an object to provide nucleic acids, vectors,

transformed cells, vaccine compositions, and other useful means for molecular cloning as well as for therapy and diagnosis with relevance for *K. pneumoniae*.

SUMMARY OF THE INVENTION

It has been found by the present inventor(s) that *K. pneumoniae*, in particular drug resistant
5 *K. pneumoniae*, expresses a number of hitherto unknown putatively surface exposed proteins which are candidates as vaccine targets as well as candidates as immunizing agents for preparation of antibodies that target *K. pneumoniae*.

So, in a first aspect the present invention relates to a polypeptide comprising

a) an amino acid sequence selected from the group consisting of any one of SEQ ID NOs: 1-

10 30, 93, and 94, or

b) an amino acid sequence consisting of at least or exactly or at most 5 contiguous amino acid residues from any one of SEQ ID NOs: 1-30, 93, and 94, or

c) an amino acid sequence having a sequence identity of at least 60% with the amino acid sequence of a),

15 d) an amino acid sequence having a sequence identity of at least 60% with the amino acid sequence of b), or

e) an assembly of amino acids derived from any one of SEQ ID NOs: 1-30, 93, and 94, which has essentially the same 3D conformation as in the protein from which said assembly is derived so as to constitute a B-cell epitope, said polypeptide being antigenic in a mammal.

20 In a second aspect, the invention relates to an isolated nucleic acid fragment, which comprises

i) a nucleotide sequence encoding a polypeptide of the invention, or

ii) a nucleotide sequence consisting of any one of SEQ ID NOs: 31-90 and 95-102.

iii) a nucleotide sequence consisting of at least or exactly or at most 10 consecutive

25 nucleotides in any one of SEQ ID NOs: 31-90 and 95-102,

iv) a nucleotide sequence having a sequence identity of at least 60% with the nucleotide sequence in i) or ii),

v) a nucleotide sequence having a sequence identity of at least 60% with the nucleotide sequence in iii),

30 vi) a nucleotide sequence complementary to the nucleotide sequence in i)-v), or

vii) a nucleotide sequence which hybridizes under stringent conditions with the nucleotide sequence in i)-vi).

In a third aspect, the invention relates to a vector comprising the nucleic acid of the invention, such as a cloning vector or an expression vector.

In fourth aspect, the invention relates to a cell which is transformed so as to carry the vector of the invention.

- 5 In a fifth aspect, the invention relates to a pharmaceutical composition comprising a polypeptide of the invention, a nucleic acid fragment of the invention, a vector of the invention, or a transformed cell of the invention, and a pharmaceutically acceptable carrier, vehicle or diluent.

- 10 In a sixth aspect, the invention relates to a method for inducing immunity in an animal by administering at least once an immunogenically effective amount of a polypeptide of the invention, a nucleic acid fragment of the invention, a vector of the invention, a transformed cell of the invention, or a pharmaceutical composition of the fifth aspect of the invention so as to induce adaptive immunity against *K. pneumoniae* in the animal.

- 15 In a seventh and eighth aspect, the invention relates to 1) a polyclonal antibody in which the antibodies specifically bind to at least one polypeptide of the invention, and which is essentially free from antibodies binding specifically to other *K. pneumoniae* polypeptides, and to 2) an isolated monoclonal antibody or antibody analogue which binds specifically to a polypeptide of the invention. In a related ninth aspect, the invention relates to a pharmaceutical composition comprising such a polyclonal or monoclonal antibody and a
20 pharmaceutically acceptable carrier, vehicle or diluent.

In a 10th aspect, the invention relates to a method for prophylaxis, treatment or amelioration of infection with *K. pneumoniae*, comprising administering a therapeutically effective amount of an antibody of the 7th or 8th aspect of the invention or a pharmaceutical composition of the eighth aspect to an individual in need thereof.

- 25 In an 11th aspect, the invention relates to a method for determining, quantitatively or qualitatively, the presence of *K. pneumoniae*, in particular the presence of *K. pneumoniae*, in a sample, the method comprising contacting the sample with an antibody of aspects 8 or 9 of the invention and detecting the presence of antibody bound to material in the sample.

- 30 In an 12th aspect of the invention is provided a method for determining, quantitatively or qualitatively, the presence of antibodies specific for *K. pneumoniae*, in particular the presence of antibodies specific for *K. pneumoniae*, in a sample, the method comprising contacting the

sample with a polypeptide of the invention and detecting the presence of antibody that specifically bind said polypeptide.

In a 13th aspect, the invention relates to a method for determining, quantitatively or qualitatively, the presence of a nucleic acid characteristic of *K. pneumoniae*, in particular the presence of a nucleic acid characteristic of *K. pneumoniae*, in a sample, the method comprising contacting the sample with a nucleic acid fragment of the invention and detecting the presence of nucleic acid in the sample that hybridizes to said nucleic acid fragment.

In a 14th aspect, the invention relates to a method for the preparation of the polypeptide of the invention, comprising

- culturing a transformed cell of the present invention, which is capable of expressing the nucleic acid of the invention, under conditions that facilitate that the transformed cell expresses the nucleic acid fragment of the invention, which encodes a polypeptide of the invention, and subsequently recovering said polypeptide, or
- preparing said polypeptide by means of solid or liquid phase peptide synthesis.

In a 15th aspect, the invention relates to a method for determining whether a substance, such as an antibody, is potentially useful for treating infection with *K. pneumoniae*, the method comprising contacting the polypeptide of the invention with the substance and subsequently establishing whether the substance has at least one of the following characteristics:

- 1) the ability to bind specifically to said polypeptide,
- 2) the ability to compete with said polypeptide for specific binding to a ligand/receptor, and
- 3) the ability to specifically inactivate said polypeptide.

Finally, in a 16th aspect, the invention relates to a method for determining whether a substance, such as a nucleic acid, is potentially useful for treating infection with *K. pneumoniae*, the method comprising contacting the substance with the nucleic acid fragment of claim of the invention and subsequently establishing whether the substance has either the ability to

- 1) bind specifically to the nucleic acid fragment, or
- 2) bind specifically to a nucleic acid that hybridizes specifically with the nucleic acid fragment.

LEGENDS TO THE FIGURE

Figs. 1-6 show Kaplan-Meier survival plots in groups of mice subjected to challenge infection with *K. pneumoniae*, i.e. survival plot corresponding to the data in tables 1-6 herein.

Figs. 1 and 3-6 show the survival plots from experiments 1 and 3-6, respectively, where mice received the infectious challenge via the intranasal route, whereas Fig. 2 shows the survival plots for mice challenged via the intraperitoneal route.

DETAILED DISCLOSURE OF THE INVENTION

5 Definitions

The term "polypeptide" is in the present context intended to mean both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 11 to 100 amino acid residues, and polypeptides of more than 100 amino acid residues. Furthermore, the term is also intended to include proteins, i.e. functional biomolecules comprising at least one polypeptide; when
 10 comprising at least two polypeptides, these may form complexes, be covalently linked, or may be non-covalently linked. The polypeptide (s) in a protein can be glycosylated and/or lipidated and/or comprise prosthetic groups.

The term "subsequence" means any consecutive stretch of at least 3 amino acids or, when relevant, of at least 3 nucleotides, derived directly from a naturally occurring amino acid
 15 sequence or nucleic acid sequence, respectively

The term "amino acid sequence" is the order in which amino acid residues, connected by peptide bonds, lie in the chain in peptides and proteins.

The term "adjuvant" has its usual meaning in the art of vaccine technology, i.e. a substance or a composition of matter which is 1) not in itself capable of mounting a specific immune
 20 response against the immunogen of the vaccine, but which is 2) nevertheless capable of enhancing the immune response against the immunogen. Or, in other words, vaccination with the adjuvant alone does not provide an immune response against the immunogen, vaccination with the immunogen may or may not give rise to an immune response against the immunogen, but the combined vaccination with immunogen and adjuvant induces an
 25 immune response against the immunogen which is stronger than that induced by the immunogen alone.

"Sequence identity" is in the context of the present invention determined by comparing 2 optimally aligned sequences of equal length (e.g. DNA, RNA or amino acid) according to the following formula: $(N_{\text{ref}} - N_{\text{dif}}) \cdot 100 / N_{\text{ref}}$, wherein N_{ref} is the number of residues in one of the 2
 30 sequences and N_{dif} is the number of residues which are non-identical in the two sequences

when they are aligned over their entire lengths and in the same direction. So, two sequences 5'-ATTCGGAACC-3' and 5'- ATACGGGACC-3' will provide the sequence identity 80% ($N_{\text{ref}}=10$ and $N_{\text{dif}}=2$).

An "assembly of amino acids" means two or more amino acids bound together by physical or chemical means.

The "3D conformation" is the 3 dimensional structure of a biomolecule such as a protein. In monomeric polypeptides/proteins, the 3D conformation is also termed "the tertiary structure" and denotes the relative locations in 3 dimensional space of the amino acid residues forming the polypeptide.

"An immunogenic carrier" is a molecule or moiety to which an immunogen or a hapten can be coupled in order to enhance or enable the elicitation of an immune response against the immunogen/hapten. Immunogenic carriers are in classical cases relatively large molecules (such as tetanus toxoid, KLH, diphtheria toxoid etc.) which can be fused or conjugated to an immunogen/hapten, which is not sufficiently immunogenic in its own right – typically, the immunogenic carrier is capable of eliciting a strong T-helper lymphocyte response against the combined substance constituted by the immunogen and the immunogenic carrier, and this in turn provides for improved responses against the immunogen by B-lymphocytes and cytotoxic lymphocytes. More recently, the large carrier molecules have to a certain extent been substituted by so-called promiscuous T-helper epitopes, *i.e.* shorter peptides that are recognized by a large fraction of HLA haplotypes in a population, and which elicit T-helper lymphocyte responses.

A "T-helper lymphocyte response" is an immune response elicited on the basis of a peptide, which is able to bind to an MHC class II molecule (e.g. an HLA class II molecule) in an antigen-presenting cell and which stimulates T-helper lymphocytes in an animal species as a consequence of T-cell receptor recognition of the complex between the peptide and the MHC Class II molecule present

An "immunogen" is a substance of matter which is capable of inducing an adaptive immune response in a host, whose immune system is confronted with the immunogen. As such, immunogens are a subset of the larger genus "antigens", which are substances that can be recognized specifically by the immune system (e.g. when bound by antibodies or, alternatively, when fragments of the antigens bound to MHC molecules are being recognized by T-cell receptors) but which are not necessarily capable of inducing immunity - an antigen is, however, always capable of *eliciting* immunity, meaning that a host that has an

established memory immunity against the antigen will mount a specific immune response against the antigen.

A "hapten" is a small molecule, which can neither induce or elicit an immune response, but if conjugated to an immunogenic carrier, antibodies or TCRs that recognize the hapten can be induced upon confrontation of the immune system with the hapten carrier conjugate.

An "adaptive immune response" is an immune response in response to confrontation with an antigen or immunogen, where the immune response is specific for antigenic determinants of the antigen/immunogen – examples of adaptive immune responses are induction of antigen specific antibody production or antigen specific induction/activation of T helper lymphocytes or cytotoxic lymphocytes.

A "protective, adaptive immune response" is an antigen-specific immune response induced in a subject as a reaction to immunization (artificial or natural) with an antigen, where the immune response is capable of protecting the subject against subsequent challenges with the antigen or a pathology-related agent that includes the antigen. Typically, prophylactic vaccination aims at establishing a protective adaptive immune response against one or several pathogens.

"Stimulation of the immune system" means that a substance or composition of matter exhibits a general, non-specific immunostimulatory effect. A number of adjuvants and putative adjuvants (such as certain cytokines) share the ability to stimulate the immune system. The result of using an immunostimulating agent is an increased "alertness" of the immune system meaning that simultaneous or subsequent immunization with an immunogen induces a significantly more effective immune response compared to isolated use of the immunogen.

Hybridization under "stringent conditions" is herein defined as hybridization performed under conditions by which a probe will hybridize to its target sequence, to a detectably greater degree than to other sequences. Stringent conditions are target-sequence-dependent and will differ depending on the structure of the polynucleotide. By controlling the stringency of the hybridization and/or washing conditions, target sequences can be identified which are 100% complementary to a probe (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. Generally, stringent wash temperature conditions are selected to be about 5°C to about 2°C lower than the melting point (T_m) for the specific sequence at a defined ionic

strength and pH. The melting point, or denaturation, of DNA occurs over a narrow temperature range and represents the disruption of the double helix into its complementary single strands. The process is described by the temperature of the midpoint of transition, T_m , which is also called the melting temperature. Formulas are available in the art for the determination of melting temperatures.

The term "animal" is in the present context in general intended to denote an animal species (preferably mammalian), such as *Homo sapiens*, *Canis domesticus*, etc. and not just one single animal. However, the term also denotes a population of such an animal species, since it is important that the individuals immunized according to the method of the invention substantially all will mount an immune response against the immunogen of the present invention.

As used herein, the term "antibody" refers to a polypeptide or group of polypeptides composed of at least one antibody combining site. An "antibody combining site" is the three-dimensional binding space with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows a binding of the antibody with the antigen. "Antibody" includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, humanised antibodies, altered antibodies, univalent antibodies, Fab proteins, and single domain antibodies.

"Specific binding" denotes binding between two substances which goes beyond binding of either substance to randomly chosen substances and also goes beyond simple association between substances that tend to aggregate because they share the same overall hydrophobicity or hydrophilicity. As such, specific binding usually involves a combination of electrostatic and other interactions between two conformationally complementary areas on the two substances, meaning that the substances can "recognize" each other in a complex mixture.

The term "vector" is used to refer to a carrier nucleic acid molecule into which a heterologous nucleic acid sequence can be inserted for introduction into a cell where it can be replicated and expressed. The term further denotes certain biological vehicles useful for the same purpose, e.g. viral vectors and phage – both these infectious agents are capable of introducing a heterologous nucleic acid sequence

The term "expression vector" refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, when the transcription product is an mRNA molecule, this is in turn translated into a protein, polypeptide, or peptide.

*Specific embodiments of the invention*The polypeptides of the invention

In some embodiments the at least or exactly 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention constitute at least or exactly 5, at least
5 or exactly or at most 6, at least or exactly or at most 7, at least or exactly or at most 8, at least or exactly or at most 9, at least or exactly or at most 10, at least or exactly or at most 11, at least or exactly or at most 12, at least or exactly or at most 13, at least or exactly or at most 14, at least or exactly or at most 15, at least or exactly or at most 16, at least or exactly or at most 17, at least or exactly or at most 18, at least or exactly or at most 19, at
10 least or exactly or at most 20, at least or exactly or at most 21, at least or exactly or at most 22, at least or exactly or at most 23, at least or exactly or at most 24, at least or exactly or at most 25, at least or exactly or at most 26, at least or exactly or at most 27 at least or exactly or at most 28, at least or exactly or at most 29, at least or exactly or at most 30, at least or exactly or at most 31, at least or exactly or at most 32, at least or exactly or at most 33, at least or exactly or at most 34, at least or exactly or at most 35, at least or exactly or at most 36, at least or exactly or at most 37, at least or exactly or at most 38, at least or exactly or at most 39, at least or exactly or at most 40, at least or exactly or at most 41, at least or exactly or at most 42, at least or exactly or at most 43, at least or exactly or at most 44, at least or exactly or at most 45, at least or exactly or at most 46, at least or exactly or at most 47, at least or exactly or at most 48, at least or exactly or at most 49, at least or exactly or at most 50, at least or exactly or at most 51, at least or exactly or at most 52, at least or exactly or at most 53, at least or exactly or at most 54, at least or exactly or at most 55, at least or exactly or at most 56, at least or exactly or at most 57, at least or exactly or at most 58, at least or exactly or at most 59, at least or exactly or at most 60, at least or exactly or at most 61, at least or exactly or at most 62, at least or exactly or at most 63, at least or exactly or at most 64, at least or exactly or at most 65, at least or exactly or at most 66, at least or exactly or at most 67, at least or exactly or at most 68, at least or exactly or at most 69, at least or exactly or at most 70, at least or exactly or at most 71, at least or exactly or at most 72, at least or exactly or at most 73, at least or exactly or at most 74, at
25 least or exactly or at most 75, at least or exactly or at most 76, at least or exactly or at most 77, at least or exactly or at most 78, at least or exactly or at most 79, at least or exactly or at most 80, at least or exactly or at most 81, at least or exactly or at most 82, at least or exactly or at most 83, at least or exactly or at most 84, at least or exactly or at most 85, at least or exactly or at most 86, at least or exactly or at most 87, at least or exactly or at most 88, at least or exactly or at most 89, at least or exactly or at most 90, at least or exactly or

at most 91, at least or exactly or at most 92, and at least or exactly or at most 93 contiguous amino acid residues.

The number of contiguous amino acids can be higher, for all of SEQ ID NOs: 2-30. Another way to phrase this is that for each of SEQ ID NOs: 1-30, 93, and 94, the number of the
5 contiguous amino acid residues is at least or exactly or at most $N-n$, where N is the length of the sequence ID in question and n is any integer between $N-5$ and 0; that is, the at least 5 contiguous amino acids can be at least any number between 5 and the length of the reference sequence minus one, in increments of one. Consequently:

Insofar as embodiment b relates to SEQ ID NO: 2-30, 93, and 94, the at least 5 contiguous
10 amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 94, at least or exactly or at most 95, at least or exactly or at most 96, at least or exactly or at most 97, at least or exactly or at most 98, at least or exactly or at most 99, at least or exactly or at most 100, at least or exactly or at
15 exactly or at most 101, at least or exactly or at most 102, at least or exactly or at most 103, at least or exactly or at most 104, at least or exactly or at most 105, at least or exactly or at most 106, at least or exactly or at most 107, at least or exactly or at most 108, at least or exactly or at most 109, at least or exactly or at most 110, at least or exactly or at most 111, at least or exactly or at most 112, at least or exactly or at most 113, at least or exactly or at most 114, at least or exactly or at most 115, and at least or exactly or at most 116 contiguous amino
20 acid residues.

Insofar as embodiment b relates to SEQ ID NO: 3-30, 93, and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 117, or at least or exactly or at most 118 contiguous amino acid residues.

25 Insofar as embodiment b relates to SEQ ID NO: 4-30, 93, and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 119 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 5-30, 93, and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may
30 also constitute at least or exactly or at most 120 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 6-30, 93, and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 121 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 7-30, 93, and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 122, at least or exactly or at most 123, at least or exactly or at most 124, at least or exactly or at most 125, at least or exactly or at most 126, at least or exactly or at most 127, at least or exactly or at most 128, at least or exactly or at most 129, at least or exactly or at most 130, at least or exactly or at most 131, at least or exactly or at most 132, at least or exactly or at most 133, at least or exactly or at most 134, at least or exactly or at most 135, at least or exactly or at most 136, at least or exactly or at most 137, at least or exactly or at most 138, at least or exactly or at most 139, or at least or exactly or at most 140 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 8-30, 93, and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 141, at least or exactly or at most 142, at least or exactly or at most 143, at least or exactly or at most 144, at least or exactly or at most 145, at least or exactly or at most 146, at least or exactly or at most 147, at least or exactly or at most 148, at least or exactly or at most 149, or at least or exactly or at most 150 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 9-30, 93, and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 151, at least or exactly or at most 152, at least or exactly or at most 153, at least or exactly or at most 154, at least or exactly or at most 155, at least or exactly or at most 156, at least or exactly or at most 157, at least or exactly or at most 158, at least or exactly or at most 159, at least or exactly or at most 160, at least or exactly or at most 161, at least or exactly or at most 162, at least or exactly or at most 163, at least or exactly or at most 164, at least or exactly or at most 165, at least or exactly or at most 166, or at least or exactly or at most 167 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 10-30, 93, and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 168, at least or exactly or at most 169, at least or exactly or at most 170, at least or exactly or at most 171, at least or exactly or at most 172, at least or exactly or at most 173, at least or exactly or at most 174, at least or exactly or at most 175, at least or exactly or at most 176, at least or exactly or at most 177, at least or exactly or at most 178, at least or exactly or at most 179, at least or exactly or at most 180, at least or exactly or at most 181, at least or exactly or at most 182, at least or exactly or at most 183, at least or exactly or at most 184, at least or exactly or at most 185, at least or exactly or at most 186, at least or exactly or at most 187, at least or exactly or at most

188, at least or exactly or at most 189, at least or exactly or at most 190, at least or exactly or at most 191, or at least or exactly or at most 192 at least or exactly or at most 193, at least or exactly or at most 194, at least or exactly or at most 195, at least or exactly or at most 196, at least or exactly or at most 197, at least or exactly or at most 198, at least or exactly or at most 199, at least or exactly or at most 200, at least or exactly or at most 201, at least or exactly or at most 202, at least or exactly or at most 203, at least or exactly or at most 204, at least or exactly or at most 205, at least or exactly or at most 206, at least or exactly or at most 207, or at least or exactly or at most 208 at least or exactly or at most 209, at least or exactly or at most 210, at least or exactly or at most 211, at least or exactly or at most 212, at least or exactly or at most 213, at least or exactly or at most 214, at least or exactly or at most 215, at least or exactly or at most 216, at least or exactly or at most 217, at least or exactly or at most 218, at least or exactly or at most 219, at least or exactly or at most 220, at least or exactly or at most 221, at least or exactly or at most 222, at least or exactly or at most 223, at least or exactly or at most 224, at least or exactly or at most 225, at least or exactly or at most 226, at least or exactly or at most 227, or at least or exactly or at most 228 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 11-30, 93, and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 229, at least or exactly or at most 230, at least or exactly or at most 231, at least or exactly or at most 232, at least or exactly or at most 233, at least or exactly or at most 234, at least or exactly or at most 235, at least or exactly or at most 236, at least or exactly or at most 237, at least or exactly or at most 238, at least or exactly or at most 239, at least or exactly or at most 240, or at least or exactly or at most 241, at least or exactly or at most 242, at least or exactly or at most 243, at least or exactly or at most 244, or at least or exactly or at most 245 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 11-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 246, at least or exactly or at most 247, at least or exactly or at most 248, at least or exactly or at most 249, at least or exactly or at most 250, at least or exactly or at most 251, at least or exactly or at most 252, at least or exactly or at most 253, at least or exactly or at most 254, at least or exactly or at most 255, at least or exactly or at most 256, at least or exactly or at most 257, at least or exactly or at most 258, at least or exactly or at most 259, at least or exactly or at most 260, at least or exactly or at most 261, at least or exactly or at most 262, at least or exactly or at most 263, at least or exactly or at most 264, at least or exactly or at most 265, at least or exactly or at most 266, at least or exactly or at most 267, at least or exactly or at most 268, at least or exactly or at most 269, at least or exactly or at most 270, at least or exactly or at most 271, at least

or exactly or at most 272, at least or exactly or at most 273, at least or exactly or at most 274, at least or exactly or at most 275, at least or exactly or at most 276, at least or exactly or at most 277, at least or exactly or at most 278, at least or exactly or at most 279, at least or exactly or at most 280, at least or exactly or at most 281, at least or exactly or at most 282, at least or exactly or at most 283, at least or exactly or at most 284, at least or exactly or at most 285, at least or exactly or at most 286, at least or exactly or at most 287, at least or exactly or at most 288, at least or exactly or at most 289, at least or exactly or at most 290, at least or exactly or at most 291, at least or exactly or at most 292, at least or exactly or at most 293, at least or exactly or at most 294, at least or exactly or at most 295, at least or exactly or at most 296, at least or exactly or at most 297, at least or exactly or at most 298, at least or exactly or at most 299, at least or exactly or at most 300, at least or exactly or at most 301, at least or exactly or at most 302, at least or exactly or at most 303, at least or exactly or at most 304, at least or exactly or at most 305, at least or exactly or at most 306, at least or exactly or at most 307, at least or exactly or at most 308, at least or exactly or at most 309, at least or exactly or at most 310, at least or exactly or at most 311, at least or exactly or at most 312, at least or exactly or at most 313, at least or exactly or at most 314, at least or exactly or at most 315, at least or exactly or at most 316, at least or exactly or at most 317, at least or exactly or at most 318, at least or exactly or at most 319, at least or exactly or at most 320, or at least or exactly or at most 321 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 12-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 322, at least or exactly or at most 323, at least or exactly or at most 324, at least or exactly or at most 325, or at least or exactly or at most 326, at least or exactly or at most 327, at least or exactly or at most 328, at least or exactly or at most 329, at least or exactly or at most 330, at least or exactly or at most 331, at least or exactly or at most 332, at least or exactly or at most 333, at least or exactly or at most 334, at least or exactly or at most 335, at least or exactly or at most 336, at least or exactly or at most 337, at least or exactly or at most 338, at least or exactly or at most 339, at least or exactly or at most 340, at least or exactly or at most 341, at least or exactly or at most 342, at least or exactly or at most 343, at least or exactly or at most 344, at least or exactly or at most 345, at least or exactly or at most 346, at least or exactly or at most 347, at least or exactly or at most 348, at least or exactly or at most 349, at least or exactly or at most 350, at least or exactly or at most 351, at least or exactly or at most 352, at least or exactly or at most 353, at least or exactly or at most 354, at least or exactly or at most 355, at least or exactly or at most 356 at least or exactly or at most 357, at least or exactly or at most 358, at least or exactly or at most 359, at least or exactly or at most 360, at least or exactly or at most 361, at least or exactly or at most 362, at least or exactly or at most 363, at least

or exactly or at most 364, at least or exactly or at most 365, at least or exactly or at most 366, at least or exactly or at most 367, at least or exactly or at most 368, at least or exactly or at most 369, at least or exactly or at most 370, at least or exactly or at most 371, at least or exactly or at most 372, at least or exactly or at most 373, at least or exactly or at most 374, or at least or exactly or at most 375 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 13-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 376, at least or exactly or at most 377, at least or exactly or at most 378, at least or exactly or at most 379, at least or exactly or at most 380, or at least or exactly or at most 381 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 14-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 382, at least or exactly or at most 383, at least or exactly or at most 384, at least or exactly or at most 385, at least or exactly or at most 386, at least or exactly or at most 387, at least or exactly or at most 388, at least or exactly or at most 389, at least or exactly or at most 390, at least or exactly or at most 391, at least or exactly or at most 392, at least or exactly or at most 393, at least or exactly or at most 394, at least or exactly or at most 395, at least or exactly or at most 396, at least or exactly or at most 397, at least or exactly or at most 398, at least or exactly or at most 399, at least or exactly or at most 400, at least or exactly or at most 401, at least or exactly or at most 402, at least or exactly or at most 403, at least or exactly or at most 404, at least or exactly or at most 405, at least or exactly or at most 406, at least or exactly or at most 407, at least or exactly or at most 408, at least or exactly or at most 409, at least or exactly or at most 410, at least or exactly or at most 411, at least or exactly or at most 412, at least or exactly or at most 413, at least or exactly or at most 414, at least or exactly or at most 415, at least or exactly or at most 416, at least or exactly or at most 417, at least or exactly or at most 418, at least or exactly or at most 419, at least or exactly or at most 420, at least or exactly or at most 421, at least or exactly or at most 422, at least or exactly or at most 423, at least or exactly or at most 424, at least or exactly or at most 425, at least or exactly or at most 426, or at least or exactly or at most 427 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 15-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 428, at least or exactly or at most 429, at least or exactly or at most 430, at least or exactly or at most 431, at least or exactly or at most 432, at least or exactly or at most 433, at least or exactly or at most 434, at least or exactly or at most 435, at least or exactly or at most 436, at least or exactly or at most 437, at least

or exactly or at most 438, at least or exactly or at most 439, or at least or exactly or at most 440 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 16-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 441, at least or exactly or at most 442, at least or exactly or at most 443, at least or exactly or at most 444, at least or exactly or at most 445, at least or exactly or at most 446, at least or exactly or at most 447, at least or exactly or at most 448, at least or exactly or at most 449, at least or exactly or at most 450, at least or exactly or at most 451, at least or exactly or at most 452, at least or exactly or at most 453, at least or exactly or at most 454, at least or exactly or at most 455, at least or exactly or at most 456, at least or exactly or at most 457, at least or exactly or at most 458, at least or exactly or at most 459, at least or exactly or at most 460, at least or exactly or at most 461, at least or exactly or at most 462, at least or exactly or at most 463, at least or exactly or at most 464, at least or exactly or at most 465, at least or exactly or at most 466, at least or exactly or at most 467, at least or exactly or at most 468, at least or exactly or at most 469, at least or exactly or at most 470, at least or exactly or at most 471, at least or exactly or at most 472, at least or exactly or at most 473, at least or exactly or at most 474, at least or exactly or at most 475, at least or exactly or at most 476, at least or exactly or at most 477, at least or exactly or at most 478, at least or exactly or at most 479, at least or exactly or at most 480, at least or exactly or at most 481, at least or exactly or at most 482, or at least or exactly or at most 483 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 17-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 484, at least or exactly or at most 485, at least or exactly or at most 486, at least or exactly or at most 487, at least or exactly or at most 488, at least or exactly or at most 489, at least or exactly or at most 490, at least or exactly or at most 491, at least or exactly or at most 492, at least or exactly or at most 493, or at least or exactly or at most 494 at least or exactly or at most 495, at least or exactly or at most 496, at least or exactly or at most 497, at least or exactly or at most 498, at least or exactly or at most 499, at least or exactly or at most 500, at least or exactly or at most 501, at least or exactly or at most 502, at least or exactly or at most 503, at least or exactly or at most 504, at least or exactly or at most 505, at least or exactly or at most 506, at least or exactly or at most 507, at least or exactly or at most 508 at least or exactly or at most 509, at least or exactly or at most 510, at least or exactly or at most 511, at least or exactly or at most 512, at least or exactly or at most 513, at least or exactly or at most 514, at least or exactly or at most 515, at least or exactly or at most 516, at least or exactly or at most 517, at least or exactly or at most 518, at least or exactly or at most 519, at least or exactly or at

most 520, at least or exactly or at most 521, at least or exactly or at most 522, at least or exactly or at most 523, at least or exactly or at most 524, at least or exactly or at most 525, at least or exactly or at most 526, at least or exactly or at most 527, at least or exactly or at most 528, at least or exactly or at most 529, at least or exactly or at most 530, at least or exactly or at most 531, at least or exactly or at most 532, at least or exactly or at most 533, or at least or exactly or at most 534 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 18-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 535, at least or exactly or at most 536, at least or exactly or at most 537, at least or exactly or at most 538, at least or exactly or at most 539, at least or exactly or at most 540, at least or exactly or at most 541, at least or exactly or at most 542, at least or exactly or at most 543, at least or exactly or at most 544, at least or exactly or at most 545, at least or exactly or at most 546, at least or exactly or at most 547, at least or exactly or at most 548, at least or exactly or at most 549, at least or exactly or at most 550, at least or exactly or at most 551, at least or exactly or at most 552, at least or exactly or at most 553, at least or exactly or at most 554, at least or exactly or at most 555, at least or exactly or at most 556, at least or exactly or at most 557, at least or exactly or at most 558, at least or exactly or at most 559, at least or exactly or at most 560, at least or exactly or at most 561, at least or exactly or at most 562, or at least or exactly or at most 563, at least or exactly or at most 564, at least or exactly or at most 565, at least or exactly or at most 566, at least or exactly or at most 567, at least or exactly or at most 568, at least or exactly or at most 569, at least or exactly or at most 570, at least or exactly or at most 571, at least or exactly or at most 572, at least or exactly or at most 573, at least or exactly or at most 574, at least or exactly or at most 575, at least or exactly or at most 576, at least or exactly or at most 577, at least or exactly or at most 578, at least or exactly or at most 579, at least or exactly or at most 580, at least or exactly or at most 581, at least or exactly or at most 582, at least or exactly or at most 583, at least or exactly or at most 584, at least or exactly or at most 585, at least or exactly or at most 586, at least or exactly or at most 587, at least or exactly or at most 588, at least or exactly or at most 589, at least or exactly or at most 590, at least or exactly or at most 591, at least or exactly or at most 592, at least or exactly or at most 593, at least or exactly or at most 594, at least or exactly or at most 595, or at least or exactly or at most 596 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 19-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 597, at least or exactly or at most 598, at least or exactly or at most 599, at least or exactly or at most 600, at least or exactly or at most 601, at least or exactly or at most 602, at least or exactly or at most 603, at least or exactly

or at most 604, at least or exactly or at most 605, at least or exactly or at most 606, at least or exactly or at most 607, at least or exactly or at most 608, at least or exactly or at most 609, at least or exactly or at most 610, at least or exactly or at most 611, at least or exactly or at most 612, at least or exactly or at most 613, at least or exactly or at most 614, at least or exactly or at most 615, at least or exactly or at most 616, at least or exactly or at most 617, at least or exactly or at most 618, at least or exactly or at most 619, at least or exactly or at most 620, at least or exactly or at most 621, at least or exactly or at most 622, or at least or exactly or at most 623 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 20-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 624, at least or exactly or at most 625, at least or exactly or at most 626, at least or exactly or at most 627, at least or exactly or at most 628, at least or exactly or at most 629, at least or exactly or at most 630, at least or exactly or at most 631, at least or exactly or at most 632, at least or exactly or at most 633, at least or exactly or at most 634, at least or exactly or at most 635, at least or exactly or at most 636, at least or exactly or at most 637, at least or exactly or at most 638, at least or exactly or at most 639, at least or exactly or at most 640, at least or exactly or at most 641, at least or exactly or at most 642, at least or exactly or at most 643, at least or exactly or at most 644, at least or exactly or at most 645, at least or exactly or at most 646, at least or exactly or at most 647, at least or exactly or at most 648, at least or exactly or at most 649, at least or exactly or at most 650, at least or exactly or at most 651, at least or exactly or at most 652, at least or exactly or at most 653, at least or exactly or at most 654, at least or exactly or at most 655, or at least or exactly or at most 656 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 21-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 657, at least or exactly or at most 658, at least or exactly or at most 659, at least or exactly or at most 660, at least or exactly or at most 661, at least or exactly or at most 662, at least or exactly or at most 663, at least or exactly or at most 664, at least or exactly or at most 665, at least or exactly or at most 666, at least or exactly or at most 667, at least or exactly or at most 668, at least or exactly or at most 669, at least or exactly or at most 670, at least or exactly or at most 671, at least or exactly or at most 672, at least or exactly or at most 673, or at least or exactly or at most 674 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 22-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 675, at least or exactly or at most 676, at least

or exactly or at most 677, at least or exactly or at most 678, at least or exactly or at most 679, at least or exactly or at most 680, at least or exactly or at most 681, at least or exactly or at most 682, at least or exactly or at most 683, at least or exactly or at most 684, at least or exactly or at most 685, at least or exactly or at most 686, at least or exactly or at most 687, at least or exactly or at most 688, at least or exactly or at most 689, at least or exactly or at most 690, at least or exactly or at most 691, at least or exactly or at most 692, at least or exactly or at most 693, at least or exactly or at most 694, at least or exactly or at most 695, at least or exactly or at most 696, at least or exactly or at most 697, at least or exactly or at most 698, at least or exactly or at most 699, or at least or exactly or at most 700 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 23-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 701, at least or exactly or at most 702, at least or exactly or at most 703, at least or exactly or at most 704, at least or exactly or at most 705, at least or exactly or at most 706, at least or exactly or at most 707, at least or exactly or at most 708, at least or exactly or at most 709, at least or exactly or at most 710, at least or exactly or at most 711, at least or exactly or at most 712, at least or exactly or at most 713, at least or exactly or at most 714, at least or exactly or at most 715, at least or exactly or at most 716, at least or exactly or at most 717, at least or exactly or at most 718, at least or exactly or at most 719, at least or exactly or at most 720, at least or exactly or at most 721, at least or exactly or at most 722, at least or exactly or at most 723, at least or exactly or at most 724, at least or exactly or at most 725, at least or exactly or at most 726, at least or exactly or at most 727, at least or exactly or at most 728, at least or exactly or at most 729, at least or exactly or at most 730, at least or exactly or at most 731, at least or exactly or at most 732, at least or exactly or at most 733, at least or exactly or at most 734, at least or exactly or at most 735, at least or exactly or at most 736, at least or exactly or at most 737, at least or exactly or at most 738, at least or exactly or at most 739, at least or exactly or at most 740, at least or exactly or at most 741, at least or exactly or at most 742, at least or exactly or at most 743, at least or exactly or at most 744, at least or exactly or at most 745, at least or exactly or at most 746, at least or exactly or at most 747, at least or exactly or at most 748, at least or exactly or at most 749, at least or exactly or at most 750, or at least or exactly or at most 751 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 24-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 752, at least or exactly or at most 753, at least or exactly or at most 754, at least or exactly or at most 755, at least or exactly or at most

756, at least or exactly or at most 757, at least or exactly or at most 758, at least or exactly or at most 759, or at least or exactly or at most 760 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 25-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 761, at least or exactly or at most 762, at least or exactly or at most 763, at least or exactly or at most 764, at least or exactly or at most 765, at least or exactly or at most 766, at least or exactly or at most 767, at least or exactly or at most 768, at least or exactly or at most 769, at least or exactly or at most 770, at least or exactly or at most 771, at least or exactly or at most 772, at least or exactly or at most 773, at least or exactly or at most 774, at least or exactly or at most 775, at least or exactly or at most 776, at least or exactly or at most 777, at least or exactly or at most 778, at least or exactly or at most 779, at least or exactly or at most 780, at least or exactly or at most 781, at least or exactly or at most 782, at least or exactly or at most 783, at least or exactly or at most 784, at least or exactly or at most 785, at least or exactly or at most 786, at least or exactly or at most 787, at least or exactly or at most 788, or at least or exactly or at most 789 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 26-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 790, at least or exactly or at most 791, at least or exactly or at most 792, at least or exactly or at most 793, at least or exactly or at most 794, at least or exactly or at most 795, at least or exactly or at most 796, at least or exactly or at most 797, at least or exactly or at most 798, at least or exactly or at most 799, at least or exactly or at most 800, at least or exactly or at most 801, at least or exactly or at most 802, at least or exactly or at most 803, at least or exactly or at most 804, at least or exactly or at most 805, at least or exactly or at most 806, at least or exactly or at most 807, or at least or exactly or at most 808 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 27-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 809, at least or exactly or at most 810, at least or exactly or at most 811, at least or exactly or at most 812, at least or exactly or at most 813, at least or exactly or at most 815, at least or exactly or at most 816, at least or exactly or at most 817, at least or exactly or at most 818, at least or exactly or at most 819, at least or exactly or at most 820, at least or exactly or at most 821, at least or exactly or at most 811, at least or exactly or at most 823, at least or exactly or at most 824, at least or exactly or at most 825, at least or exactly or at most 826, at least or exactly or at most 827, at least or exactly or at most 828, at least or exactly or at most 829, at least or exactly or at most

830, at least or exactly or at most 831, at least or exactly or at most 832, at least or exactly or at most 833, at least or exactly or at most 834, at least or exactly or at most 835, at least or exactly or at most 836, at least or exactly or at most 837, at least or exactly or at most 838, at least or exactly or at most 839, at least or exactly or at most 840, at least or exactly or at most 841, at least or exactly or at most 842, at least or exactly or at most 843, at least or exactly or at most 844, at least or exactly or at most 845, at least or exactly or at most 846, at least or exactly or at most 847, at least or exactly or at most 848, at least or exactly or at most 849, at least or exactly or at most 850, at least or exactly or at most 851, at least or exactly or at most 852, at least or exactly or at most 853, at least or exactly or at most 854, at least or exactly or at most 855, at least or exactly or at most 856, at least or exactly or at most 857, at least or exactly or at most 858, at least or exactly or at most 859, at least or exactly or at most 860, at least or exactly or at most 861, at least or exactly or at most 862, at least or exactly or at most 863, at least or exactly or at most 864, at least or exactly or at most 865, at least or exactly or at most 866, at least or exactly or at most 867, at least or exactly or at most 868, at least or exactly or at most 869, at least or exactly or at most 870, at least or exactly or at most 871, at least or exactly or at most 872, at least or exactly or at most 873, at least or exactly or at most 874, at least or exactly or at most 875, at least or exactly or at most 876, at least or exactly or at most 877, at least or exactly or at most 878, at least or exactly or at most 879, at least or exactly or at most 880, at least or exactly or at most 881, at least or exactly or at most 882, at least or exactly or at most 883, at least or exactly or at most 884, at least or exactly or at most 885, at least or exactly or at most 886, at least or exactly or at most 887, at least or exactly or at most 888, at least or exactly or at most 889, at least or exactly or at most 890, at least or exactly or at most 891, at least or exactly or at most 892, at least or exactly or at most 893, at least or exactly or at most 894, or at least or exactly or at most 895 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 28-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 896, at least or exactly or at most 897, at least or exactly or at most 898, at least or exactly or at most 899, at least or exactly or at most 900, at least or exactly or at most 901, at least or exactly or at most 902, at least or exactly or at most 903, at least or exactly or at most 904, at least or exactly or at most 905, at least or exactly or at most 906, at least or exactly or at most 907, at least or exactly or at most 908, at least or exactly or at most 909, at least or exactly or at most 910, at least or exactly or at most 911, at least or exactly or at most 912, at least or exactly or at most 913, at least or exactly or at most 914, at least or exactly or at most 915, at least or exactly or at most 916, at least or exactly or at most 917, at least or exactly or at most 918, at least or exactly or at most 919, at least or exactly or at most 920, at least or exactly or at most 921, at least or exactly or at most 922, at least or exactly or at most 923, at least or exactly or at most

[illegible]

exactly or at most 1027, at least or exactly or at most 1028, at least or exactly or at most 1029, at least or exactly or at most 1030, at least or exactly or at most 1031, at least or exactly or at most 1032, at least or exactly or at most 1033, at least or exactly or at most 1034, at least or exactly or at most 1035, at least or exactly or at most 1036, at least or exactly or at most 1037, at least or exactly or at most 1038, at least or exactly or at most 1039, at least or exactly or at most 1040, at least or exactly or at most 1041, at least or exactly or at most 1042, at least or exactly or at most 1043, at least or exactly or at most 1044, at least or exactly or at most 1045, at least or exactly or at most 1046, at least or exactly or at most 1047, at least or exactly or at most 1048, at least or exactly or at most 1049, at least or exactly or at most 1050, at least or exactly or at most 1051, at least or exactly or at most 1052, at least or exactly or at most 1053, at least or exactly or at most 1054, at least or exactly or at most 1055, at least or exactly or at most 1056, at least or exactly or at most 1057, at least or exactly or at most 1058, at least or exactly or at most 1059, at least or exactly or at most 1060, at least or exactly or at most 1061, at least or exactly or at most 1062, at least or exactly or at most 1063, at least or exactly or at most 1064, at least or exactly or at most 1065, at least or exactly or at most 1066, at least or exactly or at most 1067, at least or exactly or at most 1068, at least or exactly or at most 1069, at least or exactly or at most 1070, at least or exactly or at most 1071, at least or exactly or at most 1072, at least or exactly or at most 1073, at least or exactly or at most 1074, at least or exactly or at most 1075, or at least or exactly or at most 1076 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 29-30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 1077, at least or exactly or at most 1078, at least or exactly or at most 1079, at least or exactly or at most 1080, at least or exactly or at most 1081, at least or exactly or at most 1082, at least or exactly or at most 1083, at least or exactly or at most 1084, at least or exactly or at most 1085, at least or exactly or at most 1086, at least or exactly or at most 1087, at least or exactly or at most 1088, at least or exactly or at most 1089, at least or exactly or at most 1090, at least or exactly or at most 1091, at least or exactly or at most 1092, at least or exactly or at most 1093, at least or exactly or at most 1094, at least or exactly or at most 1095, at least or exactly or at most 1096, at least or exactly or at most 1097, at least or exactly or at most 1098, at least or exactly or at most 1099, at least or exactly or at most 1100, at least or exactly or at most 1101, at least or exactly or at most 1102, at least or exactly or at most 1103, at least or exactly or at most 1104, at least or exactly or at most 1105, at least or exactly or at most 1106, at least or exactly or at most 1107, at least or exactly or at most 1108, at least or exactly or at most 1109, at least or exactly or at most 1110, at least or exactly or at most 1111, at least or exactly or at most 1112, at least or exactly or at most 1113, at least or

exactly or at most 1114, at least or exactly or at most 1115, at least or exactly or at most 1116, at least or exactly or at most 1117, at least or exactly or at most 1118, at least or exactly or at most 1119, at least or exactly or at most 1120, at least or exactly or at most 1121, at least or exactly or at most 1122, at least or exactly or at most 1123, at least or exactly or at most 1124, at least or exactly or at most 1125, at least or exactly or at most 1126, at least or exactly or at most 1127, at least or exactly or at most 1128, at least or exactly or at most 1129, at least or exactly or at most 1130, at least or exactly or at most 1131, at least or exactly or at most 1132, at least or exactly or at most 1133, at least or exactly or at most 1134, at least or exactly or at most 1135, at least or exactly or at most 1136, at least or exactly or at most 1137, at least or exactly or at most 1138, at least or exactly or at most 1139, at least or exactly or at most 1140, at least or exactly or at most 1141, at least or exactly or at most 1142, at least or exactly or at most 1143, at least or exactly or at most 1144, at least or exactly or at most 1145, at least or exactly or at most 1146, at least or exactly or at most 1147, at least or exactly or at most 1148, at least or exactly or at most 1149, at least or exactly or at most 1150, at least or exactly or at most 1151, at least or exactly or at most 1152, at least or exactly or at most 1153, at least or exactly or at most 1154, at least or exactly or at most 1155, at least or exactly or at most 1156, at least or exactly or at most 1157, or at least or exactly or at most 1158 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 30 and 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also constitute at least or exactly or at most 1159, at least or exactly or at most 1160, at least or exactly or at most 1161, at least or exactly or at most 1162, at least or exactly or at most 1163, at least or exactly or at most 1164, at least or exactly or at most 1165, at least or exactly or at most 1166, at least or exactly or at most 1167, at least or exactly or at most 1168, at least or exactly or at most 1169, at least or exactly or at most 1170, at least or exactly or at most 1171, at least or exactly or at most 1172, at least or exactly or at most 1173, at least or exactly or at most 1174, at least or exactly or at most 1175, at least or exactly or at most 1176, at least or exactly or at most 1177, at least or exactly or at most 1178, at least or exactly or at most 1179, at least or exactly or at most 1180, at least or exactly or at most 1181, at least or exactly or at most 1182, at least or exactly or at most 1183, at least or exactly or at most 1184, at least or exactly or at most 1185, at least or exactly or at most 1186, at least or exactly or at most 1187, at least or exactly or at most 1188, at least or exactly or at most 1189, at least or exactly or at most 1190, at least or exactly or at most 1191, at least or exactly or at most 1192, at least or exactly or at most 1193, at least or exactly or at most 1194, at least or exactly or at most 1195, at least or exactly or at most 1196, at least or exactly or at most 1197, at least or exactly or at most 1198, at least or exactly or at most 1199, at least or exactly or at most 1200, at least or

[illegible]

[illegible]

exactly or at most 1396, at least or exactly or at most 1397, at least or exactly or at most 1398, at least or exactly or at most 1399, at least or exactly or at most 1400, at least or exactly or at most 1401, at least or exactly or at most 1402, at least or exactly or at most 1403, at least or exactly or at most 1404, at least or exactly or at most 1405, at least or exactly or at most 1406, at least or exactly or at most 1407, at least or exactly or at most 1408, at least or exactly or at most 1409, at least or exactly or at most 1410, or at least or exactly or at most 1411 contiguous amino acid residues.

Insofar as embodiment b relates to SEQ ID NO: 94, the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention may also

constitute at least or exactly or at most 1412, at least or exactly or at most 1413, at least or exactly or at most 1414, at least or exactly or at most 1415, at least or exactly or at most 1416, at least or exactly or at most 1417, at least or exactly or at most 1418, at least or exactly or at most 1419, at least or exactly or at most 1420, at least or exactly or at most 1421, at least or exactly or at most 1422, at least or exactly or at most 1423, at least or exactly or at most 1424, at least or exactly or at most 1425, at least or exactly or at most 1426, at least or exactly or at most 1427, at least or exactly or at most 1428, at least or exactly or at most 1429, at least or exactly or at most 1430, at least or exactly or at most 1431, at least or exactly or at most 1432, at least or exactly or at most 1433, at least or exactly or at most 1434, at least or exactly or at most 1435, at least or exactly or at most 1436, at least or exactly or at most 1437, at least or exactly or at most 1438, at least or exactly or at most 1439, at least or exactly or at most 1440, at least or exactly or at most 1441, at least or exactly or at most 1442, at least or exactly or at most 1443, at least or exactly or at most 1444, at least or exactly or at most 1445, at least or exactly or at most 1446, at least or exactly or at most 1447, at least or exactly or at most 1448, at least or exactly or at most 1449, at least or exactly or at most 1450, at least or exactly or at most 1451, at least or exactly or at most 1452, at least or exactly or at most 1453, at least or exactly or at most 1454, at least or exactly or at most 1455, at least or exactly or at most 1456, at least or exactly or at most 1457, at least or exactly or at most 1458, at least or exactly or at most 1459, at least or exactly or at most 1460, at least or exactly or at most 1461, at least or exactly or at most 1462, at least or exactly or at most 1463, at least or exactly or at most 1464, at least or exactly or at most 1465, at least or exactly or at most 1466, at least or exactly or at most 1467, at least or exactly or at most 1468, at least or exactly or at most 1469, at least or exactly or at most 1470, at least or exactly or at most 1471, at least or exactly or at most 1472, at least or exactly or at most 1473, at least or exactly or at most 1474, at least or exactly or at most 1475, at least or exactly or at most 1476, at least or exactly or at most 1477, at least or exactly or at most 1478, at least or exactly or at most 1479, at least or exactly or at most 1480, at least or exactly or at most 1481, at least or exactly or at most 1482, at least or exactly or at most 1483, at least or

[illegible]

1581, at least or exactly or at most 1582, at least or exactly or at most 1583, at least or
exactly or at most 1584, at least or exactly or at most 1585, at least or exactly or at most
1586, at least or exactly or at most 1587, at least or exactly or at most 1588, at least or
exactly or at most 1589, at least or exactly or at most 1590, at least or exactly or at most
5 1591, at least or exactly or at most 1592, at least or exactly or at most 1593, at least or
exactly or at most 1594, at least or exactly or at most 1595, at least or exactly or at most
1596, at least or exactly or at most 1597, at least or exactly or at most 1598, at least or
exactly or at most 1599, at least or exactly or at most 1600, at least or exactly or at most
1601, at least or exactly or at most 1602, at least or exactly or at most 1603, at least or
10 exactly or at most 1604, at least or exactly or at most 1605, at least or exactly or at most
1606, at least or exactly or at most 1607, at least or exactly or at most 1608, at least or
exactly or at most 1609, at least or exactly or at most 1610, at least or exactly or at most
1611, at least or exactly or at most 1612, at least or exactly or at most 1613, at least or
exactly or at most 1614, at least or exactly or at most 1615, at least or exactly or at most
15 1616, at least or exactly or at most 1617, at least or exactly or at most 1618, at least or
exactly or at most 1619, at least or exactly or at most 1620, at least or exactly or at most
1621, at least or exactly or at most 1622, at least or exactly or at most 1623, at least or
exactly or at most 1624, at least or exactly or at most 1625, at least or exactly or at most
1626, at least or exactly or at most 1627, at least or exactly or at most 1628, at least or
20 exactly or at most 1629, at least or exactly or at most 1630, at least or exactly or at most
1631, at least or exactly or at most 1632, at least or exactly or at most 1633, at least or
exactly or at most 1634, at least or exactly or at most 1635, at least or exactly or at most
1636, at least or exactly or at most 1637, at least or exactly or at most 1638, at least or
exactly or at most 1639, at least or exactly or at most 1640, at least or exactly or at most
25 1641, at least or exactly or at most 1642, at least or exactly or at most 1643, at least or
exactly or at most 1644, at least or exactly or at most 1645, at least or exactly or at most
1646, at least or exactly or at most 1647, at least or exactly or at most 1648, at least or
exactly or at most 1649 amino acid residues.

In some embodiments the invention relates to a polypeptide comprising an amino acid
30 sequence consisting of at most 5 contiguous amino acid residues from any one of SEQ ID
NOs 1-30. In these embodiment, the at most 5 contiguous amino acids can, for example,
constitute 2, 3, 4 contiguous amino acid residues; preferably 4 contiguous amino acids.

In some embodiments, the polypeptide of the invention also has a sequence identity with the
amino acid sequence of a) defined above of at least 65%, such as at least 70%, at least
35 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.
Similarly, the polypeptide of the invention in some embodiments also has a sequence identity

with the amino acid sequence of b) defined above of at least 60%, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

5 In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 10 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, and 90 in any one of SEQ ID NOs: 1-30, 93, and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 20 109, 110, 111, 112, and 113 in any on of SEQ ID NOs: 2-30, 93, and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 114 and 115 in any one of SEQ ID NOs: 3-30, 93, and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits –the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to amino acid residue 116 in any one of SEQ ID NOs: 4-30, 93, and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits –the N-terminal first residue will not be higher

numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b).

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any amino acid residue 117 in any one of SEQ ID NOs: 5-30, 93, and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b).

10 In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to amino acid residue 118 in any one of SEQ ID NOs: 6-30, 93, and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher
15 numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b).

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid
20 residues 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, and 137 in any one of SEQ ID NOs: 7-30, 93, and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b).

25 In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 138, 139, 140, 141, 142, 143, 144, 145, 146, and 147 in any one of SEQ ID NOs: 8-30, 93, and 94, if the length of the at least or exactly or at most 5 amino acid residues so
30 permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b).

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b)

above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, and 164 in any one of SEQ ID NOs: 9-30, 93, and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, or 192 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, or 208 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, and 225 in any one of SEQ ID NOs: 10-30, 93, and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, and 241 and 318 in any one of SEQ ID NOs: 11-30, 93 and 94 if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, and 318 in any one of SEQ ID NOs: 11-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, or 356 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, and 372 in any one of SEQ ID NOs: 12-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 373, 374, 375, 376, 377, and 378 in any one of SEQ ID NOs: 13-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, and 424 in any one of SEQ ID NOs: 14-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, and 437 in any one of SEQ ID NOs: 15-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, and 480 in any one of SEQ ID NOs: 16-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, and 531 in any one of SEQ ID NOs: 17-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, or 563, 427564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, and 593 in any one of SEQ ID NOs: 18-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, and 620 in any one of SEQ ID NOs: 19-

30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

- 5 In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, and 653 in
10 any one of SEQ ID NOs: 20-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

- In the embodiments defined by option b) above, the polypeptide of the invention is also one
15 that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, and 671 in any one of SEQ ID NOs: 21-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher
20 numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

- In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid
25 residues 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, and 697 in any one of SEQ ID NOs: 22-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for
30 option b.

- In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid
35 residues 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731,

732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, and 748 in any one of SEQ ID NOs: 23-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 749, 750, 751, 752, 753, 754, 755, 756 and 757 in any one of SEQ ID NOs: 24-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785 and 786 in any one of SEQ ID NOs: 25-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804 and 805 in any one of SEQ ID NOs: 26-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 806, 807, 808, 809, 810, 811, 812, 813, 815, 816, 817, 818, 819, 820, 821, 811, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840,

841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891 and 892 in any one of SEQ ID NOs: 27-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072 and 1073 in any one of SEQ ID NOs: 28-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154 and 1155 in any one of SEQ ID NOs: 29-30 and 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-

L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b)

5 above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1190, 1191, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1200, 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 10 1211, 1212, 1213, 1214, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226, 1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, 1254, 1255, 1256, 1257, 1258, 1259, 1260, 1261, 1262, 1263, 1264, 1265, 1266, 1267, 1268, 1269, 1270, 1271, 1272, 1273, 1274, 1275, 1276, 1277, 1278, 1279, 1280, 15 1281, 1282, 1283, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1349, 1350, 20 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, 1360, 1361, 1362, 1363, 1364, 1365, 1366, 1367, 1368, 1369, 1370, 1371, 1372, 1373, 1374, 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1382, 1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394, 1395, 1396, 1397, 1398, 1399, 1400, 1401, 1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409 and 1410 in SEQ ID NO: 30 or 94, if the length of the at least or exactly or 25 at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b)

30 above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453, 1454, 1455, 1456, 1457, 1458, 1459, 1460, 1461, 1462, 35 1463, 1464, 1465, 1466, 1467, 1468, 1469, 1470, 1471, 1472, 1473, 1474, 1475, 1476, 1477, 1478, 1479, 1480, 1481, 1482, 1483, 1484, 1485, 1486, 1487, 1488, 1489, 1490, 1491, 1492, 1493, 1494, 1495, 1496, 1497, 1498, 1499, 1500, 1501, 1502, 1503, 1504,

- 1505, 1506, 1507, 1508, 1509, 1510, 1511, 1512, 1513, 1514, 1515, 1516, 1517, 1518, 1519, 1520, 1521, 1522, 1523, 1524, 1525, 1526, 1527, 1528, 1529, 1530, 1531, 1532, 1533, 1534, 1535, 1536, 1537, 1538, 1539, 1540, 1541, 1542, 1543, 1544, 1545, 1546, 1547, 1548, 1549, 1550, 1551, 1552, 1553, 1554, 1555, 1556, 1557, 1558, 1559, 1560, 5 1561, 1562, 1563, 1564, 1565, 1566, 1567, 1568, 1569, 1570, 1571, 1572, 1573, 1574, 1575, 1576, 1577, 1578, 1579, 1580, 1581, 1582, 1583, 1584, 1585, 1586, 1587, 1588, 1589, 1590, 1591, 1592, 1593, 1594, 1595, 1596, 1597, 1598, 1599, 1600, 1601, 1602, 1603, 1604, 1605, 1606, 1607, 1608, 1609, 1610, 1611, 1612, 1613, 1614, 1615, 1616, 1617, 1618, 1619, 1620, 1621, 1622, 1623, 1624, 1625, 1626, 1627, 1628, 1629, 1630, 10 1631, 1632, 1633, 1634, 1635, 1636, 1637, 1638, 1639, 1640, 1641, 1642, 1643, 1644, and 1645 in SEQ ID NO: 94, if the length of the at least or exactly or at most 5 amino acid residues so permits – the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.
- 15 The polypeptide of the invention is in certain embodiments also fused or conjugated to an immunogenic carrier molecule; or, phrased otherwise, the polypeptide of the invention also includes such an immunogenic carrier molecule in addition to the material derived from SEQ ID NOs: 1-30. The immunogenic carrier molecule is a typically polypeptide that induces T-helper lymphocyte responses in a majority of humans, such as immunogenic carrier proteins 20 selected from the group consisting of keyhole limpet hemocyanino or a fragment thereof, tetanus toxoid or a fragment thereof, diphtheria toxoid or a fragment thereof. Other suitable carrier molecules are discussed infra. One further fusion partner which is preferably incorporated is a "His tag", i.e. a stretch of amino acids, which is rich in or only consists of histidiny residues so as to facilitate protein purification.
- 25 In preferred embodiments, the polypeptide of the invention detailed above is capable of inducing an adaptive immune response against the polypeptide in a mammal, in particular in a human being. Preferably, the adaptive immune response is a protective adaptive immune response against infection with *K. pneumoniae*.. The polypeptide may in these cases induce a humeral and/or a cellular immune response.
- 30 A particularly preferred polypeptide of the invention is derived from SEQ ID NO: 6 and is otherwise as defined above.

Epitopes

SEQ ID NOs: 1-30 include antigenic determinants (epitopes) that are as such recognized by antibodies and/or when bound to MHC molecules by T-cell receptors. For the purposes of the present invention, B-cell epitopes (*i.e.* antibody binding epitopes) are of particular relevance.

- 5 It is relatively uncomplicated to identify linear B-cell epitopes – one very simple approach entails that antibodies raised against *K. pneumoniae* or *K. pneumoniae* derived proteins disclosed herein are tested for binding to overlapping oligomeric peptides derived from any one of SEQ ID NO: 1-30. Thereby, the regions of the *K. pneumoniae* polypeptide which are responsible for or contribute to binding to the antibodies can be identified.
- 10 Alternatively, or additionally, one can produce mutated versions of the polypeptides of the invention, e.g. version where each single non-alanine residue in any one of SEQ ID NOs: 1-30 are point mutated to alanine – this method also assists in identifying complex assembled B-cell epitopes; this is the case when binding of the same antibody is modified by exchanging amino acids in different areas of the full-length polypeptide.
- 15 Also, in silico methods for B-cell epitope prediction can be employed: useful state-of-the-art systems for β -turn prediction is provided in Petersen B et al. (November 2010), Plos One 5(11): e15079; prediction of linear B-cell epitopes, cf: Larsen J E P et al. (April 2006), Immunome Research, 2:2; prediction of solvent exposed amino acids: Petersen B et al (July 2009), BMC Structural Biology, 9:51.

- 20 The nucleic acid fragments of the invention

The nucleic acid fragment of the invention referred to above is preferably is a DNA fragment (of a sequence such as SEQ ID NOs: 31-60 and 95-98) or an RNA fragment (of a sequence such as SEQ ID NOs 61-90 and 99-102).

- 25 In some embodiments the at least or exactly 10 consecutive nucleotides referred to in option iii) in the definition of the second aspect consists of at least or exactly 10, such as at least or exactly or at most 11, such as at least or exactly or at most 12, at least or exactly or at most 13, at least or exactly or at most 14, at least or exactly or at most 15, at least or exactly or at most 16, at least or exactly or at most 17 at least or exactly or at most 18, at least or exactly or at most 19, at least or exactly or at most 20, at least or exactly or at most 21, at
- 30 least or exactly or at most 22, at least or exactly or at most 23, at least or exactly or at most 24, at least or exactly or at most 25, at least or exactly or at most 26, at least or exactly or

[illegible]

[illegible]

most 247, at least or exactly or at most 248, at least or exactly or at most 249, at least or exactly or at most 250, at least or exactly or at most 251, at least or exactly or at most 252, at least or exactly or at most 253, at least or exactly or at most 254, at least or exactly or at most 255, at least or exactly or at most 256, at least or exactly or at most 257, at least or exactly or at most 258, at least or exactly or at most 259, at least or exactly or at most 260, at least or exactly or at most 271, at least or exactly or at most 272, at least or exactly or at most 273, at least or exactly or at most 274, at least or exactly or at most 275, at least or exactly or at most 276, at least or exactly or at most 277, at least or exactly or at most 278, at least or exactly or at most 279, at least or exactly or at most 280, at least or exactly or at most 281, at least or exactly or at most 282, at least or exactly or at most 283, at least or exactly or at most 284, and at least or exactly or at most 285 consecutive nucleotides in any one of SEQ ID NOs:31-60. Longer fragments are contemplated, *i.e.* fragments having at least 200, at least 300 at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1500, at least 2000, at least 2500, at least 3000, at least 3500, and at least 4000 consecutive nucleotides from those of SEQ ID NOs: 31-90 and 95-102 that encompass fragments of such lengths.

In some embodiments the at most 10 consecutive nucleotides referred to in option iii) in the definition of the second aspect of the invention constitute 6, 7, 8, 9 or 10 nucleotides.

The nucleic acid fragment of the invention discussed above typically has a sequence identity with the nucleotide sequence defined for i) or ii) above, which is at least 65%, such as at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

The nucleic acid fragment of the invention discussed above may also have a sequence identity with the nucleotide sequence defined for iii) above, which is at least 65%, such as at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

The nucleic acid fragment of the invention described above comprises in certain embodiments at least or exactly or at most X distinct nucleic acid sequences each encoding a polypeptide of the invention, where each of said X distinct nucleic acid sequences encodes at least or exactly or at most one immunogenic amino acid sequence present in or derived from any one of SEQ ID NOs: 1-30 and wherein said X distinct nucleic acid sequences together encode immunogenic amino acid sequences present in or derived from at least or exactly or at most X of SEQ ID NOs: 1-30, 93 or 94, wherein X is an integer selected from 2, 3, 4, 5, 6, 7, 8, 9,

10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, and 32. In other words, such a nucleic acid fragment encodes several polypeptides of the invention. In some embodiments, the X nucleic acid sequences are expressed as separate encoded proteins and in other embodiments as "pearls on a string", i.e. fused proteins. In some
5 embodiments, immunogenic amino acid sequences from any one of SEQ ID NOs: 1-30, 93 and 94 are only present in one of said X nucleic acid sequences.

It will be understood that the nucleic acid fragments of the invention may be used for both production, carrier and vaccine purposes – the latter will require that the sequences are included in expression vectors that may lead to production of immunogenic proteins in the
10 host animal receiving the vector.

The vectors of the invention

Vectors of the invention fall into several categories discussed *infra*. One preferred vector of the invention comprises in operable linkage and in the 5'-3' direction, an expression control region comprising an enhancer/promoter for driving expression of the nucleic acid fragment
15 defined for option i) above, optionally a signal peptide coding sequence, a nucleotide sequence defined for option i), and optionally a terminator. Hence, such a vector constitutes an expression vector useful for effecting production in cells of the polypeptide of the invention. Since the polypeptides of the invention are bacterial of origin, recombinant production is conveniently effected in bacterial host cells, so here it is preferred that the
20 expression control region drives expression in prokaryotic cell such as a bacterium, e.g. in E coli. However, if the vector is to drive expression in mammalian cell (as would be the case for a DNA vaccine vector), the expression control region should be adapted to this particular use.

At any rate, certain vectors of the invention are capable of autonomous replication.

Also, the vector of the invention may be one that is capable of being integrated into the
25 genome of a host cell – this is particularly useful if the vector is used in the production of stably transformed cells, where the progeny will also include the genetic information introduced via the vector. Alternatively, vectors incapable of being integrated into the genome of a mammalian host cell are useful in e.g. DNA vaccination.

Typically, the vector of the invention is selected from the group consisting of a virus, such as
30 a attenuated virus (which may in itself be useful as a vaccine agent), a bacteriophage, a plasmid, a minichromosome, and a cosmid.

Particularly interesting vectors are viral vectors (in particular those useful as vaccine agents). These may be selected from the group consisting of a retrovirus vector, such as a lentivirus vector, an adenovirus vector, an adeno-associated virus vector, and a pox virus vector. Certain pox virus vectors are preferred, in particular vaccinia virus vectors. A
5 particularly preferred vaccinia virus vector is a modified vaccinia Ankara (MVA) vector.

A more detailed discussion of vectors of the invention is provided in the following:

Polypeptides of the invention may be encoded by a nucleic acid molecule comprised in a vector. A nucleic acid sequence can be "heterologous," which means that it is in a context foreign to the cell in which the vector is being introduced, which includes a sequence
10 homologous to a sequence in the cell but in a position within the host cell where it is ordinarily not found. Vectors include naked DNAs, RNAs, plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). One of skill in the art would be well equipped to construct a vector through standard recombinant techniques (for example Sambrook et al, 2001; Ausubel et al, 1996, both
15 incorporated herein by reference). In addition to encoding the polypeptides of this invention, a vector of the present invention may encode polypeptide sequences such as a tag or immunogenicity enhancing peptide (e.g. an immunogenic carrier or a fusion partner that stimulates the immune system, such as a cytokine or active fragment thereof). Useful vectors encoding such fusion proteins include pIN vectors (Inouye et al, 1985), vectors
20 encoding a stretch of histidines, and pGEX vectors, for use in generating glutathione S-transferase (GST) soluble fusion proteins for later purification and separation or cleavage.

Vectors of the invention may be used in a host cell to produce a polypeptide of the invention that may subsequently be purified for administration to a subject or the vector may be purified for direct administration to a subject for expression of the protein in the subject (as
25 is the case when administering a nucleic acid vaccine).

Expression vectors can contain a variety of "control sequences," which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host organism. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid
30 sequences that serve other functions as well and are described *infra*.

1. Promoters and Enhancers

A "promoter" is a control sequence. The promoter is typically a region of a nucleic acid sequence at which initiation and rate of transcription are controlled. It may contain genetic

elements at which regulatory proteins and molecules may bind such as RNA polymerase and other transcription factors. The phrases "operatively positioned," "operatively linked," "under control," and "under transcriptional control" mean that a promoter is in a correct functional location and/or orientation in relation to a nucleic acid sequence to control transcriptional initiation and expression of that sequence. A promoter may or may not be used in conjunction with an "enhancer," which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.

A promoter may be one naturally associated with a gene or sequence, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment or exon. Such a promoter can be referred to as "endogenous." Similarly, an enhancer may be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence. Alternatively, certain advantages will be gained by positioning the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer refers also to an enhancer not normally associated with a nucleic acid sequence in its natural state. Such promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other prokaryotic, viral, or eukaryotic cell, and promoters or enhancers not "naturally occurring," i.e., containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCR™, in connection with the compositions disclosed herein (see U.S. Patent 4,683,202, U.S. Patent 5,928,906, each incorporated herein by reference).

Naturally, it may be important to employ a promoter and/or enhancer that effectively direct(s) the expression of the DNA segment in the cell type or organism chosen for expression. Those of skill in the art of molecular biology generally know the use of promoters, enhancers, and cell type combinations for protein expression (see Sambrook et al, 2001, incorporated herein by reference). The promoters employed may be constitutive, tissue-specific, or inducible and in certain embodiments may direct high level expression of the introduced DNA segment under specified conditions, such as large-scale production of recombinant proteins or peptides.

Examples of inducible elements, which are regions of a nucleic acid sequence that can be activated in response to a specific stimulus, include but are not limited to Immunoglobulin Heavy Chain (Banerji et al, 1983; Gilles et al, 1983; Grosschedl et al, 1985; Atchinson et al, 1986, 1987; toiler et al, 1987; Weinberger et al, 1984; Kiledjian et al, 1988; Porton et al;

- 1990), Immunoglobulin Light Chain (Queen et al, 1983; Picard et al, 1984), T Cell Receptor (Luria et al, 1987; Winoto et al, 1989; Redondo et al; 1990), HLA DQ α and/or DQ β (Sullivan et al, 1987), β -Interferon (Goodbourn et al, 1986; Fujita et al, 1987; Goodbourn et al, 1988), Interleukin-2 (Greene et al, 1989), Interleukin-2 Receptor (Greene et al, 1989; Lin et al, 5 1990), MHC Class II 5 (Koch et al, 1989), MHC Class II HLA-DR α (Sherman et al, 1989), β -Actin (Kawamoto et al, 1988; Ng et al; 1989), Muscle Creatine Kinase (MCK) (Jaynes et al, 1988; Horlick et al, 1989; Johnson et al, 1989), Prealbumin (Transthyretin) (Costa et al, 1988), Elastase I (Omitz et al, 1987), Metallothionein (MTII) (Karin et al, 1987; Culotta et al, 1989), Collagenase (Pinkert et al, 1987; Angel et al, 1987), Albumin (Pinkert et al, 1987; 10 Tranche et al, 1989, 1990), α -Fetoprotein (Godbout et al, 1988; Campere et al, 1989), γ -Globin (Bodine et al, 1987; Perez-Stable et al, 1990), β -Globin (Trudel et al, 1987), c-fos (Cohen et al, 1987), c-HA-ras (Triesman, 1986; Deschamps et al, 1985), Insulin (Edlund et al, 1985), Neural Cell Adhesion Molecule (NCAM) (Hirsh et al, 1990), α 1-Antitrypsin (Larimer et al, 1990), H2B (TH2B) Histone (Hwang et al, 1990), Mouse and/or Type I Collagen (Ripe 15 et al, 1989), Glucose-Regulated Proteins (GRP94 and GRP78) (Chang et al, 1989), Rat Growth Hormone (Larsen et al, 1986), Human Serum Amyloid A (SAA) (Edbrooke et al, 1989), Troponin I (TN I) (Yutzey et al, 1989), Platelet-Derived Growth Factor (PDGF) (Pech et al, 1989), Duchenne Muscular Dystrophy (Klamut et al, 1990), SV40 (Banerji et al, 1981; 20 Moreau et al, 1981 ; Sleigh et al, 1985; Firak et al, 1986; Herr et al, 1986; Imbra et al, 1986; Kadesch et al, 1986; Wang et al, 1986; Ondek et al, 1987; Kuhl et al, 1987; Schaffner et al, 1988), Polyoma (Swartzendruber et al, 1975; Vasseur et al, 1980; Katinka et al, 1980, 1981; Tyndell et al, 1981 ; Dandolo et al, 1983; de Villiers et al, 1984; Hen et al, 1986; Satake et al, 1988; Campbell et al, 1988), Retroviruses (Kriegler et al, 1982, 1983; Levinson et al, 1982; Kriegler et al, 1983, 1984a, b, 1988; Bosze et al, 1986; Miksicsek et al, 1986; 25 Celander et al, 1987; Thiesen et al, 1988; Celander et al, 1988; Choi et al, 1988; Reisman et al, 1989), Papilloma Virus (Campo et al, 1983; Lusky et al, 1983; Spandidos and Wilkie, 1983; Spalholz et al, 1985; Lusky et al, 1986; Cripe et al, 1987; Gloss et al, 1987; Hirochika et al, 1987; Stephens et al, 1987), Hepatitis B Virus (Bulla et al, 1986; Jameel et al, 1986; Shaul et al, 1987; Spandau et al, 1988; Vannice et al, 1988), Human Immunodeficiency 30 Virus (Muesing et al, 1987; Hauber et al, 1988; Jakobovits et al, 1988; Feng et al, 1988; Takebe et al, 1988; Rosen et al, 1988; Berkhout et al, 1989; Laspias et al, 1989; Sharp et al, 1989; Braddock et al, 1989), Cytomegalovirus (CMV) IE (Weber et al, 1984; Boshart et al, 1985; Foecking et al, 1986), Gibbon Ape Leukemia Virus (Holbrook et al, 1987; Quinn et al, 1989).
- 35 Inducible Elements include, but are not limited to MT II - Phorbol Ester (TFA)/Heavy metals (Palmiter et al, 1982; Haslinger et al, 1985; Searle et al, 1985; Stuart et al, 1985; Imagawa et al, 1987, Karin et al, 1987; Angel et al, 1987b; McNeall et al, 1989); MMTV (mouse mammary tumor virus) - Glucocorticoids (Huang et al, 1981; Lee et al, 1981; Majors et al,

1983; Chandler et al, 1983; Lee et al, 1984; Ponta et al, 1985; Sakai et al, 1988); β -Interferon - poly(rI)x/poly(rc) (Tavernier et al, 1983); Adenovirus 5 E2 - E1A (Imperiale et al, 1984); Collagenase - Phorbol Ester (TPA) (Angel et al, 1987a); Stromelysin - Phorbol Ester (TPA) (Angel et al, 1987b); SV40 - Phorbol Ester (TPA) (Angel et al, 1987b); Murine MX Gene
 5 - Interferon, Newcastle Disease Virus (Hug et al, 1988); GRP78 Gene - A23187 (Resendez et al, 1988); α -2-Macroglobulin - IL-6 (Kunz et al, 1989); Vimentin - Serum (Rittling et al, 1989); MHC Class I Gene H-2kb - Interferon (Blonar et al, 1989); HSP70 - E1A/SV40 Large T Antigen (Taylor et al, 1989, 1990a, 1990b); Proliferin - Phorbol Ester/TPA (Mordacq et al, 1989); Tumor Necrosis Factor - PMA (Hensel et al, 1989); and Thyroid Stimulating Hormone
 10 Gene - Thyroid Hormone (Chatterjee et al, 1989).

Also contemplated as useful in the present invention are the dectin-1 and dectin-2 promoters. Additionally any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of structural genes encoding oligosaccharide processing enzymes, protein folding accessory proteins, selectable marker
 15 proteins or a heterologous protein of interest.

The particular promoter that is employed to control the expression of peptide or protein encoding polynucleotide of the invention is not believed to be critical, so long as it is capable of expressing the polynucleotide in a targeted cell, preferably a bacterial cell. Where a human cell is targeted, it is preferable to position the polynucleotide coding region adjacent to and
 20 under the control of a promoter that is capable of being expressed in a human cell. Generally speaking, such a promoter might include either a bacterial, human or viral promoter.

In various embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, and the Rous sarcoma virus long terminal repeat can be used to obtain high level expression of a related polynucleotide to this invention. The use of other
 25 viral or mammalian cellular or bacterial phage promoters, which are well known in the art, to achieve expression of polynucleotides is contemplated as well.

In embodiments in which a vector is administered to a subject for expression of the protein, it is contemplated that a desirable promoter for use with the vector is one that is not down-regulated by cytokines or one that is strong enough that even if down-regulated, it produces
 30 an effective amount of the protein/polypeptide of the current invention in a subject to elicit an immune response. Non-limiting examples of these are CMV IE and RSV LTR. In other embodiments, a promoter that is up-regulated in the presence of cytokines is employed. The MHC I promoter increases expression in the presence of IFN- γ .

Tissue specific promoters can be used, particularly if expression is in cells in which expression of an antigen is desirable, such as dendritic cells or macrophages. The mammalian MHC I and MHC II promoters are examples of such tissue-specific promoters. 2. Initiation Signals and Internal Ribosome Binding Sites (IRES)

5 A specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be "in-frame" with the
10 reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic and may be operable in bacteria or mammalian cells. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements.

In certain embodiments of the invention, the use of internal ribosome entry sites (IRES)
15 elements are used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988). IRES elements from two members of the picornavirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well an IRES from a mammalian message (Macejak and
20 Sarnow, 1991). IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message (see U.S. Patents 5,925,565 and
25 5,935,819, herein incorporated by reference).

2. Multiple Cloning Sites

Vectors can include a multiple cloning site (MCS), which is a nucleic acid region that contains multiple restriction enzyme sites, any of which can be used in conjunction with standard recombinant technology to digest the vector. (See Carbonelli et al, 1999, Levenson et al,
30 1998, and Cocea, 1997, incorporated herein by reference.) Frequently, a vector is linearized or fragmented using a restriction enzyme that cuts within the MCS to enable exogenous sequences to be ligated to the vector. Techniques involving restriction enzymes and ligation reactions are well known to those of skill in the art of recombinant technology.

3. Splicing Sites

Most transcribed eukaryotic RNA molecules will undergo RNA splicing to remove introns from the primary transcripts. If relevant in the context of vectors of the present invention, vectors containing genomic eukaryotic sequences may require donor and/or acceptor splicing sites to ensure proper processing of the transcript for protein expression. (See Chandler et al, 1997, incorporated herein by reference.)

4. Termination Signals

The vectors or constructs of the present invention will generally comprise at least one termination signal. A "termination signal" or "terminator" is comprised of the DNA sequences involved in specific termination of an RNA transcript by an RNA polymerase. Thus, in certain embodiments a termination signal that ends the production of an RNA transcript is contemplated. A terminator may be necessary in vivo to achieve desirable message levels.

In eukaryotic systems, the terminator region may also comprise specific DNA sequences that permit site-specific cleavage of the new transcript so as to expose a polyadenylation site.

This signals a specialized endogenous polymerase to add a stretch of about 200 A residues (poly A) to the 3' end of the transcript. RNA molecules modified with this polyA tail appear to be more stable and are translated more efficiently. Thus, in other embodiments involving eukaryotes, it is preferred that that terminator comprises a signal for the cleavage of the RNA, and it is more preferred that the terminator signal promotes polyadenylation of the message.

Terminators contemplated for use in the invention include any known terminator of transcription described herein or known to one of ordinary skill in the art, including but not limited to, for example, the bovine growth hormone terminator or viral termination sequences, such as the SV40 terminator. In certain embodiments, the termination signal may be a lack of transcribable or translatable sequence, such as due to a sequence truncation.

5. Polyadenylation Signals

In expression, particularly eukaryotic expression (as is relevant in nucleic acid vaccination), one will typically include a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and/or any such sequence may be employed. Preferred embodiments include the SV40 polyadenylation signal and/or the bovine growth hormone polyadenylation signal, convenient and/or known to function well in various target cells.

Polyadenylation may increase the stability of the transcript or may facilitate cytoplasmic transport.

6. Origins of Replication

In order to propagate a vector in a host cell, it may contain one or more origins of replication sites (often termed "on"), which is a specific nucleic acid sequence at which replication is initiated. Alternatively an autonomously replicating sequence (ARS) can be employed if the host cell is yeast.

7. Selectable and Screenable Markers

In certain embodiments of the invention, cells containing a nucleic acid construct of the present invention may be identified in vitro or in vivo by encoding a screenable or selectable marker in the expression vector. When transcribed and translated, a marker confers an identifiable change to the cell permitting easy identification of cells containing the expression vector. Generally, a selectable marker is one that confers a property that allows for selection. A positive selectable marker is one in which the presence of the marker allows for its selection, while a negative selectable marker is one in which its presence prevents its selection. An example of a positive selectable marker is a drug resistance marker.

Usually the inclusion of a drug selection marker aids in the cloning and identification of transformants, for example, markers that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin or histidinol are useful selectable markers. In addition to markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions, other types of markers including screenable markers such as GFP for colorimetric analysis. Alternatively, screenable enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be utilized. One of skill in the art would also know how to employ immunologic markers that can be used in conjunction with FACS analysis. The marker used is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a protein of the invention. Further examples of selectable and screenable markers are well known to one of skill in the art.

The transformed cells of the invention

Transformed cells of the invention are useful as organisms for producing the polypeptide of the invention, but also as simple "containers" of nucleic acids and vectors of the invention.

Certain transformed cells of the invention are capable of replicating the nucleic acid fragment defined for option i) of the second aspect of the invention. Preferred transformed cells of the invention are capable of expressing the nucleic acid fragment defined for option i).

- 5 For recombinant production it is convenient, but not a prerequisite that the transformed cell according is prokaryotic, such as a bacterium, but generally both prokaryotic cells and eukaryotic cells may be used.

Suitable prokaryotic cells are bacterial cells selected from the group consisting of *Escherichia* (such as *E. coli*), *Bacillus* (e.g. *Bacillus subtilis*), *Salmonella*, and *Mycobacterium* (preferably non-pathogenic, e.g. *M. bovis* BCG).

- 10 Eukaryotic cells can be in the form of yeasts (such as *Saccharomyces cerevisiae*) and protozoans. Alternatively, the transformed eukaryotic cells are derived from a multicellular organism such as a fungus, an insect cell, a plant cell, or a mammalian cell.

- 15 For production purposes, it is advantageous that the transformed cell of the invention is stably transformed by having the nucleic acid defined above for option i) stably integrated into its genome, and in certain embodiments it is also preferred that the transformed cell secretes or carries on its surface the polypeptide of the invention, since this facilitates recovery of the polypeptides produced. A particular version of this embodiment is one where the transformed cell is a bacterium and secretion of the polypeptide of the invention is into the periplasmic space.

- 20 As noted above, stably transformed cells are preferred – these i.a. allows that cell lines comprised of transformed cells as defined herein may be established – such cell lines are particularly preferred aspects of the invention.

Further details on cells and cell lines are presented in the following:

- 25 Suitable cells for recombinant nucleic acid expression of the nucleic acid fragments of the present invention are prokaryotes and eukaryotes. Examples of prokaryotic cells include *E. coli*; members of the *Staphylococcus* genus, such as *S. epidermidis*; members of the *Lactobacillus* genus, such as *L. plantarum*; members of the *Lactococcus* genus, such as *L. lactis*; members of the *Bacillus* genus, such as *B. subtilis*; members of the *Corynebacterium* genus such as *C. glutamicum*; and members of the *Pseudomonas* genus such as *Ps. fluorescens*.
30 Examples of eukaryotic cells include mammalian cells; insect cells; yeast cells such as members of the *Saccharomyces* genus (e.g. *S. cerevisiae*), members of the *Pichia* genus (e.g. *P. pastoris*), members of the *Hansenula* genus (e.g. *H. polymorpha*), members of

the *Kluyveromyces* genus (e.g. *K. lactis* or *K. fragilis*) and members of the *Schizosaccharomyces* genus (e.g. *S. pombe*).

Techniques for recombinant gene production, introduction into a cell, and recombinant gene expression are well known in the art. Examples of such techniques are provided in references such as Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-2002, and Sambrook et al., Molecular Cloning, A Laboratory Manual, 2 nd Edition, Cold Spring Harbor Laboratory Press, 1989.

As used herein, the terms "cell," "cell line," and "cell culture" may be used interchangeably. All of these terms also include their progeny, which is any and all subsequent generations. It is understood that all progeny may not be identical due to deliberate or inadvertent mutations. In the context of expressing a heterologous nucleic acid sequence, "host cell" refers to a prokaryotic or eukaryotic cell, and it includes any transformable organism that is capable of replicating a vector or expressing a heterologous gene encoded by a vector. A host cell can, and has been, used as a recipient for vectors or viruses. A host cell may be "transfected" or "transformed," which refers to a process by which exogenous nucleic acid, such as a recombinant protein-encoding sequence, is transferred or introduced into the host cell. A transformed cell includes the primary subject cell and its progeny.

Host cells may be derived from prokaryotes or eukaryotes, including bacteria, yeast cells, insect cells, and mammalian cells for replication of the vector or expression of part or all of the nucleic acid sequence(s). Numerous cell lines and cultures are available for use as a host cell, and they can be obtained through the American Type Culture Collection (ATCC), which is an organization that serves as an archive for living cultures and genetic materials (www.atcc.org) or from other depository institutions such as Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). An appropriate host can be determined by one of skill in the art based on the vector backbone and the desired result. A plasmid or cosmid, for example, can be introduced into a prokaryote host cell for replication of many vectors or expression of encoded proteins. Bacterial cells used as host cells for vector replication and/or expression include *Staphylococcus* strains, DH5 α , JM109, and KC8, as well as a number of commercially available bacterial hosts such as SURE(R) Competent Cells and SOLOPACK(TM) Gold Cells (STRATAGENE®, La Jolla, CA). Alternatively, bacterial cells such as *E. coli* LE392 could be used as host cells for phage viruses. Appropriate yeast cells include *Saccharomyces cerevisiae*, *Saccharomyces pombe*, and *Pichia pastoris*.

Examples of eukaryotic host cells for replication and/or expression of a vector include HeLa, NIH3T3, Jurkat, 293, Cos, CHO, Saos, and PC12. Many host cells from various cell types and organisms are available and would be known to one of skill in the art. Similarly, a viral vector

may be used in conjunction with either a eukaryotic or prokaryotic host cell, particularly one that is permissive for replication or expression of the vector.

Some vectors may employ control sequences that allow it to be replicated and/or expressed in both prokaryotic and eukaryotic cells. One of skill in the art would further understand the conditions under which to incubate all of the above described host cells to maintain them and to permit replication of a vector. Also understood and known are techniques and conditions that would allow large-scale production of vectors, as well as production of the nucleic acids encoded by vectors and their cognate polypeptides, proteins, or peptides.

Expression Systems

Numerous expression systems exist that comprise at least a part or all of the compositions discussed above. Prokaryote- and/or eukaryote-based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.

The insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, such as described in U.S. Patents 5,871,986, 4,879,236, both herein incorporated by reference, and which can be bought, for example, under the name MAXBAC® 2.0 from INVITROGEN® and BACPACK™ Baculovirus expression system from CLONTECH®

In addition to the disclosed expression systems of the invention, other examples of expression systems include STRATAGENE®'s COMPLETE CONTROL™ Inducible Mammalian Expression System, which involves a synthetic ecdysone-inducible receptor, or its pET Expression System, an E. coli expression system. Another example of an inducible expression system is available from INVITROGEN®, which carries the T-REX™ (tetracycline-regulated expression) System, an inducible mammalian expression system that uses the full-length CMV promoter. INVITROGEN® also provides a yeast expression system called the Pichia methanolica Expression System, which is designed for high-level production of recombinant proteins in the methylotrophic yeast Pichia methanolica. One of skill in the art would know how to express a vector, such as an expression construct, to produce a nucleic acid sequence or its cognate polypeptide, protein, or peptide.

Amplification of Nucleic Acids

Nucleic acids used as a template for amplification may be isolated from cells, tissues or other samples according to standard methodologies (Sambrook et al, 2001). In certain embodiments, analysis is performed on whole cell or tissue homogenates or biological fluid samples without substantial purification of the template nucleic acid. The nucleic acid may be genomic DNA or fractionated or whole cell RNA. Where RNA is used, it may be desired to first convert the RNA to a complementary DNA.

The term "primer," as used herein, is meant to encompass any nucleic acid that is capable of priming the synthesis of a nascent nucleic acid in a template-dependent process. Typically, primers are oligonucleotides from ten to twenty and/or thirty base pairs in length, but longer sequences can be employed. Primers may be provided in double-stranded and/or single-stranded form, although the single-stranded form is preferred.

Pairs of primers designed to selectively hybridize to nucleic acids corresponding to sequences of genes identified herein are contacted with the template nucleic acid under conditions that permit selective hybridization. Depending upon the desired application, high stringency hybridization conditions may be selected that will only allow hybridization to sequences that are completely complementary to the primers. In other embodiments, hybridization may occur under reduced stringency to allow for amplification of nucleic acids containing one or more mismatches with the primer sequences. Once hybridized, the template-primer complex is contacted with one or more enzymes that facilitate template-dependent nucleic acid synthesis. Multiple rounds of amplification, also referred to as "cycles," are conducted until a sufficient amount of amplification product is produced.

The amplification product may be detected or quantified. In certain applications, the detection may be performed by visual means. Alternatively, the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of incorporated radiolabel or fluorescent label or even via a system using electrical and/or thermal impulse signals (Bellus, 1994).

A number of template dependent processes are available to amplify the oligonucleotide sequences present in a given template sample. One of the best known amplification methods is the polymerase chain reaction (referred to as PCR(TM)) which is described in detail in U.S. Patents 4,683,195, 4,683,202 and 4,800,159, and in Innis et al., 1988, each of which is incorporated herein by reference in their entirety.

Alternative methods for amplification of target nucleic acid sequences that may be used in the practice of the present invention are disclosed in U.S. Patents 5,843,650, 5,846,709, 5,846,783, 5,849,546, 5,849,497, 5,849,547, 5,858,652, 5,866,366, 5,916,776, 5,922,574, 5,928,905, 5,928,906, 5,932,451, 5,935,825, 5,939,291 and 5,942,391, GB Application No. 2 202 328, and in PCT Application No. PCT/US89/01025, each of which is incorporated herein by reference in its entirety.

Methods of Gene Transfer

Suitable methods for nucleic acid delivery to effect expression of compositions of the present invention are believed to include virtually any method by which a nucleic acid (e.g., DNA, including viral and nonviral vectors) can be introduced into a cell, a tissue or an organism, as described herein or as would be known to one of ordinary skill in the art. Such methods include, but are not limited to, direct delivery of DNA such as by injection (U.S. Patents 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466 and 5,580,859, each incorporated herein by reference), including microinjection (Harland and Weintraub, 1985; U.S. Patent 5,789,215, incorporated herein by reference); by electroporation (U.S. Patent No. 5,384,253, incorporated herein by reference); by calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe et al., 1990); by using DEAE dextran followed by polyethylene glycol (Gopal, 1985); by direct sonic loading (Fechheimer et al, 1987); by liposome mediated transfection (Nicolau and Sene, 1982; Fraley et al, 1979; Nicolau et al, 1987; Wong et al, 1980; Kaneda et al, 1989; Kato et al, 1991); by microprojectile bombardment (PCT Application Nos. WO 94/09699 and 95/06128; U.S. Patents 5,610,042; 5,322,783 5,563,055, 5,550,318, 5,538,877 and 5,538,880, and each incorporated herein by reference); by agitation with silicon carbide fibers (Kaeppler et al, 1990; U.S. Patents 5,302,523 and 5,464,765, each incorporated herein by reference); by Agrobacterium mediated transformation (U.S. Patents 5,591,616 and 5,563,055, each incorporated herein by reference); or by PEG mediated transformation of protoplasts (Omirulleh et al, 1993; U.S. Patents 4,684,611 and 4,952,500, each incorporated herein by reference); by desiccation/inhibition mediated DNA uptake (Potrykus et al, 1985). Through the application of techniques such as these, organelle(s), cell(s), tissue(s) or organism(s) may be stably or transiently transformed.

The antibodies of the invention – and their production/isolation

Antibodies directed against the proteins of the invention are useful for affinity chromatography, immunoassays, and for distinguishing/identifying *Klebsiella* proteins as well as for passive immunisation and therapy.

Antibodies to the proteins of the invention, both polyclonal and monoclonal, may be prepared by conventional methods. In general, the protein is first used to immunize a suitable animal, preferably a mouse, rat, rabbit or goat. Rabbits and goats are preferred for the preparation of polyclonal sera due to the volume of serum obtainable, and the availability of labeled anti-rabbit and anti-goat antibodies. Immunization is generally performed by mixing or emulsifying the protein in saline, preferably in an adjuvant such as Freund's complete adjuvant, and injecting the mixture or emulsion parenterally (generally subcutaneously or intramuscularly). A dose of 50-200 µg/injection is typically sufficient. Immunization is generally boosted 2-6 weeks later with one or more injections of the protein in saline, preferably using Freund's incomplete adjuvant. One may alternatively generate antibodies by *in vitro* immunization using methods known in the art, which for the purposes of this invention is considered equivalent to *in vivo* immunization. Polyclonal antiserum is obtained by bleeding the immunized animal into a glass or plastic container, incubating the blood at 25 C for one hour, followed by incubating at 4 C for 2-18 hours. The serum is recovered by centrifugation (eg. 1,000 g for 10 minutes). About 20-50 ml per bleed may be obtained from rabbits.

Monoclonal antibodies are prepared using the standard method of Kohler & Milstein [Nature (1975) 256 : 495-96], or a modification thereof. Typically, a mouse or rat is immunized as described above. However, rather than bleeding the animal to extract serum, the spleen (and optionally several large lymph nodes) is removed and dissociated into single cells. If desired, the spleen cells may be screened (after removal of nonspecifically adherent cells) by applying a cell suspension to a plate or well coated with the protein antigen. B-cells expressing membrane-bound immunoglobulin specific for the antigen bind to the plate, and are not rinsed away with the rest of the suspension. Resulting B-cells, or all dissociated spleen cells, are then induced to fuse with myeloma cells to form hybridomas, and are cultured in a selective medium (e.g. hypoxanthine, aminopterin, thymidine medium, "HAT"). The resulting hybridomas are plated by limiting dilution, and are assayed for production of antibodies, which bind specifically to the immunizing antigen (and which do not bind to unrelated antigens). The selected MAb-secreting hybridomas are then cultured either *in vitro* (eg. in tissue culture bottles or hollow fiber reactors), or *in vivo* (as ascites in mice).

If desired, the antibodies (whether polyclonal or monoclonal) may be labeled using conventional techniques. Suitable labels include fluorophores, chromophores, radioactive atoms (particularly ³²P and ¹²⁵I), electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert 3,3', 5,5'-tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer. "Specific binding partner" refers to a protein capable of binding a ligand molecule with high

specificity, as for example in the case of an antigen and a monoclonal antibody specific therefor. Other specific binding partners include biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. It should be understood that the above description is not meant to categorize the various labels into distinct classes, as the same label may serve in several different modes. For example, 1151 may serve as a radioactive label or as an electron-dense reagent. HRP may serve as enzyme or as antigen for a MAb. Further, one may combine various labels for desired effect. For example, MAbs and avidin also require labels in the practice of this invention: thus, one might label a MAb with biotin, and detect its presence with avidin labeled with, 125I, or with an anti-biotin MAb labeled with HRP. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the instant invention.

According to the invention, the isolated monoclonal antibody or antibody analogue is preferably a monoclonal antibody selected from a multi-domain antibody such as a murine antibody, a chimeric antibody such as a humanized antibody, a fully human antibody, and single-domain antibody of a llama or a camel, or which is an antibody analogue selected from a fragment of an antibody such as an Fab or an F(ab')₂, an scFV; cf. also the definition of the term "antibody" presented above.

Compositions of the invention; vaccines

Pharmaceutical compositions, in particular vaccines, according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie, to treat disease after infection).

Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid(s), usually in combination with "pharmaceutically acceptable carriers", which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition.

In some embodiments of the invention, the pharmaceutical compositions such as vaccines include merely one single antigen, immunogen, polypeptide, protein, nucleic acid or vector of the invention, but in other embodiments, the pharmaceutical compositions comprise "cocktails" of the antigens or of the immunogens or of the polypeptides or of the protein or of the nucleic acids or of the vectors of the invention.

In particularly interesting embodiments, the pharmaceutical composition is an MVA vector mentioned herein, which encodes and can effect expression of at least 2 nucleic acid fragments of the invention.

Another interesting embodiment of a pharmaceutical composition comprises RNA as the active principle, i.e. at least one mRNA encoding a polypeptide of the invention.

An embodiment of a pharmaceutical composition of the invention comprises Y or at least Y or at most Y distinct polypeptides of the invention described above, where each of said Y or at least Y or at most Y distinct polypeptides comprises an immunogenic amino acid sequence present in or derived from any one of SEQ ID NOs: 1-30 and wherein said Y or at least Y or at most Y distinct polypeptides together comprise immunogenic amino acid sequences present in or derived from Y or at least Y or at most Y of SEQ ID NOs: 1-30, 93 or 94, wherein Y is an integer selected from 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, and 32.

Another embodiment of the pharmaceutical composition of the invention comprises Z or at least Z or at most Z distinct nucleic acid molecules (such as DNA and RNA) each encoding a polypeptide of the invention, where each of said Z or at least Z or at most Z distinct nucleic acid molecules encodes an immunogenic amino acid sequence present in or derived from any one of SEQ ID NOs: 1-30, 93, or 94 and wherein said at Z or least Z distinct nucleic acid molecules together encode immunogenic amino acid sequences present in or derived from Z or at least Z or at most Z of SEQ ID NOs: 1-30, 93, or 94, wherein Z is an integer selected from 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, and 32.

Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles.

Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, etc. pathogen, cf. the description of immunogenic carriers supra.

The pharmaceutical compositions of the invention thus typically contain an immunological adjuvant, which is commonly an aluminium based adjuvant or one of the other adjuvants described in the following:

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59 (WO 90/14837; Chapter 10 in Vaccine design: the subunit and adjuvant approach, eds. Powell & Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA), (b) SAF, containing 10% Squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-

MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphoryl lipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); (3) saponin adjuvants such as Stimulon™ (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (eg. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (eg. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; and (6) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59™ adjuvants are preferred.

As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2"-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.

The immunogenic compositions (eg. the immunising antigen or immunogen or polypeptide or protein or nucleic acid, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or

encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.

Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic or immunogenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (eg. nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies or generally mount an immune response, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. However, for the purposes of protein vaccination, the amount administered per immunization is typically in the range between 0.5 μ g and 500 mg (however, often not higher than 5,000 μ g), and very often in the range between 10 and 200 μ g.

The immunogenic compositions are conventionally administered parenterally, eg, by injection, either subcutaneously, intramuscularly, or transdermally/transcutaneously (eg. W098/20734). Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. In the case of nucleic acid vaccination, also the intravenous or intraarterial routes may be applicable.

Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

As an alternative to protein-based vaccines, DNA vaccination (also termed nucleic acid vaccination or gene vaccination) may be used [eg. Robinson & Torres (1997) Seminars in Immunol 9: 271-283; Donnelly et al. (1997) Annu Rev Immunol 15 : 617-648; later herein].

A further aspect of the invention is as mentioned above the recognition that combination vaccines can be provided, wherein 2 or more antigens disclosed herein are combined to enhance the immune response by the vaccinated animal, including to optimize initial immune response and duration of immunity. For the purposes of this aspect of the invention, multiple antigenic fragments derived from the same, longer protein can also be used, such as the use of a combination of different lengths of polypeptide sequence fragments from one protein.

Thus, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 1 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
5 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 2 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
10 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed
15 herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 3 or a variant or fragment thereof
20 disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 4 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
25 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed
30 herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein
35 wherein the first of said immunogens is SEQ ID NO: 5 or a variant or fragment thereof

disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 6 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 7 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 8 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 9 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed

herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein

5 wherein the first of said immunogens is SEQ ID NO: 10 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
10 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein

wherein the first of said immunogens is SEQ ID NO: 11 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
15 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein

20 wherein the first of said immunogens is SEQ ID NO: 12 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
25 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein

wherein the first of said immunogens is SEQ ID NO: 13 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
30 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 14 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
5 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 3, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 15 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
10 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed
15 herein of any one of SEQ ID NOs: 1, 3, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 16 or a variant or fragment thereof
20 disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 17 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
25 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed
30 herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein
35 wherein the first of said immunogens is SEQ ID NO: 18 or a variant or fragment thereof

disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 19 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 20 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 21 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 22 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed

herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein

5 wherein the first of said immunogens is SEQ ID NO: 23 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
10 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein

wherein the first of said immunogens is SEQ ID NO: 24 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
15 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein

20 wherein the first of said immunogens is SEQ ID NO: 25 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed
25 herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein

wherein the first of said immunogens is SEQ ID NO: 26 or a variant or fragment thereof
30 disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 27 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
5 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 28 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
10 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed
15 herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 29 or a variant or fragment thereof
20 disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 30 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of
25 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed
30 herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein
35 wherein the first of said immunogens is SEQ ID NO: 93 or a variant or fragment thereof

disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Also, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens is SEQ ID NO: 94 or a variant or fragment thereof disclosed herein in combination with a proteinaceous immunogen selected from any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94 or in combination with a variant or fragment disclosed herein of any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 93, and 94.

Treatment methods of the invention

The method of the sixth aspect of the invention generally relates to induction of immunity and as such also entails method that relate to treatment, prophylaxis and amelioration of disease.

When immunization methods entail that a polypeptide of the invention or a composition comprising such a polypeptide is administered the animal (e.g. the human) typically receives between 0.5 and 5,000 µg of the polypeptide of the invention per administration.

In preferred embodiments of the sixth aspect, the immunisation scheme includes that the animal (e.g. the human) receives a priming administration and one or more booster administrations.

Preferred embodiments of the 6th aspect of the invention comprise that the administration is for the purpose of inducing protective immunity against *K. pneumoniae*. In this embodiment it is particularly preferred that the protective immunity is effective in reducing the risk of attracting infection with *K. pneumoniae* or is effective in treating or ameliorating infection with *K. pneumoniae*.

As mentioned herein, the preferred vaccines of the invention induce humoral immunity, so it is preferred that the administration is for the purpose of inducing antibodies specific for *K.*

pneumoniae and wherein said antibodies or B-lymphocytes producing said antibodies are subsequently recovered from the animal.

But, as also mentioned the method of the 6th aspect may also be useful in antibody production, so in other embodiments the administration is for the purpose of inducing antibodies specific for *K. pneumoniae* and wherein B-lymphocytes producing said antibodies are subsequently recovered from the animal and used for preparation of monoclonal antibodies.

Pharmaceutical compositions can as mentioned above comprise polypeptides, antibodies, or nucleic acids of the invention. The pharmaceutical compositions will comprise a therapeutically effective amount thereof.

The term "therapeutically effective amount" or "prophylactically effective amount" as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. Reference is however made to the ranges for dosages of immunologically effective amounts of polypeptides, cf. above.

However, the effective amount for a given situation can be determined by routine experimentation and is within the judgement of the clinician.

For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids,

polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N. J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

As is apparent from the claims, the invention also relates to related embodiments to the treatment and prophylaxis disclosed herein: the invention also includes embodiments where

- the polypeptide of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *K. pneumoniae*;

- the nucleic acid fragment of the invention or the vector of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *K. pneumoniae*;

- the transformed cell of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *K. pneumoniae*.

- the antibody, antibody fragment or antibody analogue of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *K. pneumoniae*.

SEQUENCE INFORMATION

The sequence listing included sets forth the sequences of polypeptides and nucleic acids of the present invention. For easy reference, the sequences are presented in the following:

The polypeptides of the invention have or derive from the following amino acid sequences:

5 SEQ ID NO:1

MKKLALLSAVMTLGMSSWAFAADNPPPPPEKGAQHQGKPPVKNQHEGKQAQYNRKQPQRDQKQPQH
DQKQPQHNGKQPPKGSEHSGKPLPPKA

SEQ ID NO:2

MKRYATALLFCTLSLTSLAARADIIDDAIGNIQQAINDAYNPGSSRSDDDDRYDDDDGRYDDGRYQGSQ
10 QSRDSQRQYDERQRQLDERRRQLDERQRQLDRDRRQLESQRRLLDDSY

SEQ ID NO:3

MFRSLILAAVLLAAGPLVANAGEITLLPSVKLQIGDRDNYGNYWDGGSWRDRDYWRRHYEWRDNRWHR
HDNGWHKGWYKGRDKAWERGYRAGWNRDDHRGGWGRGPGGRGHGHGHGH

SEQ ID NO:4

15 MKEIGLPLLLLTALASPAFAADCQPNGIGGSFCINDGTTTTDTPNEVNGMDTYSNNGGYTSSLPDRSGA
DEALEGSSLSTQQGVGSGQSDSALAGRDWHSPANLNDGAATSSMSLLDKP

SEQ ID NO:5

MNMKKLTLLLTATLGLASGAALAADTGAQSNNGQANSSADAGQVAPDARENVAPNNVDNSQINSGSG
GTTGSTMTQDNMSSNEVHKNSMCKDGRCPDTGKKLDNGGNTTQDNSKTDGTTQ

20 SEQ ID NO:6

MKHRIALLLVLTSLASALAASPCQEKEQDIQREISYAEKHHNQSRIDGLNTALRQVRENCSDSKLKADH
QQKIAKQREEIAERQRDLQEARKKGDADKINKRQHKLNEAQQELKTLESRDY

SEQ ID NO:7

25 MRLITRHVREDIMKKAMIALSAILVAAPVFAATTHATDDTVAAANANANTAKEKLHQAQHEGEEQQLKAK
HAAEGKQDSVGSQVSEGAQKTWNKTKEGTEKGWDKTEVSEKGWNATKSGAEGWDKTKTGAEELK
NKVTE

SEQ ID NO:8

MKKMISLAVILSCVLSVPAFADGPNRGHRPEQPTVWQNGPDHDGHAPQGGPDAHHQGDHDQRGPD RD

GHDKRDLARHEQDHFARWGNDFRKGHPAPAPFRGDEYRVRDWSRGLPPPPEGHHWSYIDGNYVLIAA
ATGIITSILVSGALGH

SEQ ID NO:9

MKKPTSATRGKSGRKSREELNQEARDRKRQKKHRGHAAGSRANGGDAASAGKKQRQAQDPRVGSKKP
5 IPLGVSESSVPAPKQHKPKSEKPMMLSPQAELELLENDERLDALLERLEEGGTLNAAEQSWVDAKLDRIDEL
MQLGLSYDDEDEEEEEERQEDMMRLLKGGN

SEQ ID NO:10

MASKFQNRVLVTIVLVALGVILPGLLDGQKKHYQDEFAAIPLVPKPGDRDEPDMLPAATQALPSQPPEGA
AEEVRAGDAAAPSLDPSRIPVNSNSFDDVQEPVVAAPKPKPQPKPQPPQASTPTPPPAKPPQPPQ
10 QQAALPAPTGKAYVVQLGALKNADKVNEIVGKLRASGFKVYTSPSTPVQGKITRILVGPDAKDKLKGQL
GDLQQISGLSGVVMGFTPN

SEQ ID NO:11

MAQRDYVRRSQPASSRRKKSTTRSSRNKQSSLPASIPAMVAIAAAVLVAFIGGLYFITHHKKEEAEMQN
RQAAGNGLPPKPEERWRYIKELESRQPGVRAPTEPTAGGEVMKPEQLTDEQRQLLAQMQADMRQQPTQL
15 TEVPWNEQTPAQRQQTLQRQLAQQQQQAQQQWAQTQAQTVQQPPRVQQPKPVQQQPKQTAS
NQQPYQDLLQTPAHTNTTQPRTQAAAPVTRVEEAPKTTAEKKDDRSWMIQCGSFKGAEQAETVRAQLAF
EGFASHITTNGWNRVVIGPLKGKESANEMITRLKMAGHANCIRLAARG

SEQ ID NO:12

MSAGSTKFTVSRIAALSLVSLWLAGCTNTNNPPAPVSSAGGAASSSTNSGMLITPPPSGVKSAPQAQPIQ
20 PMQTQTIQAPVAQEPVQTVNGRIVYNRKYGDIPKGSYTGSTYTVKRGDTLFYIAWVTGNDFRDLAQRN
NIPAPYALNVGQVLQVGNASGQPITGENAVSQASARASGGATTSTTSAQKSTAVVASQPTITYSESSGEQ
SATKMLPNKPATTTTTTVVAPVTAPTSTTQPTASSTSTSSPISAWRWPTDGKVIENFSGAEGGNKGIDI
AGSKGQAIATADGRVVYAGNALRGYGNLIIKHNDYLSAYAHNDTMLVREQQEVKAGQKIATMGSTG
TSSTRLHFEIRYKGKSVNPLQYLPQR

25 SEQ ID NO:13

MRKQWLICIAAGLLAACSSDDVQKTVSTPQPAVCNGPTVEISGADPQYETPNATANQDYERDGSYK
IVQDPANFTQAGFAAIYDAEPNSNLTAAGEAFDPTQLTAAHPTLIPSYARITNLANGRMIVVRINDRGPYG
NDRVISLSRASADRLNTSNNTKVRIDPIIVAPDGSLSGPGMACTTVAKQTYALPARPNLDGGDAAGMSQP
APT DVRPISNSTLTADSVGAPVNSGGFLGAPTPLNNGVLESSEPAATAAAGATPTAPVTAPGSIQG
30 NVVPAAATAAAGAVAASSSATSSASGNFVVQVGAVSDQTRAQQYQQRLSQQFSVPGRVMQNGAVWR
IQLGPFADKAQASAVQQRLQSEAQLQSFITRAN

SEQ ID NO:14

MDDFKPEDDMKADRNDRRAGRSRQSSERDADPQINFDDVDLDADEGRPTRAGKARREREEEEFEELD

AQDEEMLEEQPVERRPRKRKKAPAKPASRQYIMMGVILVLLLLLIVGIGSALKSPSSSSSQQTASGEKSINL
SDDQSASMPAAGQDQTAAANSTSQQDVTVPPIAANPTQGQAAVAPQGQQRIEVQGDLLNALTQQQGGQ
LDGAVANSTLPTPATVAPIRNGANGTAAPRQATERQTAATPRPAERKHTVIEAKPQSKPQAVAKTPVESK
PVQPKHVESTATTAPAKTSVSESKPVATAQSKPTTTTAAAPAATAAAAAAPAAKTGKTAGDVSSMKTAPSGH
5 YTLQLSSSSNYDNLNNWAKKEKLDKYVVYETSRNGQPWYVLVSGIYASKDEAKRAVTSLPADVQAKNPW
AKPLHQVQADLK

SEQ ID NO:15

MSKATEQNDKLRARIIISVALHIILIALLIWSSFDEHLDASAGGGGGSSIDAVMVDPGAVNNYNRQQQQ
QASARRAAEQREKQAQQQAEELREKQAAEQERLKQLEQERLQAQEAAKEAKEQQKQAEAAAAKAAAAA
10 KAKADAQAKEAQEAAAKAAAEAKAKADAQAKAAEQAAAKAAADAKKQAEAAAKAAAEAKKQAEAEAA
KAAAEAQKKAEEAAAKKAQQEAEKKAQQEAAKQAAAEKAAAEKAAAEKAAAEKAAAEKAAAEK
AAAAKAAAEKAAADKAAKAAAKAAAKKAAAKAAAEADGVDNLLGDLSSGKNAPKTGGGAKGNNASAA
GSGNTKNSASGADINNYAGQIKSAIESKFYDASSYAGKTCTLRILAPDGLLLNIQSEGGDPALCQAALAA
ARQAKFPKPPSQAVYEVFKNAPLDFKPQ

15 SEQ ID NO:16

MFFLSIFYMEMTKVKLSALFIALIPLLGSPIHAETTAAPVLENRAAQGDITTPGGARRLTGDQTEALRASLI
NPKAKNVILLIGDGMGDSEITAARNYAEGAGGFFKGIDALPLTGQYTHYSLDKKTGKPDYVTDASAATA
WTTGVKTYNGALGVDIHENAHQTILELAKAAGLATGNVSTAEQDATPAALVAHVTSRKYGPTVTSEKC
PSNALEKGGKGSITEQLLNARPDVTLGGGAKTFTETATAGEWQGKTLREQAARGYQIVTDAASLAAATE
20 ASQDKPLLGLFADGNMMPVRWEGPKASYHGNIDKPPVTCTPNPKRDASVPTLAQMTEKAIDLLSRNEKGFF
LQVEGASIDKQDHAANPCGQIGETVDLDEAVQKALEFARKDGNTLVIVTADHAHASQIIPADSKAPGLTQ
ALNTHDGAVMVMSYGNSEESMEHTGTQLRIAAYGPHAANVVGLTDQTDLFTTMKAALSLK

SEQ ID NO:17

MSLPFKPHIALLCSAGLLAAAGTLYVQSRTPATIAEPPAQAPAPAASTTQPVAATYTQAQIDQWVAPIAL
25 YPDSLLSQVLMASTYPDNLQAVQWSQDNPMKGDAAVQAVASQPWDPVSVKSLVAFALLAMMGENPP
WVENLGNAFLAQPHDVMDSVQRLRAIAAQTGTALKSTPQQKVIVTPAAPVSASSSTAATAHTAAPAPTQ
VIKIEPTNPQVVVYPSYNPSTVYGTWPNSAYPPVYLPPPPGEQFTDSFVKFGYSLGVATTWALFSSIDWD
DDDDHHHHDDDDYHHGDYSHNGDNININNVNFNHITGENLPGNHVNWQHNPAYRGHTPYPDNTVAQRFH
QTNVSGGLSATQHAPVDREAQRQAAMTQLQHNVPATAGNLAANNASRDAQRQAASAQLKQATQRSN
30 YRGYDSTPTQQQRREAAKTQLKNPTPQQQRREARSHEQNRTPTQQQQRQQFQSATPAQRQQTLSHL
RANALSGNESRAPSWQAQQERGLQSRQFSGVNRELRDGTRELRSEHHELRRR

SEQ ID NO:18

MFKFKASYVALAAVLTSSVVYADPTSYTHSSGATVIDIEKPNAAGVSHNLYRDFNVGANGTILNNSGDDV
SHSTFGNIARNNNLTAGSASVILNEVTSKNASSLKGFIEVNGQKADVIANPNGITCSGCSFVNTNKAILT
35 TGKVNMTDDGAIGSYTVTGGTLTIGENGMAANGYAVLLADAININGKVQANNALVSAGNFTMDNSSG

SVTSAGKKATLIQMTVNPQYSIDVSSLGGIEANSISMVGNNIGFVVRNKGSIIVANSSSLQLTNSGNLLNKG
TIKSNGLLSQVATASGITNDGSIAGAYYMLSSGDYIVNTGSLSGGQLIATANGNITNGDSGTMTGTSGL
SLTSGGKIRNEEKASLLSNNQIAATAIGDFLNEGKISAKHTSLTFVGDSFKNTGNINSTGQTTIQSLKQDG
SANTGEIYNLGNITGENINLQTNGTLAQSSSGRIEATNAITAHSYWLNQNGYMNAAADITTDHGVVNNYG
5 NITAKNISITTYSDITNEGQISSTGDLTLNTKNKGAIYNYSTLSAGGNMTLTATKVVNGGKSCGILGLAKC
GVGTLTADKLVNLSSQKYVSDMGGKQYFKSTEVNTVK

SEQ ID NO:19

MMDNLRTAANSVVLKIIFGIIIVSFILTVSGYLIGGGKNYAAKVNGQEIGRGQFENAVASERNRMQQQL
GDQFSELAANENYMKTMRQQVLNRLIDESLLDQYARELGLSISDEQVKQAIFQTQAFQTNGKFDNQRFS
10 GIVAQMGMTTDQYAQALRNQLTTQQQLINAIAGTDFMLPGESDQLAALVSQQRVVREATINVNALAAKQT
ASDEEINAFWQQNQARFMAPEQFRVSYIKMDAASMQUESASDEEIQSWYDQHKDQFTQPQRNRYSVIQT
KTEADAKAVLAELQKGADFATLAKEKSTDIISARNGGDMGWMEDASTVPELKDAGLKEKGQLSGVIKSS
VGFLVARLDDVQPAQVKPLADVNRNDIAAKVKQEKALDAYYALQQKVS DAASNDNESLASAAQVAGLKVV
ETGWFGDNLPEELNFKPVADAI FNGGLVGENGAPGSNSDIITVDGDRAFLRISEHKAEAVKPLAEVKA
15 QVSDIVKHNAEQQAKLEADKLLAALKDGKGDEAMKAAGLSFGAPQTL SRTGQDPLSQLAFTLPLPQQG
KPVYGVGSNMQGDVVLVALDEVKAGSMPEEQKKAMVQGITQNNAQIAFEALMSNLRKAAKIKLGDSIDQ
QQ

SEQ ID NO:20

MFRLNPFIRAGLSASVVSLAFPALADVNEETLVVTASATEQNVKDAPASISVITQQDLQRKPVQNLKDVLR
20 DVPGVQLTNEGDNRKGV SIRGLSSSYTLILVDGKRVNSRNAVFRHNDFDLWIPVDAIERIEVVRGPMSS
LYGSDALGGVVNIITKKIGQKWTGTL SADTTIQEHRDRGDTWNGQFFTSGPLIDGVLGMKAYGSLAKRA
KDDPQSSSNATGETPRIEGFTSRDGNVEFAWTPNENHDFTAGYGFDRQDRDSDSLDRNRLERENYSLSH
NGRWDIGNSELKFYGEKVDNKNPGQSGTITSESNAIDGKYVPLGMINQLVTFGGGEWRHDKLKDVPVNL
SGGQSTSASQYALFIEDEWRIIEPLALTTGIRMDDHQTYGDHWS PRAYLVYNATDTVTVKGGWATAFKA
25 PSLLQLNPDWTTNSCRGSCSIVGNPDLKPETSESFELGLYYRGEEGWLENVEGSITTFQNNVDDMIDVLR
TSSASEAPGYPNFVGWKT VNGKRVPIFRYFNVNKARIKGVETE VKIPFGDEWKLT VNYTYNDGRDLSNGG
DKPLQTLPFHTANGTLDWKPLDDWSFYVTANYTGQQRAVSATGKTPGGYTLFDVGA AWQVTKNVKLRS
GVQNVGDKDLSRDDYSYTEEGRRYFMAVDYRF

SEQ ID NO:21

MNRAATLT LNAPLLMLVAALALSTPFTAGAAPFLDYAQQQTQQSQAQEKNDAA SAKQTQESRQSADNK
30 KTGTSTSQLQKRITSQQAIAQKDKLIQQQLKKQLAATPQTD TAGANEQAALNKRINELQVALSAATAEKE
ALIKKAGVVQNNNLQQSQAARQQIQQLTTQIQQA EAENKRLSASF TTLNKDKHALMTQLAATEKEKQA
ALEQVKALNADKQPLTTRLAAAEKEKQAVLEQVKALNADKQSLTIRLAAA EKAQQA AVDQAKALNADKQP
LATRLAAAEKEKQAVLEQVKALSADKQSLTIRLAAA EKAQQAALDQAKALNADKQPLATRLAAAEKEKQA
35 VLEQVKALNADKQSLTIRLAAA EKTQQAALDQVKALNADKQSLSTRLAAADKAPHGPANDAAAPKNEPPE
MAAIVAAYRLQADKDNAQLRMKEDEIELLRTQLSVQSKTRSGESAAAKLSASGEQQAYAIGASMGSEAL

NVLTRRTQGVTVDAGLVLQGIEDAFRGQLRLGEQERNKALFDVSQQVFQNLNKIEQKNISAGKKYQQA
 FARKKDVFKEGVYSRVDYLGKGKISGNLTVVIKEMLTGTVINDMEAKDQALTQKLDAYPPVFREPL
 KRLQNHGSVTLVVPPEKAYGSKGLPPKIPPGATMVYSVRIVDSQPEPAK

SEQ ID NO:22

5 MKILSVRHAALPALLPLIAAAQAADQTMVVTAAPTTVSELDTPAAVSVVNGDEMQRQAAPRVNLSESLGA
 VPGLQVQNRQNYAQDLQLSIRGFGSRSTYGVRLRIYVDGIPATMPDGQGQTSNIDIGSVDTIEVLRGPF
 SALYGNSSGGVINVTSTGTQPTVEASSYGSFGTWHYGMKATGAVGDGSHAGDVDTVSTNRFTTH
 GYRDHSGARKNLANARLGVRLNDVSKLTLNLSVDIKANDAGGLTADEWRDNPRQSPRGDQYNTRKNT
 RQTQAGLRYERQLSAQDDLSVMMYAGERETTQFQSIPRAPQLKPSHAGGVIDLTRHYQGIDTRLTHRGEL
 10 LVPVTLTAGLDYENMSERRKGYENFVMVNGAPQYGEQGalRRNERNLMWNVDPYLQTQWQLTDLKSLD
 AGVRYSSVWFDSNDYYITPGNGDDSGDASYHKWLPAGSLKYALTDawnVYLSAGRGFETPTINELSYRS
 DNQSGLNFGPKPSTNDTVEIGSKTRIGNGLFTAALFQTNTDNEIVVDSSSGGRTSYKNAGKTRRQGMEL
 GLDQQFGESWRLKAAWTWLDATYRTNVCDASCNGNRIPGIARNMGYASFGYQPEQGWYAGSDIRYM
 SDIMANDENTAKAPSWTVVGLTTGYKWSYGRMDMDLFRIDNLFDRYVGSVIVNESNGRYEPAPGRN
 15 YGIGLNLAWRFE

SEQ ID NO:23

MKYTSHFPLGIVIPLLACSVPLQAAENMTEQSTPDESAATAENHEETMVITAARQNLQAPGVSTITAEIIRK
 HPPARDVSELIRTQPGVNLTGNSTSGQRGNRQIDIRGMGPENTLVLDGKPVTSRNSVRYGWRGDRD
 SRGDTSWVPAEMIDHIDVIRGPAAARYGNGAMGGVVNIVTKPTTREWHGSWNTYMNAPQHRKEGATK
 20 RTNFSNLNGLSDSVSFLWGNLSKTQADAQDINAGHEAERTGSYAGSYPAGREGVVNKDIHSLRWEFA
 PMQALEFEAGYSRQGNLYAGDTQNTNTSTLVKSMYGKETNRLYRQTYGVTWTGGWDNGVTSNSYAQYE
 HTRNSRMDEGLAGGTEGIFSSSEFSDIDLADVLLHSEVNIPFTLGVDQNLTLGAewnQQRMKDGVTSTTQ
 ALSYGTIDGVSATGRSPYSSAEIFSLFTEDNMALTDSTMLTPALRFDHHSIVGNWSPSLNLSQELTDDW
 TLKLGIARAYKAPNLYQLNPYILYSNGQGCYASSSACYLMGNSDLKAETSVNKEIGLEYKHDGYQAGIT
 25 WFRNDYHNKIESGYAAVGTASNGTTNIYQWENVPKALVEGLEGLNLPVGEAVNWSNNLTWMLQSKNK
 TTGDRLSVIPQFTLNSTLSWQVREDLSLQSTFTWYGRQKPKRFNYKGEAVSGSELNEVSPYSIVGLSATW
 DVNKNLSFTSGIDNLFDIRHYRAGNAQTTGNATTGAYLYGAGAETYNESGRTFFMSVNTHF

SEQ ID NO:24

MEKNASLPFGSFNSLALFTGLCLGASPAAGIAAENSVKNSEETLVVEAAPPsLYSPGASADPKFNKPLVDT
 30 TRTITVIPEQVIKDQGVNTLTDALKNVPGVGAfYAGENGsSTTGDAIFMRGVDTSNSIYVDGIRDIGSVTR
 DTFNTQQVEVIKGPAGTDYGRSAPSGSINMISKQPRLDsGIDGSASIGSAWSRRGTLdLNQAFSDNAAF
 RLNLmGEKTHDAGRDRiENERYGIAPSLAFGLDTPTRLyLNYLHVRQNNTPDGGIPTVGLPGYSAPSPKYA
 ALNSAGKVDTSNFYGTDSYDKSTTDSGTLRFEHDLTENTTVRNTTRWSRVKQeYLLTAVMGGANnITA
 PDINDVNTWSWSRLVNTKDVSNRILTnQTnITSTfNTGSIGHDVSAGVEFTRENQTNYGVNARTAPAVN
 35 LYHPVSNLSIGGLDRNGANANGQTDTFGIYAFDTLTlTERIEINGGLRLDNYHTKYDSATACGGSGRGAIA
 CPPGQSTGSPVTTVDtAKSGNLVNWKAGALYRLtEQGNVYVNYAISQQPPGGSSfALAASGSGNSANRT

DFKPQKAKSSELGTKWQIFDNRLLLSAAIFRTDIENEVAANDDGTWSQYGKKRVEGYELSATGNLTPDW
TIIAGYTQQHATVTEGQNVAQDGSSALAYTPKHAFTLTWTQYQATSDLSVGGGVRYVGSLLRRGSDGAVGT
PDHTEGYWVADAKLGYRVNSNLDLQLNMYNLFDTDYVASINKSGYRYHPGEPRTFMLTANVHF

SEQ ID NO:25

5 MATMYKSTPSAAWCKKRLVLSLFAAIYQTSIAAADTSASVSGEAVDDTSEQMTVTAPAPVQKAGSEHSIS
ARELENKGANDFGSIMRYEPLISATGASGGSGNGKSGFDRGGYTGYNIRGMESNRVGIDVDGIAQP NAT
GRGYVGRAGLNTFGIGRDYIDPYMYGSVDIQSGATSTETANSAIGGNVSFRPKSADDYLRPGKTSAFGYR
SGYDSADRSWHNGVTVAGGDEFRLRGILVYSRRDGQETENNSGTVDAYPANWHSDAFLASGIWQPNDE
HKLTSTFDYYHKTNHHTHYDTWDSSGNSTIGTANQTSQTRRWGLSLKDDWTPMNDYLDVSTKIYYQHT
10 EAHDWTYMPDSVTRKMQTVNSNYDTDTWGLQTALAKTLGRHDL SAGFNASTSKTQRPFSQSPIPSVYSE
IMQPEADSRSYTLGGFVQDKINFDLDSHNFAVIPGVRVH HQSTKPENLSDLAANSSVLSESSVANLYGKN
SDTQVLP SLTFQYDLTPRLMTYLQYQRGAQFPNASQLYGSWNLGSSYAGSQQYALIGNTDLKTETSDNLE
WGLKGEVTEGITLRTALFYNSYKNFIAYTRYTRANNPQGFTNVPSNIYTIYQAENRDKAYIYGGEISTKFNF
GTWFEQVDGLSATLALGYSEGKSKSSYSGDKYVDLDSVAPMKAIVGVAWDDPAKRYGTALTATFVKGK
15 QATATNRESYSNSGSAITDASSDYMVRPGYGM LDWTAYWQVAKNVRLNGGVYNLTDRKYWDYLSSRNI
ETGTNQDANDKALAVMPGRTWQLGVNVDF

SEQ ID NO:26

MAMKKLLIASLLFSSATVYGAEGFVVKDIHFEGQLQRVAVGAALLSMPVRPGDTVTDDDISNTIRALFATGN
FEDVRVLRDGD TLLVQVKERPTIASITFSGNKSVKDDMLKQNL EASGVRVGESLDRTTIADIEKGLEDFFY
20 SVGKYSASVKAVVTPLPRNRVDLKLVFQEGVSAKIQQINIVGNHAFSTDELISHFQLRDEVPWWNVVD
RKYQKQKLAGDLETLSYLD RGYARFNIDSTQVSLTPDKKGIYITVNITEGDQYKFSGVQVTGNLAGHS
AEIEALTKEVPEGLYNGAKVTKMENDIKKLLGRYGYAYPRVQSQPEINDSDKTVKLHVNV DAGNRYYVRKI
RFEGNDTSKDAVLRREMRQMEGAWLGSDLV DQGKDRNLNRLGFFETVDTDTQRVPGSPDQVDVYKVKE
RNTGSFNFGIGYGTESGVSFQAGVQQDNWLGTGYAVGINGTKNDYQTYTELSVTNPNYFTVDGVSLGGRV
25 FYNDFDANDADLSDYTNKSYGTDITLGFPVNEYNTLRAGVGYVHNSLSNMQPQVAMWRYLNSMGQYPD
NTNDRNSFSANDFTFNYGWYTNKLD RGFPTGSRVNLNGKVTIPGSDNEYKATLDTATYVPIDNDHQ
WVVLGRTRFGYGDGIGGKEMPFYENFYAGGSSTVRGFQSN TIGPKAVYFPASSRHDDDDSYDNECKSTE
SAPCKSDDAVGGNAMAVASLELITPTPFISDKYANSVRTSVFWD MGTVWDTHWDSSAYAGYPDYSDPS
NIRMSAGIAVQWMSPLGPLVFSYAQPFFKKYDGDKAEQFQFNIGKTW

30 SEQ ID NO:27

MTDVTIKALASEIQTSDRLIQQFADAGIRKSADDSVTSQEKQTL LTHLNREHGSA PDKLT LQRKTRSTLN
IPGTGGKSKSVQIEVRKKRTFVKRDPQEAERLAAEEQAQREAE EQARREAEAAKREAQLKAEREAEEQA
KREVADKAKREAAEKDKVSNQHTDEMTKTAQAEKIRRENEAAELKRKSEEEARRKLEEEARRVAEEARR
MAEENEKNWSETSDSPEDSSDYHVTT SQHARQAEDDNDREVEGGRGRSRSSKAARPAKKGNKHAESK
35 ADREEARA AVRGKGKGRKGSALQQGFQKPAQAVNRDVVIGETITVGELANKMAVKGSQVIKAMMKL
GAMATINQVIDQETAQLVAEEMGHKVILRRENELEEAVMSDRDTGAAAEP RAPVVTIMGHVDHGKTSLL

DYIRSTKVASGEAGGITQHIGAYHVETDNGMITFLDTPGHAAFTSMRARGAQATDIVVLVVAADDGVMP
 QTIEAIQHAKAAQVPVVAVNKKIDKPEADPDRVKNELSQYGILPEEWGGESQFVHVSAKAGTGIDDLDA
 ILLQAEVLELKAVRNGMASGAVIESFLDKGRGPVATVLRREGTLHKGDIVLCGFYGRVRAMRDELGREVL
 EAGPSIPVEILGLSGVPAAGDEVTVVRDEKKAREVALYRQKGKREVKLARQQKSKLENMFANMTEGEVHE
 5 VNIVLKADVQGSVEAISDSLLKLSTDEVKVKIIGSGVGGITETDATLAAASNAILVGFNVRADASARKVIEA
 ESLDLRYYSVIYNLIDEVKAAMSGMLSPELKQQIIGLAEVRDVFKSPKFGAIAAGCMVTEGTIKRHNPIRVLR
 DNVVIYEGELESRRFKDDVNEVRNGMECGIGVKNYNDVRVGDMEVFEIIEIQRSID

SEQ ID NO:28

MKRMLINATQQEELRVALVDGQRLYDLIDIESPGHEQKKANIYKKGKITRIEPSLEAAAFVDYGAERHGFPLK
 10 EIAREYFPANYNAHGRPNIKDVLREGQEVIVQIDKEERGNKGAALTTFISLAGSYLVMPNNPRAGGISRRI
 EGDDRTELKEALASLELPDGMGLIVRTAGVGKSAEALQWDLFRLKHWEAIQKAAESRPAPFLIHQESNV
 IVRAFRDYLQRDIGEILIDNPVKLELARQHIAALGRPDFSSKIKLYTGEIPLFSHYQIESQIESAFQREVRLPS
 GGSIVIDSTEALTAIDINSARATRGGDIEETAFNTNLEAADEIARQLRLRDLGGLIVIDFIDMTPVRHQRAV
 ENRLREAVRQDRARIQISHISRFGLLEMSRQRLSPSLGESSHHVCPRCSGTGTVRDNESLSLSILRLIEEE
 15 ALKENTKEVHAIVPPIASVLLNEKRAAVSAIESRQGDVRVIVPNDEMQTPHYSVLRVRKGEETSTLSYLL
 PKLHEEEMALPGDDEPAERKRPEQPALAAFVMPDAPPAPMLEEPAAAPVAAAAPVAAAAPAQPGLLSRFFS
 ALKNIFSGAEEAKPAEVQVEKKAEEKPERQQERRKPRANNRRDRNDRDNDRDNDRDNDRDNDRDTRAD
 NAEGREPRESREENRRNRREKPSQNVEARDVRQTSGDDAEKAKSRDEQQPRRERTRRRSDDKRQAQQ
 EAKAQTTREEPVVQETEQEERVQTLPRRKPRQLAQKVRVESAVVEPVAEIVPEAVVAEVIAPHSEPVKAELP
 20 AGVESVADQDENGESREANGMPRRSRRSPRHLRVSGQRRRRYRDERYPTQSPMPLTVACASPEMASGK
 VWIRYPVVRPQDQQPEEVQVQDASVAKTVEAVAAPVAVVETVTAAPVTVEPATMEPVTAEPVVVEPVAAA
 EPLVVDAAEVVAPAAVEPAPQEPVTEAPAVEAPQAIAPVTLDAEPVVVEPEAVETTPVVAAPVETIAPVAETV
 EQAPVTEAAPAEPVKAEPVSKPVVAGHRHATAPMTRAPAPDYVPEAPRHSTWVRPPFAFEGKGAAGGH
 SATHKATAEPTRPQVE

25 SEQ ID NO:29

MRKLSLSLLTSLGVALPLAQAATTPAQEHLLEQVRLGEASNREDLVRQSLYRLELIDPNNPELIAARMRY
 LLRQGDAAQAQKELERLTQAPDSPELKASRNEMKSNTGEGRQALQQARLLGVAGKVDEAIAAYEKLYG
 GVPDDVDVAIEYWTLVARLPARHSEGVSQLKKLNASAPGNVSLTSLAKQMFADNKPQEGFAYLAEMAR
 SASGRGIAADMWFSEVKSMPVSKASVQALQQFLLQFPTGSVAANARVLLDQQQAQLQDPTFRARSEGLA
 30 AVKSGNTTQAVADLQKAVQADSRDSDAVGALGQAYSQRGDRARAVAQLSKAIAMDPDSPNRGKWDSL
 LQTNRYWLLIKQGDNALKAGQLSQAQNYAQAQRVDRTDSYAVLGLGDVAAARKEAAAAERYYYQQALRL
 DRGNNLAVRGLANLYRAESPEKASAWIAGLPQAQRSSIDDIERSLTNRLEKQAQALESQGNWAQAAEV
 QRRRLALDPDSVWITYRLARDLVSAGERQEADALMRTMVNRQPQDAERVYASGLYLSGNDQDDLALAQI
 AALPRSAWTDNIRELEARLQSDRVLRQANQLRDSGNEAQAIALIRQQPASVRYDLTLADWAQQRGDSQT
 35 AIANYQRVLRQEADNGDARLGLAEVYLAEGDKPAARAQVMQLKGAETESMNMQRRVALARAGLGDTAD
 AQRIFNQIVPQAKAQPPSMESALVLRDAARFATQSGAPQQALHYREAMVASGITPAQPQDNDTFTRLTR
 NDSHDDWLKRGIRSDAADLYRQQDLNVTLEHDFWGSSGTGGYSDLKAHTTMLQMDAPLADGRMFFRT

DLVNMDAGSFSTHSDGSYSPSWGTCGEIACSTSGSKNQTDSGASVAVGWKNDTWSGDIGTTPMGFNVV
 DVVGGLSYSSDVGPVGYTVNVHRRPISSSLLSFGGQKDSSSHTGATWGGVRADGGGLSLSYDRGEAHG
 IWSSLGADSLTGKNVADNWRVRWMTGYYYKVINENNRRVTVGLNNMIWHYDKDLSGYTLGQGGYYSP
 QEYLSFAVPVWTRQRTENWSWELGGSVSWSHSRTQTQARYPLLNLIPSDYRQRASELTEEGSSSHGFGY
 5 TARALVERRVTSNWFVGAAVDIQAKDYTPSHALLYVRYSAAGWQGDLDMPQPLVPYADW

SEQ ID NO:30

MSQEYTEDKEVKLTKLSSGRRLLEAMLILCSLFAIWLMAALLSFNPSPSWSQTAWHEPIHNLGGAPGAW
 LADTLFFIFGVMAITIPVIIIGGCWFAWRHQENDEYIDYFAVSLRLIGALALILTSCGLAAINADDIWYFASG
 GVIGSLLSTTLQPLLHSSGGTIALLCIWAAGLTFTGWSWVSIAEKLGGGILSVLTFASNRRTRDDTWVDE
 10 GEYEDDEEEYDDEEAARPQESRRARILRSALARRKRLAEKFTNPMGRKTDAAALFSGKRMDDGEEVVQYS
 ASGAPVAADDVLFSGASAARPAEDDVLFSGASAVRPGDFDPYDPLLNGHSIAEPVSAAAAATAAPQAWA
 ESPVGHHGAAPAYQPEASYPQQAYQPEPAPFQQAYQPEPAPFQQAAYQPPAGQTAPQAYQPEPAPYQQP
 VYDPRAGQPAPQAYQPEPAPYQQPAYDPYAGQPAPQAYQPEPAPYQQPAYDPHAGQPAPQAYQPEPAPY
 QQPAYDPYAGQPAPQAYQPEPAPYQQPTYDPYAGQPAPQTYQQPAYDPNAGQPAPQPYQPEPAAAYQPQS
 15 APVPPPEPEPEVVQEEVKRPPLYFFEEVEEKRARERELLASWYQPIPEPESPIATKPLTPPTTASKPPVETTVV
 SAVAAGVHQATAASGGAAAATSSTAASAAATPLFSPASSGPRVQVKEGIGPKLPRPNRVRVPTRRELASY
 GIKLPSQREAEQRARQAERDPHYDDELLSDEEADAMEQDELARQFAATQQQRYGHRWEDDNATDDDEA
 DAAAEAEELARQFAATQQQRYATEQPPGANPFSPADYEFSPMKTLVNDGPSEPLFTPTPEVQPQQAQRYQ
 QPAAAPQQGYQPAHQPIHHQPVPQPQSYPTASQPVQPQQPVAPQGHQPAAPAPQESLIHPLLMRNGD
 20 SRPLQKPTTLPPLDLLTPPPSEVEPVDTFALEQMARLVEARLADFRIKADVNNYSPGPVITRFELNLAPGVK
 AARISNLSRDLARSLSSTVAVRVVEVPIPGKPYVGLLEPNKKRQTVYLREVLDNAKFRDNPSPLTVVLGKDIA
 GDPVVADLAKMPHLLVAGTTGSGKSVGVNAMILSMLYKAQPEDVRFIMIDPKMLELSVYEGIPHLLTEVVT
 DMKDAANALRWSVNEMERRYKLMSALGVRNLAGYNEKIAEARMGRPIPDYWKPGDSMDAVHPVLEK
 LPYIVVLVDEFADLMMTVGKKVEELIARLAQKARAAGIHLVLATQRPSVDVITGLIKANIPTRIAFTVSSKID
 25 SRTILDQGAESLLGMGMMLYSGPNSTTPVRVHGAFVRDQEVHAVVQDWKARGRPQYVDGITSSESE
 GGGGGFDGGEELDPLFDQAVNFVTEKRKASISGVQRQFRIGYNRAARIEQMEAQGIVSEQGHNGNREV
 LAPPPF

The nucleic acid fragments of the present invention have or derive from the following sequences:

30 SEQ ID NO:31

ATGAAGAAGTTAGCTTTACTCTCCGCCGTAATGACGCTTGGAATGTCGTCATGGGCTTTTGCTGCCGA
 CAACCCGCCGCCGCCGCCGGAAGGCGCGCAGCATCAGGGTAAACCGCCGGTGAAAAACGGCCA
 ACACGAAGGTAAGCAAGCGCAATACAACAGAAAACAGCCACAACGAGACGGCAAACAGCCGCAGCAC
 GACGGTAAACAGCCGCAGCACAAACGGCAAGCAGCCGCCAAAAGGGAGCGAGCACAGCGGGAAACCG
 35 CTGCCGCCGAAAGCGTAA

SEQ ID NO:32

ATGAAACGTTACGCAACCGCACTGCTCTTTTGA

CTCTGTGCTGACCAGCCTGGCCGCTCGCGCCGA

TATTATCGATGACGCGATCGGCAATATTCAGCAAGCCATTAACGACGCCTATAACCCCGGCAGCAGTC

GCTCCGATGACGACGACAGATACGATGACGATGGCCGGTATGATGACGGGCGCTATCAGGGGAGCC

5 GTCAGCAGAGCCGTGACAGTCAGCGCCAGTATGACGAGCGGCAACGCCAGCTGGACGAGCGCCGCC

GCCAGCTGGATGAACGCCAGCGTCAGCTCGACCGCGATCGTCGTCAGTTAGAAAGCGACCAGCGTCG

TCTGGATGATAGCTACTGA

SEQ ID NO:33

ATGTTCAAGGTCACTGATTCTGGCAGCAGTACTGCTGGCCGCAGGGCCACTGGTCGCTAACGCTGGTG

10 AAATCACCCCTGCTGCCATCGGTAATAATTACAAATAGGCGATCGTGACAATTACGGTAACACTACTGGGAC

GGTGGCAGCTGGCGCGACCGTGATTACTGGCGTCGTCACTATGAATGGCGTGATAACCGTTGGCATC

GTCATGACAACGGCTGGCACAAAGGCTGGTACAAAGGCAGAGATAAAGCCTGGGAGCGCGGCTATC

GTGCTGGCTGGAACGACCGCGATGACCACCGCGGCGGCTGGGGTCGCGGCCCGGGCGGGCGCGGT

CACGGTCATGGACATGGCCATCACTAA

15 SEQ ID NO:34

ATGAAGGAAATCGGCTTACCGTTATTGCTACTGACCGCGCTGGCCAGTCCGGCTTTTGCTGCAGACTG

TCAGCCAAACGGCATTGGCGGCTCGTTTTGCATTAACGATGACGGTACGACTACCGACACGGTGCCTA

ACGAAGTCAACGGCATGGATACGTACTCGAATAATGGCGGCTATACCAAGTTCCCTGCCC

GATCGGTCA

GGGGCGGATGAAGCACTGGAAGGTTTCATCGCTGTGACGCAGCAAGGCGTCGGCAGCGGACAGAGC

20 GACAGTGCCTGGCGGGTCGCGACTGGCATTGCCCCGCCAATCTGAATGATGGCGCCGCCACCTCCA

GTATGAGCCTGCTGGATAAACCTGA

SEQ ID NO:35

ATGAATATGAAAAAACTGACGACCCTTTTGCTCACCGCCACCTTAGGTCTTGCCAGCGGCGCGGCCCT

GGCGGCAGACACCGGCGCCCAGTCCAATAATGGCCAGGCCAACTCTTCCGCGGATGCCGGTCAGGT

25 GGCGCCGGATGCCCCTGAGAACGTGGCGCCGAACAACGTGGACAATAGTCAGATCAACTCTGGCTCT

GGGGGCACACGGGCTCGACGATGACCCAGGATAATATGTCGAGCAATGAGGTACATAAAAACTCGA

TGTGTAAAGACGGCCGCTGTCCGGACACCGGTAAAAAACTGGACAACGGTGGCAATACGACCCAAGA

CAACAGCAAAACCGACGGCACCCACCCAGTAA

SEQ ID NO:36

ATGAAACACCGCATCGCTCTGCTTCTGGTCCTGACTTCACTTAGCGCCAGCGCCCTAGCCGCCTCTCC

30 CTGCCAGGAAAAAGAGCAGGATATTCAACGAGAGATCAGCTACGCCGAAAAGCATCATAATCAAAGTC

GCATTGATGGGCTAAATACCGCGCTACGTGAGGTTCTGGGAAAACTGTAGCGACAGTAACTCAAAGC

CGATCATCAGCAAAAAATTGCCAAACAGCGGGAAGAGATCGCTGAACGTCAGCGCGATCTGCAGGAA

GCCCGGAAGAAAGGCGATGCGGACAAAATTAACAAACGCCAGCATAACTCAATGAAGCGCAACAGG

35 AGTTAAAAACGCTGGAGTCTCGGGATTACTAA

SEQ ID NO:37

ATGCGACTCATAACACGACACGTGAGAGAGGATATTATGAAAAAGCAATGATTGCGTTATCGGCTAT
TCTGGTTGCGGCTCCGGTTTTTGTGCGACAACACATGCAACAGATGATACCGTCGCGGCGGCGAAT
GCCAACGCCAACACCGCTAAAGAGAAGCTGCATCAGGCCCAGCACGAGGGCGAAGAGCAGCAGCTG
5 AAGGCGAAACACGCCGCCGAAGGCAAGCAGGACAGCGTCGGCAGCCAGGTGAGCGAAGGCGCGCA
GAAAACCTGGAACAAGACCAAAGAAGGCACCGAGAAGGGGTGGGATAAGACCAAAGAGGTCAGTGA
AAAAGGCTGGAACGCCACCAAATCCGGTGCGGAAAAGGGCTGGGATAAAACCAAACCGGCGCCGA
AGAGTTAAAAATAAAGTGAATGAATAA

SEQ ID NO:38

10 ATGAAAAAGATGATTTCTCTGGCAGTAATTTTATCCTGTGTGCTGAGCGTCCCGGCCCTTTGCCGATGG
CCCGAACGACGGCCATCGCCCGGAGCAGCCACCGGTGTGGCAGAACGGTCCGGACCATGACGGGCA
TGCACCGCAGGGCGGACCTGACGCGCATCATCAGGGCGACCATGACCAGCGTGGCCCCGATCGCGA
CGGCCATGACAAACGCGATCTGGCACGTCATGAGCAGGACCATTTGCGCTGGCGCGGGAACGATTTC
CGAAAGGCCACCCGGCTCCGGCGCCGTTCCGTGGCGATGAATATCGCGTCCGCGACTGGAGCGAC
15 CGCGGCCTGCCGCCCCCGCGGAAGGCCATCACTGGTCCTATATCGACGGTAAGTATGTGCTGATCG
CCGCGGCGACCGGGATCATCACCTCGATTCTGGTGAGCGGCGCCCTCGGCCACTAA

SEQ ID NO:39

ATGAAAAAACCGACATCCGCCACCCGTGGCAAATCCGGCCGCAAGTCGCGTGAAGAGTTAAATCAGG
AAGCTCGCGATCGAAACGGCAGAAAGAAACATCGTGGCCACGCGGCAGGCAGTCGCGCGAACGGCG
20 GCGATGCGGCTTCAGCGGGTAAAAACAGCGTCAGGCGCAAGATCCGCGCGTGGGTAGCAAAAAAC
CGATCCCGCTGGGCGTGAGCGAAAGCAGCGTTCAGCTCCCAAGCAGCATAAACCAAAGAGCGAGAA
ACCTATGCTTTCACCGCAGGCTGAGCTGGAGTTGCTGGAGAATGATGAGCGCCTGGACGCGCTGCTG
GAACGTCTGGAAGAGGGCGGCACCCTGAATGCTGAAGAGCAGAGCTGGGTGGACGCCAACTGGAT
CGCATTGATGAGCTGATGCAGCAGCTCGGCCTCTCTTACGATGATGAAGATGAAGAAGAGGAAGAGC
25 GTCAGGAAGATATGATGCGTCTGCTGAAGGGTGGAATAA

SEQ ID NO:40

ATGGCGAGTAAGTTTCAGAACCGTTTAGTCGGGACAATCGTGCTGGTGGCGCTGGGGGTGATTATCC
TGCCAGGGCTGCTGGACGGGCAGAAAAAGCATTACCAGGATGAGTTTGCCGCGATCCCGCTGGTACC
GAAACCAGGCGATCGCGATGAACCGGATATGTTGCCGGCGGCAACCCAGGCGTTGCCTTCGCAACCG
30 CCGGAAGGGGCGGCGGAAGAGGTGCGGGCGGGCGATGCCGCCGCGCCATCGTTAGATCCATCGCG
TATTCCGGTGAACAGCAACAGCTTCGATGACGTTTCAGGAGCCGGTGGTGGCCGCGAAACCGCAGCCC
AAGCCGCAGCCGAAACCGCAGCCGCAACAGCAGGCCTCGACGCCAACGCCGCCGCGGCTAAGCCA
CAGCAGCAACAGCCACCGCAGCAGCAGGCGGCCCTGCCGGCGCCGACCGGCAAAGCCTATGTGGTT
CAGCTGGGCGCGTTGAAGAACGCCGATAAGGTGAATGAGATTGTCGGTAACTGCGGGCCTCGGGTT
35 TCAAAGTCTATACGTCGCCTTCGACGCCGGTACAGGGTAAATTACCCGCATCCTCGTCGGCCCGGAT

GCGTCAAAAGACAAGCTGAAAGGCCAGCTGGGCGATCTGCAGCAGATCTCCGGGCTTAGCGGGGTG
GTGATGGGCTTCACCCCGAACTGA

SEQ ID NO:41

ATGGCACAACGAGATTATGTACGCCGCAGCCAACCGGCTTCTTCGCGGCGCAAAAAGAGCACGACCC
5 GAAGCTCAAGGAATAAGCAAAGCAGCCTTCCGGCGATTTACCGGCGATGGTGGCGATCGCGGCGG
CTGTGCTGGTGGCCTTTATCGGTGGCCTCTATTTTCATTACGCATCATAAGAAAGAAGAAGCGGAAGCG
ATGCAAAATCGCCAGGCCGCCGGCAACGGCTTGCCGCCCAAACCGGAAGAGCGCTGGCGCTATATTA
AAGAGCTGGAAAGCCGCCAGCCTGGCGTCCGCGCGCCGACCGAACCGACCGCCGGTGGCGAAGTCA
TGAAACCGGAACAGCTGACCGACGAGCAGCGCCAGCTGCTCGCCCAGATGCAGGCCGATATGCGCC
10 AGCAGCCGACCCAGCTGACCGAAGTGCCGTGGAACGAACAAACGCCGGCGCAGCGCCAGCAGACGC
TTCAGCGTCAGCGTTTAGCGCAGCAACAGCAGCAGGCGCAGCAGCAACAGTGGGCGCAGACTCAGG
CGCAGACCGTCCAACAGCAGCCGCCGCGCGTTTCAGCAGCCGAAGCCGGTTCAGCAGCAACAGCCGA
AGCAGACCGCGTCAAACAGCAGCCGTACCAGGATCTGCTGCAGACGCCAGCGCATACCAATACCAC
GCAGCCGCGTACCCAGGCCGCGGCGCCGGTAACCTCGGGTGGAAAGAAGCGCCGAAAACCGCCGA
15 GAAGAAAGACGATCGTAGCTGGATGATCCAGTGCGGCTCTTTTAAAGGCGCCGAGCAGGCCGAAACC
GTCCGCGCTCAGCTGGCTTTTGAAGGGTTTGCTTCGCACATTACCACTAACAACGGCTGGAACCGCGT
GGTTATTGGCCCGTTGAAAGGCAAAGAAAGCGCCAACGAGATGATCACCCGCCTGAAGATGGCTGGA
CACGCGAACTGCATTCTGCTCTCGCCGCCAGGGGTTGA

SEQ ID NO:42

ATGAGCGCGGGAAGCACCAAATTTACCGTCAGCCGTATTGCGGCTCTTTCACTGGTTTCACTCTGGCT
20 GGCCGGGTGTACCAACACCAATAATCCGCCTGCGCCGGTTAGCTCTGCCGGCGGCGCCGCCTCTTCC
AGCACCAACTCCGGCATGCTGATTACGCCGCCACCTCCGGCGTCAAGTCCGCTCCTCAGGCGCAGC
CGATTACCCGATGCAGACCCAGACCATTACGCCGGCGCCGGTGGCGCAGGAGCCGGTACAGACGG
TAAATGGCCGGATCGTTTACAACCGCAAATATGGCGATATTCCGAAAGGTAGCTATACCGGCGGCAGT
25 ACCTATACGGTAAAACGCGGCGACACGCTATTCTATATCGCCTGGGTACCGGCAACGATTTCCGCGA
CCTGGCGCAACGTAACAATATCCCGGCCCGTACGCGCTGAACGTGGGGCAGGTAAGTGCAGGTGCGT
AACGCCTCAGGCCAGCCGATCACCGGCGAAAACGCCGTTTCTCAGGCCAGCGCAAGAGCGAGCGGC
GGTGCAGACGACCAGCACAACTTCTGCACAAAATCGACCGCGGTGGTTGCTTCACAACCGACTATTAC
GTATTCTGAATCTTCAGGTGAACAGAGTGCTACCAAGATGTTGCCTAATAATAAACAGCGACCACAA
30 CCACAACGGTTGTCGCGCCGGTGACGGCACCAACAACGGTGAGCACAAACCCAGCCGACTGCAAGCA
GTACGTCAACCAAGTTCGCCGATCTCAGCATGGCGCTGGCCGACTGATGGCAAGGTTATCGAGAACTTT
AGCGGCGCGGAAGGCGGCAATAAAGGCATCGATATTGCAGGCAGTAAGGGACAGGCTATTGTCGCG
ACCGCCGATGGGCGCGTCGTCTATGCCGGTAACGCACTGCGCGGCTACGGTAATCTTATTATCATCAA
ACACAACGATGATTACCTGAGTGCCTACGCTCATAACGATACCATGCTGGTTCGGGAGCAACAGGAAG
35 TCAAAGCGGGGCAGAAAATCGCTACCATGGGTAGCACCGGAACCGCTCAACAAGATTACATTTTGAA
ATTCGTTACAAGGGGAAATCCGTCAACCCGCTGCAGTACTTACCGCAGCGATAA

SEQ ID NO:43

ATGCGTAAGCAATGGCTGGGGATCTGCATAGCAGCGGGGCTGCTGGCGGCATGTTGAGTGATGAC
GTGCAACAAAAACGGTCAGTACTCCACAGCCGGCCGTCTGTAATGGCCCGACGGTTGAGATCAGCG
GCGCCGATCCGCAGTATGAAACGCCGAACGCCACGGCGAATCAGGATTATGAGCGCGACGGTAAAA
5 GCTACAAAATCGTTCAGGATCCGGCCAACTTTACTCAGGCCGGTTTCGCGGCGATCTATGACGCAGAA
CCCAACAGCAACCTGACCGCCAGCGGCGAAGCCTTCGATCCGACTCAGTTGACCGCAGCGCACCCGA
CGCTGCCGATCCCGAGCTACGCGCGGATCACTAACCTTGCCAACGGACGGATGATCGTCGTGCGGAT
TAACGATCGCGGTCCCTATGGCAACGATCGGGTCATCTCGCTTTCCCGCGCATCCGCTGACCGCCTGA
ACACCTCCAACAACACCAAAGTGCGCATCGACCCCATCATCGTCGCGCCTGACGGTTCGCTTTCCGGC
10 CCGGGGATGGCCTGTACCACCGTCGCCAAACAGACTTACGCCCTGCCCGCCCGTCCGAATCTGGACG
GTGGGGACGCCGCTGGCATGAGCCAGCCCGCGCCCACTGACGTTCCGCCGATCAGCAACAGCACGC
TGACGCCGGCAGACAGCGTGGGCGCGCCGGTGAACAGCGGCGGTTTCCTCGGCGCGCCGACGCCCC
TGAACAACGGCGTGCTGGAGAGTAGCGAACCAGCGGCAGCCCGCGACGGCTCCTGCCGCCGGCG
CCACGCCAACAGCGCCAGTGACCGCGCCTGGCTCCATTAGGGTAATGTGGTGCCCGCTGCGGCCAC
15 CGCCGCAGCCGCTGGCGCCGTGGCGGCCTCGTCCTCCGCGACCTCCAGCGCCAGCGGTAATTTTGT
GTCCAGGTGGGCGCAGTAAGCGACCAGACGCGGGCGCAGCAGTATCAGCAGCGCCTGAGCCAGCAG
TTTTCTGTGCCAGGCCGGGTCTGCAAAACGGCGCGGTCTGGCGTATTAGCTGGGTCCCTTTGCTG
ATAAAGCACAGGCCAGCGCCGTGCAGCAGCGCCTGCAAAGCGAAGCGCAGCTGCAGTCCTTTATTAC
TCGCGCCAACTAA

20 SEQ ID NO:44

ATGGATGATTTCAAACCAGAAGACGATATGAAAGCCGATCGCAACGATCGTCGTGCTGGTTCGTTCCCG
TCAGTCTTCCGAGCGTGATGCCGATCCGCAGATCAATTTTGACGATGTTGATCTTGATGCCGATGAAG
GCCGTCCGACGCGCGCTGGTAAGGCCCGTCGCGAGCGTGAAGAGGAAGAGTTTGAAGAAGAACTGG
ATGCGCAAGACGAGGAGATGCTCGAAGAGCAGCCTGTAGAGCGTCGTCCGCGCAAGCGTAAAAAAG
25 CGCCGGCCAAACCGGCCTCCCGCCAGTACATCATGATGGGTGTGGGGATTCTGGTGCTGCTGCTGTT
GATCGTGGGTATCGGTTCCGCACTGAAATCGCCATCATCTTCCAGCCAGCAGACCGCTTCCGGCGAG
AAGAGCATTAACTGTCTGACGACCAGTCCGCCAGCATGCCTGCTGCCGGCCAGGACCAGACTGCCG
CCGCTAACAGCACCTCACAGCAGGACGTAACGGTACCGCCTATTGCCGCGAACCCGACGCAGGGCCA
GGCAGCGGTTGCGCCGAGGGCCAGCAGCGTATCGAAGTTCAGGGCGATCTGAACAATGCCTTGAC
30 CCAGCAGCAGGGCCAACTGGACGGCGCCGTGGCTAACTCGACGCTGCCGACTGAACCGGCTACCGT
CGCGCCAATCCGGAATGGCGCCAATGGCACCGCGCGCCGCGCCAGGCGACCGAGCGTCAGACAGC
AGCGACCCCGCGTCCGGCTGAACGTAAGCATACCGTTATCGAAGCGAAGCCGCAGTCGAAGCCACAG
GCCGTGGCGAAAACGCCGGTAGAATCGAAGCCGGTCCAGCCGAAGCATGTTGAAAGCACGGCGACC
ACCGCTCCGGCGAAAACGTCCGTGAGCGAAAGCAAACCGGTGGCCACCGCTCAGAGCAAACCGACCA
35 CGACGACCGCAGCGCCAGCGGCAACGGCAGCTGCGGCAGCGCCGGCAGCGAAGACCGGGAAGACG
GCAGGTGACGTCAGCTCAATGAAAACGCGCCGTGCGGTCACTATACTCTGCAGCTCAGCAGCTCCTC
TAACTACGACAACCTCAACAACGCGGCGAAGAAAGAGAAGCTGGATAAATATGTTGTCTATGAAACGT
CGCGTAACGGCCAACCATGGTACGTGCTGGTGAGCGGTATCTATGCATCGAAAGATGAAGCGAAACG

TGCTGTACCTCGCTGCCGGCGGACGTGCAGGCGAAAAATCCATGGGCAAACCGCTGCATCAGGTT
CAGGCTGACCTGAAATAA

SEQ ID NO:45

ATGTCAAAGGCAACCGAACAAAACGACAAGCTTAAACGAGCGATCATCATTTTCAGTCGCGCTGCACAT
5 CATTCTGATCGCGCTGCTGATCTGGAGTTCGTTTGACGAGCATCTGGATGCCTCTGCCGGCGGCGGC
GGCGGATCGTCGATTGATGCCGTCATGGTCGATCCGGGGGCGGTGGTAAATAACTATAACCGTCAGC
AACAGCAGCAGGCCAGCGCACGTGCGCGCCGCTGAACAGCGTGAAAAACAGGCGCAGCAGCAGGCGG
AAGAGTTACGTGAGAAACAGGCGGCGGAACAGGAACGGCTGAAACAGCTCGAACAGGAGCGGCTGC
AGGCGCAGGAAGCGGCGAAAGAAGCGAAGGAGCAGCAGAAGCAGGCTGAAGAAGCGGCTGCCAAG
10 GCCGCCGCGGCGGCAAAAGCCAAAGCGGACGCACAGGCCAAAAGAAGCGCAGGAAGCCGCTGCCAAA
GCGGCCGCGGAGGCGAAAGCGAAGGCGGATGCCAGGCGAAAGCGGCAGAACAGGCGGCGGCCAA
GGCGGCTGCTGACGCGAAAAAGCAGGCCGAAGCCGCTGCAGCGAAAGCCGCTGCCGAGGCGAAGAA
ACAGGCGGAAGCTGAAGCGGCGAAAGCTGCGGCCGAGGCGCAGAAGAAAGCGGAAGCGGCGGCTG
CGAAGAAAGCGCAACAGGAAGCGGAGAAAAAAGCCCAGCAGGAAGCGGCTAAGCAGGCGGCAGCTG
15 AAAAAGCGGCTGCCGAAAAAGCCGCTGAGAAAGCCGCCGCGCAAAAAGCGGCCGCTGAGAAGGCCG
CCGCCGAGAAAGCCGCAGCCGCTGAAAAAGCGGCGGCAGCGAAAGCGGCTGCAGCAGAGAAGGCT
GCAGCTGATAAAGCGGCCAAAGCGGCAGCAGCAAAAGCCGCGGCGGCGAAGAAAGCGGCGGCTGC
GAAAGAAGCGGACGGCGTTGACAACCTGCTCGGCGATCTGAGTTCTGGTAAGAATGCGCCTAAACA
GGCGGTGGGGCCAAAGGAAACAATGCCTCCGCTGCCGGGAGTGGTAATACTAAAAACAGTGCCTCAG
20 GGGCTGATATCAACAACTATGCCGGACAGATAAAATCGGCGATTGAAAGTAAGTTTTATGACGCATCG
TCCTATGCGGGCAAAACATGTACCTTGCGTATCAAACCTGCTCCTGACGGCCTGTTGTTAAATATACAG
TCCGAAGGTGGTGATCCTGCTCTGTGCCAGGCCGCTCTTGCCGAGCCCGACAGGCTAAGTTTCCGA
AACCACCTAGCCAGGCAGTATATGAAGTCTTCAAAAATGCGCCACTGGACTTCAAACCTCAGTGA

SEQ ID NO:46

ATGTTTTTTTTTAAGTATTTTTTACATGGAGATGACAAAAGTGAAATTAAGCGCTCTGTTTATTGCCCTGA
25 TTCCTCTACTGGGCTCGCCGTTATTTCATGCAGAACTACTGCTGCGCCGTTCTGGAAAATCGCGCT
GCGCAGGGAGATATCACCCTCCTGGCGGCGCGCGTCGTTTAACAGGCGATCAAACCGAAGCGCTGC
GCGCCTCGTTAATCAATAAGCCAGCTAAAAACGTTATTTTGCTGATTGGCGATGGCATGGGTGATTG
GAAATTACCGCTGCGCGAACTATGCCGAGGGGGCGGGCGGTTTCTTTAAAGGAATTGATGCTCTGC
30 CGTTAACCGGGCAGTACACGCATTATTCGCTGGATAAAAAAACCGGGAACCGGACTACGTGACCGA
CTCGGCGGCCTCCGCCACCGCCTGGACCACCGGCGTGAAGACTTATAACGGCGCGCTGGGCGTCA
TATTCATGAGAATGCGCATCAGACCATCCTCGAGCTGGCGAAAGCGGCGGGGCTGGCCACCGGCAAC
GTTTCCACCGCCGAGCTGCAGGACGCCACCCCCGCGGCGTTGGTAGCGCATGTGACATCGCGTAAAT
GCTACGGCCCCGACGGTCACCAGCGAAAAATGCCCCAGCAATGCGCTGGAAAAAGGGGGCAAAGGCT
35 CCATTACCGAACAGCTGCTGAACGCCCCACCGGATGTCACCTTGGGCGGCGGCGCAAGACCTTTAC
CGAAACGGCGACGGCGGGCGAGTGGCAGGGCAAAACCTGCGCGAGCAGGCGCAAGCGCGCGGCT
ACCAGATTGTGACCGACGCGGCTTCTCTTGCCGCCGCGACGGAAGCCAGTCAGGATAAACCGCTGCT

GGGACTCTTTGCCGATGGCAATATGCCGGTACGCTGGGAAGGGCCGAAGGCGTCTTATCACGGTAAT
ATCGATAAGCCGCCGGTGACCTGTACGCCAAACCCGAAGCGTGACGCCTCGGTGCCGACGCTGGCG
CAGATGACGGAGAAAGCGATTGACCTGCTCAGTCGCAACGAGAAAGGTTTCTTCCTGCAAGTCGAAG
GCGCTTCCATCGATAAGCAGGACCATGCGGCGAATCCGTGCGGCCAGATCGGCGAAACGGTTGATCT
5 TGACGAAGCGGTGCAGAAGGCGCTGGAATTCGCGCGAAAAGACGGTAATACCCTGGTGATCGTCACC
GCCGACCATGCGCATGCCAGCCAGATCATCCCGGCGGATAGCAAAGCCCCGGGGCTGACCCAGGCT
CTGAACACGCACGATGGCGCGGTGATGGTGATGAGCTACGGCAACTCTGAGGAAGAGTCGATGGAG
CACACCGGCACCCAACTGCGCATTGCGGCCTACGGTCCGCATGCGGCTAACGTCGTAGGCCTGACCG
ATCAGACCGACCTGTTACGACCATGAAAGCTGCCCTGAGTCTCAAATAA

10 SEQ ID NO:47

ATGTCACTGCCGTTCAAACCCCATATTATCGCCCTGCTCTGTAGCGCTGGCTTACTCGCGGCGGCAGG
AACTCTATGTGCAAAGCCGAACCCAGCGACGATCGCTGAACCGCCTGCGCAGCAAGCGCCAGCG
CCCGCAGCGTCGACGACACAGCCGGTGGCCGCCACTTACACCCAGGCGCAAATTGATCAGTGGGTGCG
CCCCTATCGCGCTCTACCCGGACAGCCTGCTGTGCGCAGGTGTTGATGGCCTCCACTTATCCCGACAAC
15 GTCCTGCAGGCGGTCCAGTGGTCCCAGGATAACCCCGCGATGAAAGGGGATGCGGGCCGTGCAGGCG
GTTGCCAGCCAGCCGTGGGACCCTAGCGTCAAATCTCTTGTCGCTTTCCTGCCCTGCTGGCGATGAT
GGGCGAGAATCCGCCCTGGGTGGAATACTTGGAATGCGTTTTTGGCCAGCCGCATGATGTGATG
GATTCAGTGCAGCGCCTGCGCGCCATTGCCCAACAAACCGGACGCTGAAATCCACACCGCAGCAGA
AAGTGATTGTCACCCCTGCCGCACCGGTTTCAGCCAGCAGCAGCACGGCAGCAACCGCAACCGCCCA
20 CACAGCGGCGCCTGCGCCACGCAGGTCATTAAATAGAGCCGACCAATCCACAGGTGGTCTATGTT
CCCAGCTATAACCCCTCCACCGTCTATGGTACCTGGCCGAACAGCGCCTATCCGCCGGTCTATCTGCC
GCCCCCTCCCGGGGAGCAGTTTACCGATAGCTTCGTCAAAGGCTTCGGGTACAGCCTCGGCGTGGCC
ACCACCTGGGCGCTGTTACGAGTATCGACTGGGATGATGATGACCATCACCATCACGATGACGACTA
CCACCACGGCGATTACTCGCATAATGGCGATAACATCAATATTAATGTAAATAATTTCAATCATATAAC
25 AGGAGAAAACCTGCCGGGAAACCACGTTAACTGGCAGCACAATCCTGCCTATCGCGGACACACACCG
TATCCCGATAATACGGTAGCTCAGCGCTTCCATCAGACCAACGTTTCCGGCGGACTGAGCGCGACCCA
ACATGCGCCAGTCGATCGCGAAGCGCAGCGCCAGGCAGCGATGACCCAGCTGCAGCATAACGTACC
GACGGCCACAGCGGGCAACCTGGCGGCAAACAACGCCTCACGCGACGCCAGCGTCAGGCGGCCTC
GGCGCAGCTGAAGCAAGCCACCCAACGCAGTAATTACCGCGGTTACGACAGTACGCCGACCCAACAG
30 CAGCGTCGCGAGGCGGCAAAAACGCAGCTGAAAAACCCACGCCGAGCAACAGCAGCGTCGAGAA
GCCGCCAGGAGCCACGAGCAGAACCGCACACCTCAGCAGCAGCAGCGCCGGCAGCAGTTCCAGTCC
GCCACGCCAGCCCAGCGTCAGCAGACGCTCAGCCATCTGCGCGCCAACGCCCTTAGCGGCAACGAAA
GCCGCGCCCCCTCCTGGCAAGCGCAGCAGGAACGAGGACTGCAGAGCCGCCAGTTTTCCGGCGTAA
ACCGCGAGTTACGCGATGGCACCAGAGAACGTCTTCCGAACACCATGAACTGCGTCGCCGCTAA

35 SEQ ID NO:48

ATGTTTAAGTTTAAGGCTTCTTATGTCGCACTGGCGGCAGTATTAACCTCGTCGGTAGTTTATGCCGAC
CCCACAAGCTATACGCACTCTTCCGGCGCCACGGTTATCGATATTGAAAAGCCGAACGCCGCCGGTGT

CTCCATAACCTGTACCGCGACTTCAACGTCGGCGCCAATGGCACCATCCTCAATAACAGCGGCGATG
ATGTCAGCCACAGCACATTTGGCAATATCGCCCGAACAATAATCTGACCGCCGGCAGCGCTTCGGTG
ATTTTGAACGAGGTGACCTCCAAAAACGCCAGTAGCCTGAAGGGCTTTATCGAAGTCAACGGTCAGAA
AGCGGATGTGGTAATCGCCAACCCGAACGGCATCACCTGTTCCGGCTGTAGCTTTGTTAATACCAACA
5 AGGCTATCCTGACCACCGGCAAGGTTAATATGACCGACGATGGCGCTATCGGCAGCTATACCGTAAC
GGGCGGCACCCTCACCATCGGCGAAAATGGCATGAACGCCGCCAACGGCTATGCGGTTCTGCTCGCC
GACGCGATCAATATCAACGGTAAAGTGCAGGCCAACACGCCCTGGTCAGCGCGGGCAACTTCACCA
TGGATAACAGCTCTGGCTCGGTGACCTCCGCTGGTAAAAAGGCCACCCTGATCCAGATGACGGTTAA
CCCGCAGTACAGCATCGACGTCAGCAGCCTTGGCGGCATTGAGGCCAACAGCATCAGCATGGTCGGC
10 AATAACATCGGCTTTGGCGTACGTAATAAAGGCTCTATCGTCGCGAATAGTTCGCTGCAGCTCACCAG
CAACGGTAATCTGCTGAACAAAGGCACGATCAAAAGCAACGGTCTGCTGAGTCAGGTGCGCACCGCC
TCGGGCATACCAATGACGGTAGCATCGCCGGCGCCTATTATTTAATGCTCTCCAGTGCGGATTATAT
CGTTAACACCGGTTCTCTCTCCGGCGGCCAGCTGATTGCCACCGCTAACGGCAACATACCAACGGC
GACTCAGGCACGATGACCGGCACCAGTGGATTAAGCCTGACCAGCGGCGGGAAAATCCGCAACGAA
15 GAAAAAGCCTCCCTGCTGTCAAATAACCAGATTGCCGCCACGGCAATCGGTGATTTCTCAATGAAGG
CAAAATCAGCGCCAAACACACCAGCCTGACGTTTGTGCGCGACAGCTTTAAAAAACTGGCAATATTA
ACTCTACTGGCCAAACCACCATTCAGTCGCTTAAACAGGACGGCAGCGCCAATACGGGCGAGATCTAT
AACCTCGGCAATATCACC GGCGAAAATATCAATCTGCAGACCAATGGCACGCTGGCGCAAAGCAGCA
GTGGTCGTATTGAGGCAACCAACGCCATTACCGCCACAGCTACTGGCTGAACCAAAATGGTTATATG
20 AATGCCGCCGATATCACCACCGATCACGGCGTAGTGAATAATTATGGCAATATTACTGCCAAAAATATT
TCAATCACGACCTACTCAGATATACCAACGAAGGGCAGATCAGCAGCACCGGCGACCTGACCTTAAA
TACCAAAAATAAAGGCGCGATCTACAATTATTCAACCCTCAGCGCGGGCGGCAACATGACGTTAACCG
CCACCAAAGTGGTCAATGGTGGTAAAAGTTGCGGCATACTGGGCCTGGCGAAATGCGGCGTCGGGAC
GTAACTGCTGACAAGCTGGTACTGAACTCATCGCAGAAATATGTTAGCGACATGGGTGGAAAACAGT
25 ATTTCAAGAGCACCGAAGTCAACACGGTGAATAA

SEQ ID NO:49

ATGATGGACAACCTACGCACGGCCGCCAACAGCGTCGTGCTCAAGATTATTTTCGGTATCATTATCGT
CTCGTTCATTTTGACCGGGGTGAGTGGTTACCTGATTGGCGGTGGCAAAACTATGCCGCAAAAGTGA
ATGGCCAGGAGATTGGCCGTGGGCAGTTTGAAAACGCCGTGCGCAGCGAACGTAACCGTATGCAGCA
30 GCAGCTTGGCGATCAATTCTCCGAGCTGGCGGCGAACGAAAACACTACATGAAAACCATGCGCCAGCAG
GTGCTGAACCGCCTGATCGATGAGTCGCTTCTGGATCAGTATGCCC GCGAGCTGGGCCTCAGCATCA
GCGATGAGCAGGTGAAGCAGGCGATCTTCCAGACCCAGGCGTTCCAGACGAACGGTAAGTTCGACAA
CCAGCGTTTCAGTGGTATTGTCGCCCAGATGGGGATGACCACCGATCAGTACGCCCAGGCGCTGCGT
AACCAGCTGACCACGCAGCAGCTGATTAACGCCATTGCGGGTACCGACTTCATGCTGCCGGGCGAGT
35 CCGATCAGCTGGCGGCGCTGGTATCTCAACAGCGGGTGGTCCGCGAAGCGACCATCAACGTAAATGC
CCTGGCGGCAAAACAGACCGCCAGCGATGAGGAAATCAACGCCTTCTGGCAGCAGAATCAGGCCCGT
TTTATGGCGCCGGAGCAGTTCGCGCTCAGCTACATCAAAATGGATGCCGCCAGCATGCAGGAGAGCG
CCTCTGACGAAGAGATTCAGTATGGTACGACCAGCACAAGGATCAGTTCACTCAGCCGCAGCGCAA

CCGCTACAGCGTGATTGACACCAAACTGAAGCCGATGCGAAAGCGGTACTGGCCGAGCTGCAAAAA
GGAGCGGACTTCGCCACGCTGGCGAAAGAAAAATCGACCGATATTATCTCTGCCCGCAACGGTGGCG
ATATGGGGTGGATGGAAGATGCCTCTACCGTGCCTGAGCTGAAAGATGCCGGGCTGAAAGAGAAAAG
GCCAGCTGTCTGGCGTGATCAAATCCTCGGTTGGCTTCCTGGTAGCTCGTCTGGACGACGTCCAGCC
5 GGCGCAGGTGAAGCCGCTGGCTGACGTGCGTAATGACATTGCGGCGAAAGTGAAGCAGGAAAAAGC
GTTGGATGCTTACTACGCGCTGCAGCAGAAGGTGAGCGATGCGGCCAGCAACGATAATGAATCGCTG
GCGAGCGCAGCGCAGGTGCGCGGGCTGAAGGTCGTAGAAACCGGCTGGTTTGGCCGCGATAACCTG
CCGGAGGAGCTGAACTTTAAACCGGTCGCTGACGCTATTTTCAACGGCGGTCTGGTGGGTGAGAACG
GCGCGCCGGGCGAGCAACTCCGATATCATTACCGTTGACGGCGATCGCGCTTTTGTCTGCGCATTAGC
10 GAACACAAAGCCGAGGCGGTGAAGCCGCTGGCCGAAAGTGAAGGCACAGGTTAGCGATATCGTTAAG
CACAATAAAGCGGAACAGCAGGCGAAACTGGAGGCCGACAAGCTGCTGGCGGCGCTGAAAGACGGC
AAAGGCGATGAAGCGATGAAGGCGGCTGGCCTGAGCTTTGGCGCGCCGACAGCGCTTTCTCGTACC
GGCCAGGATCCGCTGAGCCAGCTGGCATTACCTGCCGCTGCCGACAGGGTAAACCGGTCTACG
GCGTGGGCGAGCAATATGCAAGGCGATGTGGTGTCTGGTAGCGCTGGATGAGGTGAAAGCCGGCAGCA
15 TGCCGGAAGAGCAGAAGAAGGCCATGGTTCAGGGGATCACCCAGAACAATGCCCAAATCGCTTTTGA
AGCGCTGATGAGCAACCTGCGCAAGGCGGCGAAAATTAAGCTCGGCGACAGCATCGACCAGCAGCA
GTAA

SEQ ID NO:50

ATGTTACAGGTTAAACCTTTTATCCGGGCGGGATTGTCTGCGTCCGTCGTATCGTTGGCGTTTCCGGC
20 TCTGGCCGATGTGAATGAAGAAACGCTGGTGGTGACCGCCTCGGCCACTGAACAGAATGTCAAAGAC
GCGCCGGCGAGCATCAGCGTCATCACCCAACAGGATTTACAACGCAAGCCTGTTCAGAACCTGAAAG
ACGTGCTGCGCGATGTGCCTGGGGTCCAGCTCACCAACGAAGGGGATAACCGCAAGGGCGTTAGCAT
CCGCGGTCTGAGCAGCAGCTATACCTGATCCTGGTCGACGGCAAGCGCGTTAACTCGCGGAACGCC
GTCTTCCGCCACAATGACTTCGACCTTAACTGGATCCCGGTGGATGCTATTGAGCGTATCGAAGTGGT
25 GCGCGGCCCCGATGTCCTCCCTCTACGGCTCCGATGCGCTCGGTGGGGTGGTCAACATTATTACCAAA
AAAATCGGCCAGAAATGGACCGGGACGCTGAGTGCTGATACCACTATTAGGAGCACCGCGATCGCG
GGGATACCTGGAACGGCCAGTTCTTACCAGCGGCCCGCTGATCGACGGCGTACTTGGAATGAAGGC
CTACGGCAGCCTGGCAAAACGCGCCAAGGACGATCCGCAGTCATCCAGTAATGCCACCGGCGAGACG
CCGCGCATCGAGGGCTTACCAGCCGCGATGGCAATGTTGAATTCGCCTGGACGCCGAACGAAAACC
30 ACGATTTTACCGCAGGCTACGGCTTTGACCGTCAGGATCGCGATTCCGATTCCCTTGACCGCAACCGC
CTTGAGCGGGAGAACTACTCTGAGCCATAACGGCCGCTGGGATATCGGCAATAGCGAGCTCAAGT
TCTACGGCGAAAAGGTGGATAACAAAAATCCAGGGCAGAGCGGGACTATTACCTCGGAAAGCAATGC
CATCGACGGCAAGTATGTCCTGCCGCTGGGCATGATTAACCAGCTGGTGACCTTCGGCGGCGAATGG
CGCCACGACAACTTAAAGATCCGGTCAACCTGAGCAGCGGCGGCCAGTCAACGTCGGCCAGCCAGT
35 ACGCCCTGTTTATCGAAGACGAATGGCGCATCATCGAGCCGCTGGCGCTGACCACCGGCATTTCGTAT
GGACGACCATCAGACCTATGGCGATCACTGGAGCCCGCGCGCCTATCTGGTGTATAACGCCACCGAT
ACCGTCACCGTCAAAGGCGGCTGGGCGACGGCGTTTAAAGCCCCGTCGCTGCTGCAGCTTAACCCCG
ACTGGACCACCAACTCCTGCCGCGGCTCGTGCAGCATCGTCGGTAACCCGGATCTGAAACCGGAAAC

CAGCGAAAGCTTCGAGCTCGGTCTCTACTACCGCGGGGAAGAGGGCTGGCTTGAAAATGTCGAAGGC
AGCATCACCACTTCCAGAATAATGTCGACGACATGATCGACGTTCTGCGCACCTCCAGCGCCAGCGA
AGCGCCGGGCTACCCGAACCTTTGTCGGCTGGAAAAGTGTCAACGGCAAGCGCGTGCCGATCTTCCGC
TATTTCAACGTCAACAAAGCCCGCATCAAAGGGGTGGAGACGGAGGTGAAGATCCCGTTTGCGCATG
5 AGTGGAAGCTGACGGTGAACCTACACCTACAACGATGGTCGCGATCTGAGCAATGGCGGCGACAAACC
GCTGCAGACGCTGCCGTTCCATACCGCCAACGGCACGCTCGACTGGAAACCGCTGGACGACTGGTCC
TTCTACGTGACGGCCAACTATACCGGCCAGCAGCGCGCGGTGAGCGCCACCGGCAAAACGCCGGGC
GGCTACACCCTGTTTGACGTTGGCGCGGCATGGCAGGTGACCAAAAACGTGAAACTGCGCTCCGGGG
TGCAGAACGTGGGTGATAAAGATCTGAGCCGGGACGACTACAGCTATACCGAAGAAGGCCGTCGCTA
10 CTTTATGGCGGTGGATTATCGCTTCTGA

SEQ ID NO:51

ATGAACAGAGCCGCCACGCTGACCCTCAACGCGCCCCTGCTGATGCTCGTCGCTGCGCTGGCGCTTT
CAACCCCTTTACCGCCGGCGCCGCGCCGGCCTTTCTTGATTACGCCAACAGCAAACCCAGCAATCT
CAGGCGCAAGAAAAAACGATGCCGCAAGCGCAAAACAAACACAAGAAAGCCGCCAGAGCGCAGATA
15 ATAAAAAACCGGTACCAGCACCTCACAATTACAAAAAGAATCACCAGCCAGCAGGCGGCGATTGCA
CAAAAAGATAAGCTTATACAGCAATTAAAAAACAGCTTGCCGCTACGCCGCAAACGGATACTGCCGG
AGCGAATGAGCAAGCGGCGTTGAATAAGAGAATTAATGAATTACAGGTGCCTTAAGCGCCGCTACT
GCAGAAAAAGAGGCATTAATAAAAAAGCAGGCGTTGTGCAGAATAATAATCTACAGCAAAGCCAGGC
CGCGGCGCGTCAGCAGATCCAGCAATTAACGACGCAGATTCAGCAAGCCGAAGCTGAAAATAAACGC
20 CTCAGCGCCAGCTTTACCACGCTTAATAAAGATAAACACGCGCTAATGACCCAACTGGCCGCAACGGA
AAAAGAGAAACAGGCCGCTCTTGAGCAGGTCAAAGCGCTTAACGCTGACAAACAGCCGCTGACGACC
CGGCTGGCCGCCGCGGAAAAAGAGAAACAGGCCGTCTCGAGCAGGTAAAGGCCCTTAACGCCGAT
AAACAGTCGCTGACTATTCGCCTCGCCGCTGCGGAGAAAGCGCAGCAGGCCGCTGTTGACCAGGCTA
AAGCGCTTAACGCTGACAAACAGCCGCTGGCTACCCGACTGGCCGCCGCGGAAAAAGAGAAACAGG
25 CCGTCCTCGAGCAGGTTAAGGCCCTTAGCGCCGATAAGCAGTCGCTGACTATTCGCCTCGCCGCTGC
GGAGAAGGCGCAGCAGGCCGCTCTTGACCAGGCTAAAGCGCTTAACGCTGACAAACAGCCGCTGGC
GACCCGGCTGGCCGCCGCGGAAAAAGAGAAACAGGCCGTCTCGAGCAGGTTAAAGGCCCTTAACGC
CGATAAGCAGTCGCTGACTATTCGCCTCGCCGCTGCGGAAAAGACGCAGCAGGCTGCCCTCGATCAG
GTCAAAGCCCTTAACGCCGATAAACAATCGCTGTCCACCCGGCTGGCCGCCGCGGATAAAGCGCCGC
30 ATGGCCCCGCTAACGACGCCGCTGCGCCAAAAAATGAGCCACCAGAGATGGCGGCCATAGTGGCAG
CCTATCGCCTGCAGGCGGATAAAGACAACGCCAGCTACGGATGAAAGAAGATGAAATCGAACTGCT
GAGAACGCAGCTTTCTGTACAGTCCAAAACGCGCAGCGGCGAGAGCGCCGCCGCCAACTCAGCGCA
TCGGGAGAACAGCAGGCTTATGCGATCGGCGCCTCGATGGGAAGCGAGGCGCTCAACGTCCTTACCA
CCCGTCGTA CT CAGGGAGTTACCGTCGACGCAGGCCTGGTGCTGCAGGGCATCGAAGATGCCTTTCTG
35 CGGCCAGCTTCGTCTCGGAGAGCAGGAACGTAACAAGGCGCTGTTTGATGTGTGCGCAGCAGGTTTTT
CAGAACCTGAATAAAATAGAGCAGAAAAACATCAGTGCCGGCAAGAAATATCAGCAGGCGTTTGCGC
GCAAAAAAGATGTGGTCTTTAAAGAGGGCGTCTACAGCCGCGTCGATTACCTGGGTAAAGGAAAAAT
AAGCGGTAATGACCTGGTTACCGTGGTGATCAAAGAGATGCTGACGGACGGGACGGTGATCAACGAT

ATGGAAGCGAAAGATCAGGCGCTTACGCAAAAGCTGGATGCCTATCCCCGGTGTTTCGCGAACCGC
TGAAGCGTCTACAGAACCACGGCTCCGTGACGCTCGTCGTCCCGCCTGAAAAGGCCTATGGCAGTAA
AGGATTACCGCCAAAATCCCGCCAGGCGCCACCATGGTTTATTCCGTGCGGATAGTAGATAGCCAAC
CCGAGCCGGCAAAATAG

5 SEQ ID NO:52

ATGAAAATCCTGTCCGTGCGTCACGCCGCCCTCCCGGCCCTGCTCTTGCCGCTCATTGCGGCAGCCCA
GGCCGCTGATGAACAAACCATGGTGGTGACCGCCGCGCCAACCACGGTTTCTGAACTGGATACCCCC
GCCGCCGTGAGCGTGGTGAATGGGGATGAGATGCGCCAGGCCGCGCCGCGCGTCAATCTCTCTGAA
TCGCTGGGCGCCGTGCCGGGCCTGCAGGTGCAGAACCGGCAAACTATGCCAGGATCTGCAGCTG
10 TCGATTGCGGGCTTTGGCTCGCGCTCAACCTATGGCGTGCGCGGACTGCGCATCTATGTGGATGGCA
TTCCGGCCACCATGCCCCAGCGCCAGGGGCAGACCTCAAATATTGATATCGGCAGCGTTGACACCAT
TGAGGTGCTGCGCGGCCCTTCTCTGCCCTGTACGGTAACCTCGTCCGGCGGGGTGATCAACGTCACC
AGCCAGACCGGCACCCAGCGCCACCGTGGAAGCCAGCAGCTACTATGGCAGCTTCGGCACCTGG
CACTACGGGATGAAAGCCACTGGCGCCGTTGGCGACGGCAGCCACGCAGGCGATGTGGATTACACG
15 GTCTCAACCAATCGCTTCACCACCCATGGCTATCGCGATCACAGCGGCGCGCGCAAAAATCTGGCGA
ACGCCCCGGCTGGGGGTGCGCATCAACGACGTCAGTAAGCTGACTCTGCTGCTGAATAGCGTGGATAT
CAAAGCCAATGACGCCGGTGGCCTGACCGCCGATGAATGGCGCGATAACCCGCGCCAGTCGCCGCG
CGGCGACCAAGTATAATAACCCGCAAGAATACCCGACAGACCCAGGCCGGCCTGCGCTATGAGCGCCAG
CTCAGTGCCCAGGACGATCTCAGCGTTATGATGTACGCTGGAGAACGTGAAACCACTCAGTTCCAGTC
20 GATCCCGCGCGCGCCGCAGCTGAAGCCGAGCCATGCCGGCGGGGTGATCGACCTTACCCGTCACTA
CCAGGGGATCGATACCCGGCTGACCCATCGCGGAGAGCTGCTGGTGCCCGTCACGCTCACCGCCGG
TCTCGACTACGAAAACATGAGCGAGCGGCGCAAGGGTATGAAAACCTTTGTGATGGTCAACGGCGCG
CCGCAGTATGGCGAACAGGGCGCGCTGCGCCGTAACGAACGCAACCTGATGTGGAACGTCGACCCC
TACCTGCAGACCCAGTGGCAGCTCACTGACAACTCTCGCTCGATGCCGGGGTTCTGCTACAGCTCGG
25 TATGGTTCGACTCGAACGACTACTACATCACCCCAGGCAATGGCGATGACAGCGGTGATGCCAGCTAT
CACAAATGGCTGCCCGCGGGCTCGCTGAAATATGCCCTGACCGACGCGTGGAACGTCTATCTTTCCG
CCGGCCGCGGCTTCGAGACGCCAACCATTAAACGAACTCTCCTACCGCTCCGATAACCAGAGCGGCCT
CAACTTCGGCCTGAAACCCTCCACCAACGACACGGTGGAGATCGGCAGCAAGACGCGGATCGGCAAT
GGGCTGTTACCCGCCGCCCTGTTCCAGACCAATACCGATAATGAGATTGTGGTCGACAGCAGCAGCG
30 GCGGGCGCACCAAGTTATAAAAACGCCGGCAAGACCCGCGGTGAGGGATGGAGCTGGGGCTGGATC
AGCAGTTTGGCGAGAGCTGGCGTCTGAAGGCGGCCTGGACCTGGCTGGACGCGACCTATCGCACTA
ACGTCTGCGACGACGCCAGCTGCAATGGCAATCGCATTCCGGGGATCGCGCGCAATATGGGCTACGC
CTCCTTTGGCTATCAGCCGGAGCAAGGTTGGTACGCCGGGAGCGATATTCGCTATATGAGCGATATCA
TGGCCAATGACGAAAACACCGCCAAAGCGCCCTCCTGGACGGTGGTTGGCCTGACGACTGGCTATAA
35 ATGGAGCTACGGCAGGATGGATATGGATCTGTTGCGTGCATCGACAACCTGTTGACCGGGAGTAC
GTCGGGTCTGTCATCGTTAACGAGTCTAACGGACGTTACTACGAGCCTGCCCCGGGACGTAACCTACG
GCATCGGCCTGAACCTCGCCTGGCGCTTCGAATAA

SEQ ID NO:53

ATGAAATACACGTCTCACTTCCCGCTGGGGATCGTCATTCTCTGCTCGCCTGTAGCGTGCCGCTGCA
GGCGGCAGAGAACATGACCGAACAAATCGACGCCTGACGAGAGCGCCGCCACTGCCGAAAATCACGA
GGAGACGATGGTCATAACCGCCGCCAGGCAGAACCTGCAGGCGCCGGGCGTGTGCGACCATCACCGC
5 AGAAGAGATCCGCAAACATCCCCCGCCCGCGATGTGTGCGAGTTAATTCGTACGCAGCCCGGGGTA
AACCTGACCGGCAACTCCACCAGCGGGCAGCGCGGCAACAACCGGCAAATTGATATCCGTGGCATGG
GGCCCGAGAATACGCTGGTGTCTGGTCGATGGTAAACCGGTGACCAGCCGTAACCTCGGTGCGGTATG
GCTGGCGCGGCGATCGTGACTCCCGCGGCGATACCAGTTGGGTGCCAGCGGAGATGATCGATCATAT
CGATGTGATCCGCGGCCCGGCGGCGGCGCGCTATGGTAATGGCGCGATGGGCGGGGTGTCGAACAT
10 CGTGACCAAACCGACCACGCGAGAATGGCACGGGTCTGTGAATACCTATATGAATGCTCCGCAGCAC
CGTAAAGAAGGGGCGACGAAACGTACTAACTTTAGCCTCAATGGTCCGCTGTGCGACAGTGTGAGCT
TCAATCTCTGGGGTAATCTGAGTAAAACCCAGGCCGATGCACAGGATATTAACGCCGGGCATGAAGC
GGAACGTACCGGTTCTACGCCGGTTCTTATCCCGCCGGACGTGAAGGGGTGGTGAACAAAGATATT
CACAGTAAGCTGCGCTGGGAGTTTGCCCCGATGCAGGCCCTGGAGTTTGAGGCCGGTTACAGCCGCC
15 AGGGTAATCTCTATGCCGGCGACACACAAAACACCAATACCAGTACGCTGGTGAAGAGTATGTACGG
GAAAGAGACCAACCGTCTCTACCGGCAAACCTTACGGCGTAACATGGACCGGCGGCTGGGATAATGGC
GTGACCAGCAACAGCTATGCCCAGTACGAACACACCCGTAACCTCGCGAATGGATGAAGGGCTGGCGG
GCGGTACGGAAGGGATCTTCTCCAGTAGCGAGTTTTCAGATATCGATCTGGCCGATGTCCTGCTACAT
AGTGAAGTGAATATTCCGTTTACGCTGGGGGTGATCAGAATCTGACGCTGGGGGCAGAATGGAATC
20 AGCAGCGGATGAAAGATGGCGTATCGACAACCCAGGCGCTCTCTTATGGCACTATCGATGGCGTATC
GGCTACCGGTCTGATGCCCGTACTCCAGTGCCGAGATCTTCTCGCTGTTTACCGAAGATAATATGGCGC
TAACGGACAGCACCATGCTGACACCCGCTCTGCGCTTCGATCACCACAGCATCGTCGGCAATAACTGG
AGCCCCTCACTGAACCTGTCTCAGGAGCTGACGGACGACTGGACGCTGAAGCTGGGCATTGCCCGTG
CTTACAAGGCGCCTAACCTCTACCAGTTGAACCCGAACTATATTCTCTACAGCAACGGTCAAGGCTGTT
25 ACGCCAGTAGTTCCGCCTGCTATCTGATGGGGAATAGCGATCTGAAAGCGGAGACCAGCGTTAATAA
AGAGATTGGTCTTGAGTACAAGCATGATGGCTATCAGGCGGGGATCACCTGGTTCCGTAACGACTATC
ACAATAAGATTGAGTCAGGGTATGCGGCGGTGGGTACCGCCAGCAACGGCACCAACCAATATCTATCA
GTGGGAAAACGTACCAAAGGCGTTAGTGGAAGGCCTGGAAGGAACGCTGAATCTGCCGGTGGGGGA
GGCGGTTAACTGGAGCAATAACCTGACCTGGATGCTGCAGAGCAAGAATAAGACGACCGGCGACCG
30 GCTGTGAGTGATCCCGCAGTTTACCCTGAACTCGACTTTGAGCTGGCAGGTTTCGTGAAGATCTCTCCC
TGCAGAGCACCTTTACCTGGTATGGCCGACAGAAACCAAACGCTTCAATTATAAGGGCGAGGCGGT
CAGCGGCAGCGAACTAAACGAAGTCAGCCATACAGCATTGTGCGCCTCAGTGCGACCTGGGATGTG
AACAAAAATCTGAGCTTCACCAGCGGGATAGATAACCTGTTTGATATTCGCCACTACCGGGCAGGGAA
TGCGCAAACGACCGGCAACGCGACGACGGGAGCTTATCTGTATGGCGCGGGTGCCGAGACCTATAAC
35 GAATCGGGGCGGACCTTCTTTATGAGCGTTAATACTCATTTCTGA

SEQ ID NO:54

ATGGAAAAAACGCTTCTCTGCCTTTCGGCAGTTTCAACTCATTGGCATTGTTTACAGGTCTGTGTCTG
GGAGCCTCGCCGGCAGCAGGCATCGCAGCGGAAAATTCGGTCAAAAATAGTGAAGAGACGCTGGTA

GTGGAAGCCGCTCCGCCTTCACTCTACTCCCCGGCGCTTCCGCCGATCCCAAGTTCAATAAACCGCT
GGTCGATACCAACCCGCACCATCACCGTGATCCCGGAACAGGTGATTAAAGATCAGGGCGTCACCAAC
CTGACTGACGCCCTCAAAAACGTTCCCGGCGTCGGGGCGTTTTATGCCGGGGAGAATGGCAGCTCAA
CCACCGGGGATGCCATCTTTATGCGCGGCGTGGATACCTCTAACAGCATCTATGTGGACGGCATTG
5 CGACATCGGTAGCGTGACGCGCGATACCTTCAATACCCAGCAGGTGGAAGTCATCAAAGGGCCCGCC
GGCACGGACTATGGCCGCAGCGCGCCCTCCGGCTCGATCAATATGATCAGCAAGCAGCCGCGCCTTG
ACTCCGGGATCGACGGCTCGGCCAGCATCGGCAGCGCCTGGTCGCGCCGGGGCACTCTCGACCTGA
ACCAGGCGTTTAGCGACAACGCTGCGTTCCGTCTGAACCTGATGGGGGAAAAAACGCATGACGCTGG
TCGGGACCGCATTGAAAACGAACGCTATGGCATCGCACCGTCGCTGGCCTTCGGCCTTGATACCCCA
10 ACTCGTCTGTATCTGAACTATCTGCACGTCCGGCAGAACAACACCCCGGATGGCGGGATCCCTACCGT
CGGCCTGCCGGGCTATTCGGCGCCTTCGCCGAAGTATGCCGCACTCAACTCCGCCGGGAAGGTCGAT
ACCAGCAATTTCTATGGCACCGACTCCGATTACGATAAATCTACTACCGACAGCGGTACCCTGCGCTT
CGAACACGATCTGACGGAGAATACCACCGTGCGCAATACCACCCGCTGGTCGCGAGTGAAACAGGAG
TATCTTTTGACCGCGGTGATGGGCGGCGCGAACAATATCACCGCCCCGATATCAATGACGTCAACAC
15 CTGGAGCTGGTCGCGTCTGGTTAATACCAAAGATGTCAGCAACCGTATTCTGACCAACCAGACCAATA
TCACCTCGACTTTCAATACTGGCTCGATAGGCCATGACGTCAGCGCCGGCGTGGAGTTTACCCGGGA
AAACCAGACCAACTATGGCGTTAACGCCAGGACCGCGCCGGCGGTGAATCTCTACCATCCGGTGAGC
AACCTGTGATTGGCGGGCTGGACAGAAACGGGGCGAACGCCAACGGCCAGACCGATACCTTCGGG
ATTTATGCCTTTGATACGCTGACGCTGACCGAGCGGATTGAGATCAACGGCGGGCTGCGTCTCGACA
20 ATTACCATACCAATATGACAGCGCCACCGCCTGCGGCGGCAGCGGACGCGGGGCTATCGCCTGCCC
GCCCCGACAGTCGACCGGCAGCCCGGTCACTACTGTCGATACCGCTAAATCCGGCAATCTGGTTAAC
TGGAAGCCGGGGCGCTGTACCGCTTAACCGAGCAGGGCAATGTCTACGTCAACTACGCCATCTCAC
AGCAGCCGCCGGGAGGCAGCAGCTTCGCCCTGGCCGCCAGCGGCAGCGGCAACAGCGCTAACCGGA
CCGACTTTAAGCCACAGAAGGCGAAATCCAGCGAGCTGGGCACCAAGTGGCAAATCTTCGACAACCG
25 TCTGCTGCTCAGCGCGGCGTTATTCCGCACCGATATTGAAAACGAAGTGGCCGCCAACGATGACGGA
ACCTGGTCGCAGTACGGCAAAAAGCGCGTGGAGGGGTATGAACTCTCCGCGACCGGAAACCTGACCC
CGGACTGGACGATTATCGCCGGCTACACTCAGCAGCATGCGACAGTGACGGAGGGACAGAACGTTGC
ACAGGATGGATCTTCCGCCCTGGCCTACACCCCGAAACATGCCTTTACGCTGTGGACGCAGTATCAGG
CCACCAGCGATCTGTCCGTCGGCGGCGGTGTGCGCTATGTCGGAAGCCTGCGCCGGGGCAGCGATG
30 GTGCAGTCGGTACCCCGGATCACACCGAGGGCTACTGGGTTGCCGACGCCAACTGGGCTATCGGGT
CAACAGCAACCTCGATCTGCAGCTCAATATGTATAACCTGTTTGATACCGATTACGTGGCCTCCATCAA
CAAGAGCGGCTATCGCTATCATCCGGGCGAACCCCGGACCTTTATGCTGACGGCGAACGTCCATTTCT
GA

SEQ ID NO:55

35 ATGGCGACTATGTACAAATCGACTCCGTCAGCAGCATGGTGTAAAAAACGCCTGCTGGTGACCTCTTT
GTTTGCAGCAATTTATCAGACTTCTGCCATCGCAGCAGATACTTCCGCCGTTAGCGGCGAGGCGGTGG
ATGACACCTCGGAACAAATGACCGTCACCGCCCCCGCGCCGGTGCAGAAAGCCGGTAGCGAACACAG
CATCAGCGCCCCGGGAGCTGGAGAATAAAGGCGCTAACGATTTCCGGCTCAATCATGCGCTATGAGCCG

CTCATCAGCGCCACCGGGGCCAGCGGCGGCTCCGGCAACGGCAAAAGCGGCTTCGACCGCGGAGGT
TACACCGGCTACAACATTTCGCGGTATGGAGAGCAACCGCGTAGGCATCGACGTGGACGGTATCGCGC
AACCCAACGCCACCGGCCGCGGCTACGTGCGCCGCGCCGGGCTCAACACCTTCGGCATCGGCCGCG
ATTATATCGACCCGTATATGTACGGCAGCGTTGATATCCAGTCCGGCGCCACCTCGACGGAAACGGCC
5 AACAGCGCTATCGGGGGGAATGTCTCCTTCCGCCCAGAAATCAGCGGATGATTACCTGCGCCCGGGCA
AGACCAGCGCCTTCGGCTACCGCAGCGGTTACGACTCTGCGGATCGCAGCTGGCACAACGGGGTGA
CCGTGCGCCGGCGGCGATGAGTTCCTGCGCGGGATTTTGGTCTATAGCCGCCGTGACGGCCAGGAAAC
TGAAAACAACAGCGGCACCGTCGACGCCTACCCGGCGAACTGGCACTCCGATGCTTTTCTGGCCTCC
GGGATCTGGCAGCCTAACGATGAGCACAAGCTGACCAGCACCTTCGACTATTACCATAAAACCAACCA
10 CACCCACTACGATACCTGGGACTCCAGCGGCAACAGCACCATCGGCACCGCCAACCAGACCAGCCAG
ACCCGGCGCTGGGGCCTGAGCCTGAAGGATGACTGGACGCCGATGAACGACTACCTCGACAGCGTC
TCCACAAAATCTACTACCAGCATACCGAAGCCCATGACTGGACTTATATGCCGGACAGCGTCACCCG
CAAATGCAGACGGTGAACCTCTAAGTACGATACCGACACCTGGGGCCTGCAGACCGCGCTGGCGAAA
ACCCTGGGCCGCCACGATCTGAGCGCCGGTTTCAACGCCAGCACCAGCAAAACCCAGCGGCCGTTCA
15 GCCAGTCGCCGATCCCCAGCGTTTACAGCGAGATCATGCAGCCGGAGGCAGACAGCCGCAGCTACAC
CCTCGGCGGCTTTGTCCAGGATAAGATCAACTTCGATCTCGACAGCCACAACCTTCGCCGTTATTCCCG
GCGTGCGCGTGGTGCATCAATCGACTAAGCCGAAAATCTGTCCGATCTCGCCGCCAACAGCAGCGT
GCTGAGCGAATCGTCGGTGGCGAATCTGTACGGCAAAAACAGCGATACCCAGGTTCTGCCGTGTTG
ACCTTCCAGTACGACCTCACCCCGCGCCTGATGACCTACCTGCAGTACCAGCGCGGGGCGCAGTTCC
20 CCAACGCCAGCCAGCTGTATGGCTCCTGGAACCTCGGCTCCAGCTACGCCGGCAGCCAGCAGTATGC
CCTGATCGGCAATACCGATCTGAAGACGGAAACCAGCGATAATCTCGAGTGGGGGCTGAAAGGGGAA
GTTACCGAAGGCATCACCTGCGCACGGCGCTGTTCTACAACAGCTATAAGAACTTTATCGCCTATAC
CCGCTATACCCGCGCCAACAATCCGGGCCAGTTCACGAATGTGCCGTGGAACATCTACACCATTTATC
AGGCGGAAAACCGCGATAAAGCCTATATCTACGGCGGTGAGATTAGCACCAAATTTAACTTTGGCACC
25 TGGTTTGAGCAGGTGGACGGCCTGAGCGCCACCCTCGCCCTCGGCTATAGCGAAGGGAAATCGAAAT
CCAGCTACAGCGGCGATAAATACGTGACCTCGACAGCGTGGCGCCAATGAAAGCCATCGTCGGCGT
GGCGTGGGACGATCCGGCGAAACGCTACGGCACCGCCCTGACGGCGACCTTTGTCAAAGGGAAACA
GGCGACCGCCACCAACCGCGAAAGCTACAGCAACAGCGGATCCGCCATCACCGATGCCAGCAGCGA
CTATATGCGCGTGCCGGGCTACGGCATGCTGGACTGGACCGCGTACTGGCAGGTGGCGAAAAACGT
30 GCGCCTCAATGGCGGGGTCTACAACCTACCGATCGTAAATACTGGGATTACCTGAGCAGCCGCAAT
ATCGAGACCGGCACCAACCAGGACGCCAACGATAAAGCGCTGGCGGTGATGCCGGGCCGACCTGG
CAGCTGGGCGTCAACGTGCACTTCTGA

SEQ ID NO:56

ATGGCGATGAAAAAGTTGCTCATAGCGTCGCTGCTGTTTAGCAGCGCGACTGTATACGGTGCTGAAG
35 GGTTCGTGGTGAAGGACATTCATTTGAAGGCTTGACGCGTGTGCTGTTGGTGGCGCCCTCCTCAG
TATGCCAGTGCGTCCTGGCGATACGGTGACCGACGATGATATCAGTAACACTATTCGCGCGCTGTTTG
CCACTGGCAACTTCGAGGACGTCCGCGTCTGCGCGATGGTGATACCCTGCTGGTTCAGGTGAAAGA
GCGTCCGACGATCGCCAGCATCACTTTCTCCGGCAACAAGTCGGTGAAAGATGACATGCTCAAGCAG

AACCTTGAGGCCTCAGGCGTTCGGGTGGGCGAGTCGCTTGACCGCACGACCATCGCGGATATCGAGA
AGGGTCTTGAAGACTTCTACTACAGCGTCGGTAAATACAGCGCCAGCGTCAAAGCAGTCGTTACGCC
GCTGCCGCGTAACCGTGTGATTTGAAGCTGGTCTTCCAGGAAGGCGTCTCCGCAAAAATTCAACAGA
TCAACATCGTCGGCAACCATGCGTTTTGACCGATGAGCTGATCTCCCACTTCCAGCTGCGCGATGAG
5 GTGCCGTGGTGGAACTGGTTCGGCGACCGTAAATACCAGAAGCAGAAGCTAGCGGGCGACCTTGAA
ACCCTGCGCAGCTACTACCTGGATCGCGGCTATGCCCCGTTTCAACATCGATTCTACCCAGGTCAGCCT
GACGCCGGATAAGAAAGGGATCTACATCACCGTCAACATCACCGAAGGCGATCAGTACAAGTTTTCCG
GAGTGCAGGTGACGGGCAACCTCGCTGGCCATTCCGCGGAAATCGAAGCGCTGACTAAAGTTGAGCC
AGGCGAACTGTACAACGGCGCGAAAGTGACCAAGATGGAAAACGACATCAAGAACTGTTGGGTCTG
10 TATGGTTACGCCTATCCGCGCGTGCAGTCGCAGCCGGAGATCAACGACAGCGATAAAACCGTTAAGC
TGCACGTTAACGTCGACGCAGGCAACCGTTATTACGTGCGTAAAATTCGTTTGAAGGCAACGACACC
TCTAAAGATGCCGTAAGTGCGCCGCGAAATGCGCCAGATGGAAGGCGCATGGCTGGGCAGCGACCTC
GTCGATCAGGGTAAAGACCGTCTCAATCGTTTAGGTTTCTTTGAAACGGTGGATACTGATACCCAGCG
CGTGCCGGGCGAGCCCGGACCAGGTGACGTTGTCTACAAGGTGAAAGAGCGTAACACCGGTAGCTTC
15 AACTTCGGTATCGGCTACGGCACCGAGAGCGGCGTCAGCTTCCAGGCGGGCGTTCAGCAGGATAACT
GGTTAGGTACTGGCTATGCTGTCGGGATCAACGGTACCAAAAACGACTACCAGACCTATACCGAGCT
GTCGGTGACCAACCCGTAATTCACCGTAGACGGTGTAAGCCTCGGCGGTCTGTCTTCTATAATGACT
TTGATGCGAACGATGCGGATCTGTCTGACTATACCAACAAAAGCTATGGTACAGACATTACGCTGGGC
TTCCCGGTCAACGAATACAACACGCTGCGCGCCGGCGTCGGTTATGTGCATAACTCCCTGTCCAATAT
20 GCAGCCGCGAGGTGGCAATGTGGCGTTACCTTAACTCGATGGGCCAGTATCCGGACAACACCAACGAC
CGGAACTCGTTCAGTGCGAATGACTTCACCTTCAACTACGGTTGGACCTATAACAAGCTTGACCGCGG
CTTCTTCCCAACGGAAGGTTTCGCGCGTCAACCTGAACGGTAAGGTGACCATTCCGGGCTCAGACAAC
GAGTACTACAAAGCGACGCTGGATAACCGCGACCTACGTGCCGATCGACAACGATCATCAGTGGGTAG
TACTGGGTCTGACGCGCTTTGGTTATGGCGATGGTATCGGCGGCAAAGAGATGCCGTTCTATGAGAA
25 CTTCTATGCCGGTGGTTCCAGCACCGTGCGTGGCTTCCAGTGAACACCATTGGTCCGAAGGCGGTG
TACTTCCCGGCAAGCAGTCGTCATGATGATGACGATAGTTACGATAATGAATGTAAGAGCACCGAATC
CGCACCGTGTAATCCGATGATGCGGTGGGCGGTAACGCGATGGCGGTGGCCAGCCTTGAGCTGATT
ACCCCGACGCCGTTTATTAGTGACAAATATGCGAACTCGGTCCGTAATTCGTTCTTCTGGGATATGGG
TACCGTATGGGATACTCACTGGGATTGAGCGCGTACGCTGGTTATCCGGATTACAGCGATCCGAGC
30 AACATCCGTATGTCTGCGGGTATTGCCGTGACGTGGATGTCGCCGTTGGGGCCGTTGGTCTTCTCCTA
CGCCCAACCGTTCAAAAAGTACGATGGAGACAAAGCCGAACAGTTCCAGTTTAACATTGGTAAACCT
GGTAA

SEQ ID NO:57

ATGACAGATGTGACTATTAAGCGCTGGCCTCAGAGATTCAGACCTCTGTGGATCGCCTGATACAGCA
35 ATTTGCTGACGCAGGCATCCGCAAATCGGCTGATGATTCTGTGACCTCGCAAGAGAAACAACTTTGT
TGACGCACCTGAACCGTGAACACGGCTCGGCGCCAGACAAGCTGACGTTACAGCGTAAGACGCGCAG
TACGTTAAATATTCCAGGTACCGGTGGAAAGAGTAAATCGGTACAAATCGAAGTCCGCAAGAAACGCA
CCTTTGTGAAACGCGATCCGCAAGAGGCTGAACGCCTGGCCGCGGAAGAGCAGGCGCAGCGTGAAG

CGGAAGAGCAGGCCCCGTCGTGAAGCTGAAGAAGCAGCGAAACGCGAGGCGCAATTAAAAGCTGAAC
GTGAGGCCGCGAGAACAAGCTAAACGTGAAGTCGCTGATAAAGCGAAACGTGAAGCTGCGGAAAAAGA
CAAAGTGAGCAATCAACATACCGACGAAATGACCAAAACCGCCCAGGCTGAAAAGATCCGTCGCGAG
AACGAAGCCGCGGAATTGAAGCGCAAATCGGAAGAAGAAGCACGCCGCAAACCTTGAAGAAGAAGCG
5 CGCCGTGTAGCGGAAGAAGCACGCCGTATGGCTGAAGAAAACGAAAAAAATTGGTCTGAAACCTCAG
ACAGCCCCGGAAGATAGCAGCGACTATCACGTCAACCATCACAGCATGCTCGTCAGGCTGAAGATGA
TAACGATCGTGAAGTCGAAGGCGGTGCGGCCGTAGCCGTAGCAGCAAAGCGGCTCGTCCGGCGAA
GAAAGGCAACAAACACGCTGAATCGAAAGCTGATCGTGAAGAAGCCCGCGCGGCCGTGCGCGGCGG
TAAAGGCGGTAAGCACCGTAAAGGTTCCGCTCTGCAGCAGGGCTTCCAGAAGCCAGCGCAGGCCGTT
10 AACCGTGACGTCGTAATCGGCGAAACCATCACCGTTGGCGAACTGGCTAACAAGATGGCGGTGAAAG
GTTCTCAGGTCATCAAAGCGATGATGAAGCTGGGCGCCATGGCGACCATCAACCAGGTCATCGACCA
GGAAACCGCACAGCTGGTTGCCGAAGAGATGGGCCACAAAGTTATCCTGCGTCGTGAAAACGAACTG
GAAGAAGCCGTAATGAGCGACCGTGACACCGGCGCGGCCGCTGAACCGCGCGCACCGGTCTGAGCC
ATTATGGGTCACGTTGACCACGGTAAACCTCGCTGCTGGACTACATTCGTTCTACCAAGGTTGCCTC
15 CGGCGAAGCGGGTGGTATTACCCAGCACATCGGTGCTTACCACGTCGAAACCGACAACGGCATGATC
ACCTTCCTGGATACCCCGGGCCACGCCGCGTTTACCTCCATGCGTGCTCGTGCGCGCAGGCGACGG
ATATCGTGTTCTGGTGGTGGCGGCAGACGACGGCGTGATGCCGCAGACTATCGAAGCTATCCAGCA
CGCTAAAGCGGCGCAGGTACCGGTGGTAGTGGCGGTGAACAAGATCGATAAGCCAGAAGCCGATCC
GGATCGCGTGAAGAACGAACTGTCCAGTACGGCATCCTGCCGAAGAGTGGGCGGCGAGAGCCA
20 GTTCGTCCACGTTTCCGCGAAAGCGGGTACCGGCATCGACGACCTGCTGGACGCGATCCTGCTGCAG
GCTGAAGTTCTTGAGCTGAAAGCGGTCCGCAACGGTATGGCGAGCGGCGCGGTCTCGAATCCTTCC
TTGATAAAGGTCGTGGTCCGGTAGCTACCGTTCTGGTTCGCGAAGGTACTCTGCACAAGGGCGACATT
GTTCTGTGCGGCTTCAATATGGCCGTGTGCGCGCGATGCGTGACGAACTGGGTCGCGAAGTGCTGG
AAGCGGGTCCGTCCATTCCGGTGGAAATCCTCGGCCTGTCCGGTGTGCCGGCTGCCGGTGATGAAGT
25 GACCGTAGTGCGTGACGAGAAAAAAGCGCGTGAAGTGCGCTGTATCGTCAGGGCAAATTCCGTGAA
GTTAAGCTGGCGCGTCAGCAGAAATCTAACTGGAAAACATGTTGCTAACATGACCGAAGGCGAAG
TTCACGAAGTGAACATCGTACTGAAAGCGGACGTACAGGGTTCTGTGCAAGCGATTTCCGATTCTTA
CTGAAACTGTCTACCGACGAAAGTGAAGTGAAGATCATCGGTTCCGGCGTAGGTGGTATCACCGAAA
CCGACGCTACCCTGGCAGCAGCATCCAACGCGATTCTGGTTGGCTTCAACGTTCTGCCGATGCCTCT
30 GCGCGTAAAGTTATCGAAGCGGAAAGCCTGGATCTGCGTTACTACTCCGTCATCTATAACCTGATCGA
CGAAGTGAAAGCGGCGATGAGCGGCATGCTGTCTCCGGAAGTGAACAGCAGATCATCGGTCTGGCT
GAAGTGCGTGATGTCTTCAAATCGCCGAAATTCGGCGCCATCGCGGGCTGTATGGTTACCGAAGGGA
CGATCAAACGTCACAACCCAATCCGCGTTCTGCGTGACAACGTGGTTATCTATGAAGGCGAGCTGGAA
TCCCTGCGCCGCTTCAAAGATGACGTTAACGAAGTCCGTAACGGCATGGAATGTGGTATCGGCGTGA
35 AGAACTACAACGACGTTGCGGTTGGCGATATGATCGAAGTGTTGAAATCATCGAAATCCAGCGTAGC
ATCGATTAA

SEQ ID NO:58

ATGAAAAGAATGTTAATCAACGCAACTCAGCAGGAAGAGTTGCGCGTCGCCCTTGTTGATGGGCAGC

GCCTGTACGACCTGGATATCGAAAGCCCCGGGCACGAACAGAAAAAGCGAACATCTACAAAGGCAA
AATACCCCGCATTGAACCCAGCCTTGAAGCCGCGTTTGTGATTACGGCGCCGAGCGTCATGGTTTCC
TCCCCCTCAAAGAAATCGCCCCGGAATACTTCCCCGCCAACTACAATGCGCATGGTCGTCTAATATC
AAAGACGTACTGCGGGAAGGTCAGGAAGTTATCGTGCAGATTGATAAAGAAGAACGCGGCAACAAAG
5 GCGCTGCGCTACCACTTTATCAGCCTCGCGGGCAGCTATCTGGTACTGATGCCGAACAACCCGCG
CGCCGGGGGAATTTCCCGCCGTATCGAGGGCGACGACCGTACCGAACTGAAAGAAGCGCTGGCGAG
CCTGGAGCTTCCGACGGCATGGGCCTGATCGTTCGACCCGCTGGCGTCGGCAAATCCGCCGAAGCC
CTGCAGTGGGACCTGAGCTTCCGCCTGAAGCACTGGGAAGCGATTAGAAAGCCGCGGAAAGCCGTC
CGGCGCCGTTCTGATCCACCAGGAAAGCAACGTATTGTCCGCGCCTTCCGTGACTACCTGCGCCA
10 GGACATCGGCGAAATCCTGATCGATAACCCGAAAGTGCTTGAGCTGGCGCGCCAGCATATCGCCGCG
CTGGGTGTCGGATTTTTCAGCAGCAAAAATAAACTGTACACCGGTGAAATCCCGCTGTTTACGCCATTA
TCAGATCGAATCGCAAATTGAGTCCGCCTTCCAGCGCGAAGTGCGCCTGCCTTCCGGCGGGTCTATC
GTTATCGATAGCACCGAAGCGCTGACCGCGATCGATATCAACTCCGCCCGCGCCACCCGCGGCGGCG
ATATCGAAGAGACAGCCTTCAATACCAACCTCGAAGCGGCTGACGAAATTGCCCGCCAGCTGCGTCT
15 GCGCGACCTCGGCGGCCTGATCGTTATCGACTTCATCGATATGACCCCGGTTCCGCCACCAGCGCGCC
GTGGAGAATCGTCTGCGCGAAGCCGTCCGTGAGGACCGTGCGCGCATTAGATCAGCCATATTTTCGC
GCTTCGGCCTGCTGGAGATGTCCCGTCAGCGCCTGAGCCCGTCGCTGGGCGAGTCCAGCCACCACGT
CTGCCCGCGCTGCTCCGGCACCGGCACCGTGCGTGATAACGAATCGCTGTCGCTCTCTATTCTGCGTC
TGATCGAAGAAGAAGCGCTGAAAGAGAATACCAAAGAAGTCCACGCCATTGTTCCGGTACCGATCGC
20 CTCCTATCTGCTGAACGAAAAACGTGCCGAGTGAGCGCTATCGAATCCCGTCAGGGCGATGTGCGC
GTTATTATCGTGCCAAACGACGAAATGCAAACGCCGCACTACTCCGTCCTGCGCGTGCGCAAAGGTG
AAGAAACCTCAACGCTGAGCTATCTGCTGCCGAAGCTGCATGAAGAAGAAATGGCGCTGCCAGGCGA
CGATGAGCCGGCGGAGCGGAAACGTCCGGAACAGCCGGCCCTGGCCGCTTTTGTATGCCAGATGC
GCCGCCAGCCCCGATGCTCGAAGAGCCTGCCGCCGCGCCTGTCGCCGAGCGGCACCGGTGCGGGC
25 CGCCGCACCGGCGCAGCCTGGCCTGCTCTACGCTTCTTACGCGCGCTGAAGAATATCTTCTCTGGC
GCCGAAGAGGCCAAACCGGCTGAAGTTCAGGTCGAGAAGAAAGCGGAAGAAAAACCGGAGCGTCAG
CAGGAGCGTCGTAAACCGCGCGCCAACAACCGCCGCGACCGCAACGACCGCCGTGATAACCGCGAC
AATCGTGACAACCGCGATAACCGTGACAATCGCGACACCCGTGCGGACAATGCCGAGGGCCGTGAAC
CGCGCGAATCGCGTGAAGAGAACCGTCGCAACCGTCGCGAGAAGCCGTGCGAGAACGTGGAAGCCC
30 GTGATGTTGCCCCAACCTCAGGCGACGACGCGGAGAAAGCGAAATCCCGTGACGAGCAGCAGCCGC
GCCGCGAACGCACCCGCCGCCGAGTGACGACAAACGTGAGGCGCAGCAGGAAGCCAAAGCGCAGA
CTCGCGAAGAGCCGTTGTGAGGAGACGGAGCAGGAAGAGCGTGTACAACTCTGCCGCGTCGTA
AACCGCGCCAGCTGGCACAGAAAGTGCGCGTTGAGTCCGCTGTCGTCGAGCCAGTTGCCGAGATCGT
GCCAGAAGCCGTAGTGGCTGAAGTTATCGCTCCGCACAGCGAGCCGGTGAAAGCCGAGCTGCCGGC
35 AGGGGTGGAGAGCGTGCGGACCAGGACGAAAATGGCGAATCCCGTGAAGCGAACGGTATGCCGCG
TCGCTACGTCGCTCCCCGCGTCACCTGCGCGTCAGCGGTGAGCGTCGTCGCTATCGTGACGAA
CGCTATCCGACCCAGTCGCCTATGCCGCTGACCGTAGCCTGCGCATCGCCGGAGATGGCTTCCGGTA
AAGTCTGGATCCGCTACCCGGTGGTTCGTCCGCAGGATCAGCAGCCGGAAGAGGTTAGGTTACAGGA
CGCCAGCGTCGCGAAAACGTGTCGAGGCCGTAGCGGCCCGGTCGCCGTCGTTGAAACCGTTACCGCT

GCGCCGGTCACCGTCGAGCCGGCTACCATGGAACCAGTAACCGCTGAGCCGGTAGTCGTGAGCCG
GTAGCGGCCGCCGAGCCGCTGGTCGTTGATGCTGCGGAAGTTGTCGCGCCAGCAGCCGTCGAGCCA
GCGCCTCAGGAGCCGGTCACCGAAGCACCGGCTGTCGAAGCGCCTCAGGCTATCGCGCCAGTGACG
CTCGACGCCGAGCCGGTGGTGGTAGAACCTGAAGCGGTGGAAACGACGCCTGTCGTTGCAGCGCCA
5 GTGGAAACTATCGCCCCGGTCGAGAAACCGTGGAGCAAGCGCCAGTGACCGAAGCGCCCCCTGCC
GAACCGGTCAAAGCCGAGCCCCGGTGAGCAAGCCGGTCGTAGTGGCGGGTCATCGCCATGCCACC
GCGCCAATGACCCGTGCGCCAGCTCCGACTATGTCCCGAAGCACCGCGTCATAGCACCTGGGTGC
GCCCCCGTTGCTCTTTGAAGGTAAAGGCGCCGCGGGTGGTCATAGCGCGACCCATAAAGCCACCGC
TGAACCGACTCGCCACAGCCCGTCGAGTAA

10 SEQ ID NO:59

ATGCGCAAGCTCTACTAAGTTTACTCACGCTGTCCCTCGGCGTTGCGCTGCTGCCGTTAGCGCAGGC
GGCGACGACGCCTGCCAGGAGCATCTGCTGGAGCAGGTCCGCCTCGGCGAGGCCAGCAATCGTGA
AGACCTGGTGCGCCAGTCGCTGTACCGTCTGGAGCTGATTGATCCCAACAACCCGGAGCTGATTGCC
GCGCGGATGCGCTATCTGCTGCGTCAGGGGGATGCCGCCGGGGCGCAAAAAGAGCTGGAACGACTG
15 ACGAAGCAGGCGCCGACTCCCCGAGCTGAAGGCGTCGCGCAATGAGATGAAAAGCAACACCGGC
GAGGGCCGCCAGGCGCTGCAGCAGGCGCGACTGCTGGGCGTGGCCGGAAGGTCGATGAAGCCAT
CGCCGCCTATGAAAACTGTACGGCGGGGTGCCGGATGACGTTGACGTCGCCATTGAGTACTGGACG
CTGGTGGCGCGCCTGCCGGCCCCGCATAGCGAAGGCGTCAGCCAGTTGAAAAAACTGAACGCCAGC
GCGCCGGGCAACGTCAGCCTGCTGACTTCGCTGGCGAAGCAGATGTTGCGCGATAACAAACCGCAGG
20 AGGGGTTGCTCTATCTGGCGGAGATGGCCCGATCGGCCTCGGGACGCGGTATCGCCGCCGATATGT
GGTTCAGTGAGGTGAAAAGCATGCCGGTGAGTAAGGCCAGCGTGCAGGCGTTGCAGCAATTTCTTCT
GCAGTTTCCACCGGCTCGGTGGCGGCGAACGCCCGCTTCTGCTCGACCAACAGCAGGCGCAGCT
GCAGGATCCGACTTTCCGCGCCCGCTCGGAAGGGCTGGCGGCGGTCAAGTCCGGGAATACCACGCA
GGCGGTGCGGATCTGCAGAAAGCCGTTAGGCCGACAGCCGCGACAGCGACGCGGTGGGCGCTCT
25 CGGCCAGGCCTATTCCCAGCGCGGCGACCGCGCGCGGGCAGTGGCGCAGCTCAGTAAAGCGATTGC
TATGGACCCTGACAGCCCGAACCGCGGCAAGTGGGACAGCCTGCTGCAAATAACCGCTACTGGCTG
CTGATAAAGCAGGGGGATAACGCCCTGAAAGCCGGCCAGCTTTCGAGGCGCAGAACTATTATGCCC
AGGCGCAGCGGGTCGATCGCACCGACAGCTATGCCGTGCTGGGGCTGGGGGACGTCGCGGCGGCG
CGCAAAGAGGCGGCGGCGGCGGAGCGCTATTACCAGCAGGCGTTGCGCCTGGATCGCGGCAATAAC
30 CTGGCGGTGCGCGGCCTGGCCAACCTCTATCGCGCCGAATCGCCGGAGAAAGCCAGCGCCTGGATC
GCCGGCCTCCCTCCCGCTCAGCGGCGGAGCATCGATGATATTGAGCGCAGCCTGACTAACGACCGGC
TGGAGAAACAGGCGCAGGCTCTGGAGAGCCAGGGCAACTGGGCGCAGGCGGCGGAAGTTCAGCGT
CGGCGCCTGGCGCTGGATCCGGACAGCGTCTGGATAACCTACCGTCTGGCGCGGGATCTGGTCAGC
GCCGGCGAACGCCAGGAGGCCGACGCGCTGATGCGGACGATGGTCAACCGCCAGCCGACGACGC
35 CGAACGGGTCTACGCCTCGGGACTCTACCTGTCGGGGAACGACCAGGACGATCTGGCTCTGGCGCAA
ATCGCCGCTCTGCCGCGCAGCGCGTGGACGGATAACATTCGTGAGCTCGAAGCGCGTTTGCAAAGCG
ACCGGGTGCTGCGCCAGGCCAACAGCTGCGCGACAGCGGTAACGAAGCGCAGGCGATCGCCCTTA
TCCGACAGCAGCCCGCCTCGGTGCGCTATGACCTGACGCTCGCCGACTGGGCGCAGCAGCGCGGCG

ACAGCCAGACGGCGATTGCCAACTATCAGCGGGTGCTGCGCCAGGAGGCCGACAACGGCGATGCGC
GCCTCGGCCTTGCGGAAGTCTACCTGGCCGAGGGCGATAAACCGGCCCGCCGGGCGCAGGTCATGC
AGCTGAAAGGCGCAGAGACCGAATCCATGAACATGCAGCGGCGGGTGGCGCTGGCGCGAGCTGGCC
TTGGCGATACCGCTGACGCGCAACGGATTTTTAATCAGATTGTGCCGAGGCGAAGGCGCAGCCGCC
5 CTCGATGGAGAGCGCGCTGGTGCTGCGCGATGCCGCGCGCTTTGCCACCCAGAGCGGGGCGCCGCA
GCAGGCGCTGACGCACTACCGGGAAGCTATGGTGGCCTCCGGCATTACCCCCGCGCAGCCGCAGGA
TAACGATACTTTTACGCGGCTGACGCGCAACGACAGCCATGATGACTGGCTGAAGCGCGGGATCCGC
AGCGATGCCGCCGACCTTTATCGTCAGCAGGATCTGAACGTCACCCTGGAACATGACTTCTGGGGTTC
CAGCGGCACCGGCGGCTATTCCGACCTGAAGGCGCATACCACCATGCTGCAGATGGATGCTCCGCTG
10 GCGGATGGCCGGATGTTCTTCCGCACCGACCTGGTCAATATGGATGCCGGCAGCTTTTCCACCCACA
GCGACGGGAGCTACTCGCCCAGCTGGGGCACCTGCGGGGAGATCGCCTGTACCAGCGGCAGTAAAA
ATCAGACCGACAGCGGGGCCAGCGTGGCGGTGGCTGGAAGAATGACACCTGGAGCGGGGATATCG
GCACCACGCCGATGGGCTTCAATGTCGTCGATGTGGTGGGGGGGCTGAGCTACAGCAGCGACGTCG
GGCCGGTGGGTACACGGTCAACGTCCACCGGCGGCCTATCTCCAGCTCGCTGCTCTCTTTGGCGG
15 GCAGAAGGACAGCAGCAGCCATACCGGCGCCACCTGGGGCGGCGTCCGCGCCGACGGCGGCGGCC
TGAGCCTGAGCTACGATCGCGGGGAGGCTCACGGCATCTGGTCTCGCTGGGCGCCGACTCGCTGA
CCGGTAAAAACGTGGCGGATAACTGGCGCGTGCGCTGGATGACCGGGTACTACTACAAGGTCATCAA
CGAGAATAATCGTCGCGTCACCGTCGGCCTCAACAATATGATCTGGCACTACGACAAAGATCTCAGCG
GCTACACCCTCGGCCAGGGCGGCTATTACAGCCCACAGGAGTATCTCTCGTTCCCGTGCCGGTGAC
20 CTGGCGTCAGCGCACCGAGAACTGGTCTGGGAGCTCGGCGGGTGGTGTGATGGTCCCATTTCGCG
CACCCAGACGCAAGCCCGCTATCCGCTGCTGAACCTGATCCCGTCCGACTACCGGCAGCGCGCCAGC
GAGCTGACGGAGGAGGGGAGCAGCAGCCATGGATTTCGGTTACACCGCCAGAGCGCTGGTGGAGCG
GCGGGTGACCAGCAACTGGTTCGTCGGCGCCGCGGTGATATTAGCAGGCGAAGGATTACCCCC
GAGCCATGCGCTGCTTTACGTCCGCTACTCGGCGGCCGGCTGGCAGGGGGATCTGGATATGCCGCC
25 CCAGCCGCTGGTGCCCTACGCCGACTGGTAG

SEQ ID NO:60

ATGAGCCAGGAATACACCGAAGACAAAGAAGTCAAATAACCAAACCTCAGCAGCGGGCGCCGACTCC
TTGAGGCGATGCTCATCCTTTGCTCCCTCTTCGCCATCTGGCTGATGGCGGCACTACTGAGCTTTAAC
CCCTCGGACCCCAGCTGGTCGCAAACGGCATGGCATGAGCCTATTCATAATTTAGGCGGCGCCCCCG
30 GCGCGTGGCTTGCCGATACCCTCTTTTTCATTTTTGGCGTCATGGCCTACACCATCCCGGTGATCATCA
TCGGCGGATGCTGGTTTGCCTGGCGGCATCAGGAAAACGACGAATACATTGATTATTTGCCGTTTCC
CTTCGCCTCATCGGTGCGTTAGCCCTGATCCTGACCTCCTGTGGTCTGGCGGCGATTAAACGCCGATGA
TATCTGGTACTTCGCCTCCGGCGGGGTGATCGGCAGCCTGCTGAGCACCACGCTGCAACCCCTGCTG
CACAGCAGCGGCGGCACCATCGCCCTGTTGTGTATCTGGGCGGCCGGGCTGACGCTGTTACCGGCT
35 GGTGCTGGGTGAGCATTGCGGAAAAGCTGGGCGGCGGCATCCTGTCCGTTCTCACCTTTGCCAGCAA
CCGTACCCGTCGGGATGATACCTGGGTGATGAAGGCGAATATGAAGACGACGAGGAAGAGTACGA
CGACGAAGAGGCGGCCAGGCCGAGGAATCGCGTCGCGCCCGTATCTTACGCAGCGCGCTGGCGCG
GCGTAAGCGTCTGGCCGAGAAGTTTACCAACCCTATGGGGCGTAAAACCGACGCTGCGCTTTTCTCC

GGCAAACGGATGGATGACGGCGAAGAGGTGGTGCAATACAGCGCCAGCGGGGCGCCTGTTGCCGCC
GACGATGTACTGTTTTCCGGCGCCAGCGCCGCGCTCCCGCAGAGGATGATGTGCTGTTCTCCGGCG
CCAGCGCCGTGCGCCCCGGGCGATTTGACCCCTACGATCCGTTGTTGAATGGCCACAGTATCGCTGA
GCCGGTAAGCGCAGCGGGCGGCTACAGCCGCGCCGAGGCGTGGGCAGAATCACCGGTGGGCC
5 ATCACGGCGCTGCGCCAGCTTATCAGCCGGAAGCCAGCTATCCGCCGAGCAGGCCTATCAGCCTGA
ACCCGCTCCGTTCCAGCAGGCCTATCAGCCTGAACCCGCTCCGTTCCAGCAGGCTGCTTATCAGCCGC
CAGCGGGGCAAACCGCACCGCAGGCGTATCAGCCTGAGCCAGCGCCGTATCAACAGCCGGTTTACGA
TCCGCGTGCCGGTCAACCTGCGCCGAGGCCTATCAGCCTGAGCCAGCGCCGTATCAGCAGCCGGCT
TACGATCCGTATGCCGGTCAACCTGCGCCGAGGCCTATCAGCCTGAACCTGCGCCGTATCAGCAGC
10 CGGCTTACGATCCGCATGCCGGTCAACCTGCACCGCAGGCCTATCAGCCTGAGCCAGCGCCGTATCA
GCAGCCGGCTTACGATCCCTATGCCGGTCAACCTGCGCCGAGGCCTATCAGCCGGAGCCAGCGCCG
TATCAGCAGCCAACTTACGATCCCTATGCCGGTCAGCCTGCGCCTCAGACCTATCAGCAGCCGGCTTA
CGATCCGAATGCCGGTCAGCCCGCGCCGAGCCGTATCAGCCGGAGCCAGCGGCGTATCAGCCGCA
AAGCGCGCCAGTTCCCCACCGGAGCCAGAGCCCGAGGTCGTGCAGGAGGAAGTGAAACGTCCGCC
15 GCTCTATTATTCGAGGAAGTGGAAGAGAAGCGGGCGCGCGAACGCGAGCTGTTGGCCTCCTGGTAT
CAGCCAATTCCTGAGCCGGAAGTCCGATTGCCACTAAACCGCTGACGCCGCCGACCACTGCGTCCA
AACCGCCAGTGGAGACAACCGTAGTCTCTGCGGTAGCGGCTGGGGTGATCAGGCTACCGCCGCCA
GCGGCGGCGCGGCGGCAGCAACCTCGTCCACTGCCGCATCCGCTGCGGCTACGCCATTGTTACGCC
CGGCGTCCAGCGGCCCAAGGGTTCAGGTGAAAGAGGGCATCGGTCCAAACTACCGCGGCCCAATC
20 GCGTGCGTGTTCTACGCGTCGGGAAGTGGCCTCCTACGGCATCAAGCTACCGTCGCAGCGGGAGGC
GGAACAGCGCGCGCGGCAGGCGGAGCGCGATCCGCATTATGATGATGAGCTGCTCTCGGATGAGGA
AGCGGATGCTATGGAGCAGGATGAACTGGCTCGCCAGTTCGCCGCCACCCAGCAGCAGCGCTACGG
TCATCGCTGGGAAGACGATAACGCGACTGATGACGATGAGGCCGACGCCGCGGCGGAAGCGGAGCT
GGCGCGTCAGTTTGCCGCTACCCAGCAGCAGCGGTACGCTACCGAGCAGCCGCCGGGCGCCAACCC
25 GTTCTCGCCGGCAGATTATGAATTCTCGCCGATGAAAACGTTGGTCAATGACGGCCCCGAGCGAACCG
CTGTTTACGCCGACGCCGGAAGTCCAGCCGAGCAGCCGGGCCAGCGCTATCAACAACCGGCGGCC
GCTCCGAGCAGGGTTATCAACCTGCGCAGCATCAGCCGATACACCATCAGCCTGTGCCGCCACAGC
CGCAGTCCCTATCCGACTGCGTCGCAGCCCGTACAGCCGCAACAACCGGTTGCCCCGCAGGGGCATCA
GCCTGCCGCCCTGCGCCGAGGAGACCTGATCCACCCGCTGCTGATGCGCAATGGCGATAGTCGA
30 CCGCTGCAAAAGCCGACCACGCCACTGCCGTCGCTGGATCTGCTTACCCCGCCGCCGAGTGAAGTCG
AGCCGGTGGATACCTTTGCTCTCGAGCAGATGGCACGCCTGGTGGAAGCGCGACTCGCTGATTTCCG
CATTAAAGCGGATGTGGTGAAGTACTCACCGGGGCCGGTGATCACCCGCTTCGAAGTGAATCTGGCG
CCTGGCGTTAAGGCCGCACGGATCTTAACCTGTACGGGACCTGGCGCGATCGCTGTCAACGGTCG
CCGTGCGCGTGGTGGAGGTGATCCCGGGCAAACCGTATGTGCGGCTTGAGCTGCCGAATAAAAAACG
35 CCAGACCGTCTACCTGCGTGAAGTGCTCGACAACGCCAAGTTCGGTGATAACCCATCTCCGCTCACCG
TGGTGTTGGGTAAAGACATCGCTGGCGATCCGGTAGTAGCCGATCTGGCGAAAATGCCGCATCTGCT
GGTGGCCGGTACCACCGGTTCCGGTAAGTCTGTTGGCGTCAACGCCATGATCCTCAGCATGCTCTAC
AAGGCGCAGCCGGAAGATGTGCGTTTCATTATGATCGACCCGAAAATGCTCGAGCTGTGCGTCTACG
AAGGAATTCCGCACCTGCTGACGGAAGTGGTCACCGACATGAAAGACGCCGCCAATGCGCTGCGCTG

GAGCGTCAATGAGATGGAGCGCCGCTACAAGCTGATGTCGGCGCTGGGCGTGCGTAACCTCGCGGG
CTACAACGAGAAGATCGCCGAAGCCGCGCGCATGGGACGTCCGATCCCGGATCCGTACTGGAAGCCT
GGCGACAGCATGGACGCCGTACATCCGGTGCTGGAAAACTGCCGTACATCGTGGTGCTGGTGGATG
AATTCGCCGATCTGATGATGACCGTCCGGCAAAAAGGTGGAAGAGCTGATCGCTCGCCTGGCGCAGAA
5 AGCGCGCGCGGGGATCCACCTGGTGCTGGCGACACAGCGTCCGTCCGTAGATGTTATTACCGG
CCTGATTAAGGCCAACATCCCGACGCGCATCGCCTTTACCGTGTCGAGTAAATTGACTCACGTACCA
TTCTCGATCAGGGCGGCGCGGAATCGCTGCTGGGTATGGGGGATATGCTTTACTCCGGGCCGAATC
TACCACGCCGGTGCGTGTCACGGGGCGTTTGTGCGCGACCAGGAAGTCCACGCCGTGGTTCAGGA
CTGGAAAGCCCGCGGTCGCCCCGAATATGTGGATGGCATTACCTCCGACAGCGAAAGCGAAGGCGG
10 CGGTGGCGGCTTCGACGGCGGGGAAGAGTTGGATCCGTTGTTTCGATCAGGCAGTCAACTTTGTGACC
GAGAAGCGCAAAGCGTCGATTTCCGGGGTTTCAGCGTCAGTTCCGCATCGGCTATAACCGTGCCGCGC
GTATTATCGAACAGATGGAAGCGCAGGGTATCGTCAGCGAGCAGGGCCATAACGGTAACCGCGAAGT
GCTGGCGCCGCCGCCCTTTGAATGA

SEQ ID NO:61

15 AUGAAGAAGUUAGCUUUACUCUCCGCCGUAUUGACGCUUGGAAUGUCGUCAUGGGCUUUUGCUGC
CGACAACCCGCCGCCGCCGCCGAAAAAGGCGCGCAGCAUCAGGGUAAACCGCCGGUGAAAAACG
GCCAACACGAAGGUAAAGCAAGCGCAAUACAACAGAAAAACAGCCACAACGAGACGGCAAACAGCCGC
AGCACGACGGUAAACAGCCGCAGCACAACGGCAAGCAGCCGCCAAAAGGGAGCGAGCACAGCGGG
AAACCGCUGCCGCCGAAAGCGUAA

20 SEQ ID NO:62

AUGAAACGUUACGCAACCGCACUGCUCUUUUGCACUCUGUCGUGACCAGCCUGGCCGCUCGCGC
CGAUUUUAUCGAUGACGCGAUCCGCAAUUUCAGCAAGCCAUAACGACGCCUAUAACCCCGGCAG
CAGUCGCUCCGAUGACGACGACAGAUACGAUGACGAUGGCCGGUAUGAUGACGGGCGCUAUCAGG
GGAGCCGUCAGCAGAGCCGUGACAGUCAGCGCCAGUAUGACGAGCGGCAACGCCAGCUGGACGAG
25 CGCCGCCGCCAGCUGGAUGAACGCCAGCGUCAGCUCGACCGCGAUCGUCGUCAGUUAGAAAGCGA
CCAGCGUCGUCUGGAUGAUAGCUACUGA

SEQ ID NO:63

AUGUUCAGGUCACUGAUUUCUGGCAGCAGUACUGCUGGCCGCAGGGCCACUGGUCGCUAACGCUGG
UGAAAUCACCCUGCUGCCAUCGGUAAAAUACAAUAGGCGAUCGUGACAAUACGGUAACUACUG
30 GGACGGUGGCAGCUGGCGCGACCGUGAUUACUGGCGUCGUCACUAUGAAUGGCGUGAUAAACGU
UGGCAUCGUCAUGACAACGGCUGGCACAAAGGCUGGUACAAAGGCAGAGUAAAGCCUGGGAGCG
CGGCUAUCGUGCUGGCUGGAACGACCGCGAUGACCACCGCGGCGGCGUGGGGUCGCGGCCCGGGC
GGGCGCGGUCACGGUCAUGGACAUGGCCAUCACUAA

SEQ ID NO:64

35 AUGAAGGAAAUCGGCUUACCGUUAUUGCUACUGACCGCGCUGGCCAGUCCGGCUUUUGCUGCAGA

CUGUCAGCCAAACGGCAUUGGCGGCUCGUUUUGCAUUAACGAUGACGGUACGACUACCGACACGG
UGCCUAACGAAGUCAACGGCAUGGAUACGUACUCGAAUAAUGGCGGCUAUACCAGUUCCCCUGCCC
GAUCGGUCAGGGGCGGAUGAAGCACUGGAAGGUUCAUCGCUGUCGACGCAGCAAGGCGUCGGCA
GCGGACAGAGCGACAGUGCGCUGGCGGGUCGCGACUGGCAUUCGCCCCGCCAAUCUGAAUGAUGGC
5 GCCGCCACCUCCAGUAUGAGCCUGCUGGAUAAACCCUGA

SEQ ID NO:65

AUGAAUAUGAAAAACUGACGACCCUUUUGCUCACCGCCACCUUAGGUCUUGCCAGCGGCGCGGC
CCUGGCGGCAGACACCGGCGCCCAGUCCAUAUUGGCCAGGCCAACUCUUCGCGGAUGCCGGUC
AGGUGGCGCCGGAUGCCCGUGAGAACGUGGCGCCGAACAACGUGGACAAUAGUCAGAUCAACUCU
10 GGCUCUGGGGGCACACGGGCUCGACGAUGACCCAGGAUAAUAUGUCGAGCAAUGAGGUACAUA
AAACUCGAUGUGUAAAGACGGCCGUCUGCCGGACACCGGUAAAAACUGGACAACGGUGGCAUA
CGACCCAAGACAACAGCAAAACCGACGGCACCCACCCAGUAA

SEQ ID NO:66

AUGAAACACCGCAUCGCUCUGCUUCUGGUCCUGACUUCACUUAAGCGCCAGCGCCCUAGCCGCCUC
15 UCCCUGCCAGGAAAAAGAGCAGGAUAUUAACGAGAGAUCAAGCUACGCCGAAAAGCAUCAUAAUCA
AAGUCGCAUUGAUGGGCUAAAUACCGCGCUACGUCAGGUUCGGGAAAACUGUAGCGACAGUAAAC
UCAAGCCGAUCAUCAGCAAAAAAUUGCCAAACAGCGGGAAGAGAU CGCUGAACGUCAGCGCGAUC
UGCAGGAAGCCCGGAAGAAAGGCGAUGCGGACAAAAUUAACAAACGCCAGCAUAAACUCAUGAAG
CGCAACAGGAGUUAAAAACGCUGGAGUCUCGGGAUUACUAA

20 SEQ ID NO:67

AUGCGACUCAUAACACGACACGUGAGAGAGGAUAUUAUGAAAAAAGCAAUGAUUGCGUUAUCGGC
UAUUCUGGUUGCGGCUCGCGUUUUUGCUGCGACAACACAUGCAACAGAUGAUACCGUCGCGGCGG
CGAAUGCCAACGCCAACACCGCUAAAGAGAAGCUGCAUCAGGCCCAGCACGAGGGCGAAGAGCAGC
AGCUGAAGGCGAAACACGCCGCCGAAGGCAAGCAGGACAGCGUCGGCAGCCAGGUGAGCGAAGGC
25 GCGCAGAAAACCUUGGAACAAGACCAAAGAAGGCACCGAGAAGGGGUGGGAUAAAGACCAAAGAGGU
CAGUGAAAAAGGCUGGAACGCCACCAAUCCGGUGCGGAAAAGGGCUGGGAUAAAACCAAACCG
GCGCCGAAGAGUUAAAAAUAAAGUGACUGAAUAA

SEQ ID NO:68

AUGAAAAAGAUUAUUCUCUGGCAGUAAUUUUAUCCUGUGUGCUGAGCGUCCCGGCCUUUGCCGA
30 UGGCCCGAACGACGGCCAUCGCCCGGAGCAGCCACGGUGUGGCAGAACGGUCCGGACCAUGACG
GGCAUGCACCGCAGGGCGGACCUGACGCGCAUCAUCAGGGCGACCAUGACCAGCGUGGCCCGGAU
CGCGACGGCCAUGACAAACGCGAUCUGGCACGUCAUGAGCAGGACCAUUUCGCCUGGCGCGGGAA
CGAUUUCGCAAAGGCCACCCGGCUCGCGCCGUUCCGUGGCGAUGAAUAUCGCGUCCGCGACU
GGAGCGACCGCGGCCUGCCGCCCGCCGGAAGGCCAUCACUGGUCCUAUAUCGACGGUAACUAU

GUGCUGAUCGCCGCGGCGACCGGGAUCAUCACCUCGAUUCUGGUGAGCGGCGCCUCGGCCACUA
A

SEQ ID NO:69

AUGAAAAAACCGACAUCCGCCACCCGUGGCAAAUCCGGCCGCAAGUCGCGUGAAGAGUUAAAUCAG
5 GAAGCUCGCGAUCGCAAACGGCAGAAGAAACAUCGUGGCCACGCGGCAGGCAGUCGCGCGAACGG
CGGCGAUGCGGCUUCAGCGGGUAAAAACAGCGUCAGGCGCAAGAUCCGCGCGUGGGUAGCAAAA
AACCGAUCCCGCUGGGCGUGAGCGAAAGCAGCGUUCAGCUCCCAAGCAGCAUAAACCAAAGAGCG
AGAAACCUAUGCUIUACCCGCGAGGCUGAGCUGGAGUUGCUGGAGAAUGAUGAGCGCCUGGACGCG
CUGCUGGAACGUCUGGAAGAGGGCGGCACCCUGAAUGCUGAAGAGCAGAGCUGGGUGGACGCCAA
10 ACUGGAUCGCAUUGAUGAGCUGAUGCAGCAGCUCGGCCUCUCUACGAUGAUGAAGAUGAAGAAG
AGGAAGAGCGUCAGGAAGAUUGAUGCGUCUGCUGAAGGGUGGAAACUAA

SEQ ID NO:70

AUGGCGAGUAAGUUUCAGAACCGUUUAGUCGGGACAAUCGUCUGGUGGCGCUGGGGGUGAUUA
UCCUGCCAGGGCUGCUGGACGGGCAGAAAAGCAUUACCAGGAUGAGUUUGCCGCGAUCCCGCUG
15 GUACCGAAACCAGGCGAUCGCGAUGAACCGGAUAUGUUGCCGCGGCAACCCAGGCGUUGCCUUC
GCAACCGCCGGAAGGGGCGGCGGAAGAGGUGCGGGCGGGCGAUGCCGCCGCGCCAUCGUUAGAU
CCAUCGCGUAUUCGGUGAACAGCAACAGCUUCGAUGACGUUCAGGAGCCGGUGGUGGCCGCGAA
ACCGCAGCCCAAGCCGCGAGCCGAAACCGCAGCCGCAACAGCAGGCCUCGACGCCAACGCCGCCGCC
GGCUAAGCCACAGCAGCAACAGCCACCGCAGCAGCAGGCGGCCUGCCGGCGCCGACCGGCAAAG
20 CCUAUGUGGUUCAGCUGGGCGCGUUGAAGAACGCCGAUAAGGUGAAUGAGAUUGUCGGUAAACUG
CGGGCCUCGGGUUCAAAGUCUAUACGUCGCCUUCGACGCCGGUACAGGGUAAAUUACCCGCAU
CCUCGUCGGCCCGGAUGCGUCAAAGACAAGCUGAAAGGCCAGCUGGGCGAUCUGCAGCAGAUUCU
CCGGGCUUAGCGGGGUGGUGAUGGGCUUCACCCCGAACUGA

SEQ ID NO:71

AUGGCACAACGAGAUUAUGUACGCCGAGCCAACCGGCUUCUUCGCGGCGCAAAAAGAGCACGACC
CGAAGCUC AAGGAAUAAGCAAAGCAGCCUUCGGCGAUUUCACCGGCGAUGGUGGCGAUCGCGGC
GGCUGUGCUGGUGGCCUUUAUCGGUGGCCUCUAUUCAUUAACGCAUCAUAAGAAAGAAGAAGCGG
AAGCGAUGCAAAAUCCGAGGCCGCCGCGCAACGGCUUGCCGCCCAAACCGGAAGAGCGCUGGCGC
UAUAUUAAGAGCUGGAAAGCCGCCAGCCUGGCGUCCGCGCGCCGACCGAACCGACCGCCGGUGG
30 CGAAGUCAUGAAACCGGAACAGCUGACCGACGAGCAGCGCCAGCUGCUCGCCCAGAUUCAGGCCG
AUAUGCGCCAGCAGCCGACCCAGCUGACCGAAGUGCCGUGGAACGAACAAACGCCGGCGCAGCGC
CAGCAGACGCUUCAGCGUCAGCGUUUAGCGCAGCAACAGCAGCAGGCGCAGCAGCAACAGUGGGC
GCAGACUCAGGCGCAGACCGUCCAACAGCAGCCGCCGCGCGUUCAGCAGCCGAAGCCGGUUCAGC
AGCAACAGCCGAAGCAGACCGCGUCAAAACAGCAGCCGUACCAGGAUCUGCUGCAGACGCCAGCGC
35 AUACCAAUACCACGCAGCCGCGUACCCAGGCCGCGGCGCCGGUAACUCGGGUGGAAGAAGCGCCG
AAAACCACCGCCGAGAAGAAAGACGAUCGUAGCUGGAUGAUCCAGUGCGGCUCUUUUAAAGGCGC

CGAGCAGGCCGAAACCGUCCGCGCUCAGCUGGCUUUCGAAGGGUUUGCUUCGCACAUUACCACUA
ACAACGGCUGGAACCGCGUGGUUAUUGGCCCGUUGAAAGGCAAAGAAAGCGCCAACGAGAUGAUC
ACCCGCCUGAAGAUGGCUGGACACGCGAACUGCAUUCGUCUCGCCGCCAGGGGUUGA

SEQ ID NO:72

5 AUGAGCGCGGGAAGCACCAAAUUUACCGUCAGCCGUUUUGCGGCUCUUUCACUGGUUUACUCUCUG
GCUGGCCGGGUGUACCAACACCAAUAAUCCGCCUGCGCCGGUUAGCUCUGCCGGCGGCGCCGCCU
CUUCCAGCACCAACUCCGGCAUGCUGAUUACGCCGCCACCCUCCGGCGUCAAGUCCGCUCCUCAGG
CGCAGCCGAUUCAGCCGAUGCAGACCCAGACCAUUCAGCCGGCGCCGGUGGGCGCAGGAGCCGGUA
CAGACGGUAAAUGGCCGGAUCGUUUACAACCGCAAUAUUGGCGAUUUCGAAAGGUAGCUAUAC
10 CGGCGGCAGUACCUAUACGGUAAAACGCGGCGACACGCUAUUCUAUUCGCCUGGGUCACCGGCA
ACGAUUUCCGCGACCUGGGCGCAACGUAACAAUAUCCCGGCCCGUACGCGCUGAACGUGGGGCAG
GUACUGCAGGUCGGUAACGCCUCAGGCCAGCCGAUACCCGGCGAAAACGCCGUUUCUCAGGCCAG
CGCAAGAGCGAGCGGCGGUGCGACGACCAGCACAACUUCUGCACAAAAUUCGACCGCGGUGGUUG
CUUCACAACCGACUAUUCGUAUUCUGAAUCUUCAGGUGAACAGAGUGCUACCAAGAUGUUGCCUA
15 AUAUAUAAACAGCGACCACAACCAACCGUUGUCGCGCCGGUGACGGCACCAACAACGGUGAGCA
CAACCCAGCCGACUGCAAGCAGUACGUCAACCAGUUCGCCGAUCUCAGCAUGGCGCUGGCCGACU
GAUGGCAAGGUUAUCGAGAACUUUAGCGGCGCGGAAGGCGGCAUAUAAAGGCAUCGAUUAUUGCAGG
CAGUAAGGGACAGGCUAUUGUCGCGACCGCCGAUGGGCGCGUCGUCUAUGCCGGUAACGCACUGC
GCGGCUACGGUAAUCUUAUUAUCAUCAAACACAACGAUGAUUACCUGAGUGCCUACGCUCAUAACG
20 AUACCAUGCUGGUUCGGGAGCAACAGGAAGUCAAGCGGGGCAGAAAUCGCUACCAUGGGUAGC
ACCGGAACCAGCUCAACAAGAUUACAUUUUGAAAUUCGUUACAAGGGGAAAUCCGUCAACCCGCUG
CAGUACUUAACCGCAGCGAUAA

SEQ ID NO:73

AUGCGUAAGCAAUGGCUGGGGAUCUGCAUAGCAGCGGGGCUGCUGGCGGCAUGUUCGAGUGAUG
25 ACGUGCAACAAAAACGGUCAGUACUCCACAGCCGGCCGUCUGUAAUGGCCCGACGGUUGAGAUC
AGCGGCGCCGAUCCGCAGUAUGAAACGCCGAACGCCACGGCGAAUCAGGAUUAUGAGCGCGACGG
UAAAAGCUACAAAUCGUUCAGGAUCCGGCCAACUUUACUCAGGCCGGUUCGCGGCGAUCUAUG
ACGCAGAACCCAACAGCAACCUGACCGCCAGCGGCGAAGCCUUCGAUCCGACUCAGUUGACCGCAG
CGCACCCGACGCUGCCGAUCCCGAGCUACGCGCGGAUCACUAACCUUGCCAACGGACGGAUGAUC
30 GUCGUGCGGAUUAACGAUCGCGGUCCCUAUGGCAACGAUCGGGUCAUCUCGCUUUCGCGCAUC
CGCUGACCGCCUGAACACCUCCAACAACACCAAAGUGCGCAUCGACCCCAUCAUCGUCGCGCCUGA
CGGUUCGCUUUCGGGCCCGGGGAUGGCCUGUACCACCGUCGCCAAACAGACUUAACGCCUUGCCCG
CCCGUCCGAAUCUGGACGGUGGGGACGCCGUGGCAUGAGCCAGCCCGCGCCACUGACGUUCGC
CCGAUCAGCAACAGCACGUGACGCCGGCAGACAGCGUGGGCGCGCCGGUGAACAGCGGCGGUUU
35 CCUCGGCGCGCCGACGCCCCUGAACAACGGCGUGCUGGAGAGUAGCGAACCAGCGGCAGCCGCCG
CGACGGCUCCUGCCGCCGGCGCCACGCCAACAGCGCCAGUGACCGCGCCUGGCUCCAUUCAGGGU
AAUGUGGUGCCCGCUGCGGCCACCGCCGACGCCGUGGCGCCGUGGCGGCCUCGUCCUCCGCGAC

CUCCAGCGCCAGCGGUAAUUUUGUUGUCCAGGUGGGCGCAGUAAGCGACCAGACGCGGGCGCAGC
AGUAUCAGCAGCGCCUGAGCCAGCAGUUUUCUGUGCCAGGCCGGGUCAUGCAAAACGGCGCGGUC
UGGCGUAUUCAGCUGGGUCCCUUUGCUGAUAAAGCACAGGCCAGCGCCGUGCAGCAGCGCCUGCA
AAGCGAAGCGCAGCUGCAGUCCUUUAUJACUCGCGCCAACUAA

5 SEQ ID NO:74

AUGGAUGAUUUCAAACCAGAAGACGAUAUGAAAGCCGAUCGCAACGAUCGUCGUGCUGGUCGUUC
CCGUCAGUCUUCGAGCGUGAUGCCGAUCCGCAGAUCAAUUUUGACGAUGUUGAUCUUGAUGCCG
AUGAAGGCCGUCCGACGCGCGCUGGUAAGGCCCGUCGCGAGCGUGAAGAGGAAGAGUUCGAAGAA
GAACUGGAUGCGCAAGACGAGGAGAUGCUGAAGAGCAGCCUGUAGAGCGUCGUCCGCGCAAGCG
10 UAAAAAAGCGCCGCCAAACCGGCCUCCCGCCAGUACAUCAUGAUGGGUGUGGGGAUUCUGGUGC
UGCUGCUGUUGAUCGUGGGUAUCGGUUCGCGACUGAAAUCGCCAUCAUCUCCAGCCAGCAGACC
GCUUCCGCGCAGAAGAGCAUUAUCUGUCUGACGACCAGUCCGCCAGCAUGCCUGCUGCCGGCCA
GGACCAGACUGCCGCCGCUAACAGCACCUCACAGCAGGACGUAACGGUACCGCCUUAUUGCCGCGAA
CCCGACGCAGGGCCAGGCAGCGGUUGCGCCGCAGGGCCAGCAGCGUAUCGAAGUUCAGGGCGAUC
15 UGAACAAUGCCUUGACCCAGCAGCAGGGCCAACUGGACGGCGCCGUGGCUAACUCGACGCUGCCG
ACUGAACCGGCUACCGUCGCGCCAAUCCGGAUUGGCGCCAAUGGCACCGCGGCGCCGCGCCAGGC
GACCGAGCGUCAGACAGCAGCGACCCCGCUGCCGGCUGAACGUAAGCAUACCGUUAUCGAAGCGA
AGCCGCAGUCGAAGCCACAGGCCGUGGCGAAAACGCCGGUAGAAUCGAAGCCGGUCCAGCCGAAG
CAUGUUGAAAGCACGGCGACCACCGCUCCGGCGAAAACGUCCGUCAGCGAAAGCAAACCGGUGGC
20 CACCGCUCAGAGCAAACCGACCACGACGACCGCAGCGCCAGCGGCAACGGCAGCUGCGGCAGCGC
CGGCAGCGAAGACCGGGAAGACGGCAGGUGACGUCAGCUCAAUGAAAACUGCGCCGUCGGGUCAC
UAUACUCUGCAGCUCAGCAGCUCCUCUAACUACGACAACCUCAAACUUGGGCGAAGAAAGAGAAG
CUGGAUAAUAUGUUGUCUAUGAAACGUCGCGUAACGGCCAACCAUGGUACGUGCUGGUGAGCGG
UAUCUAUGCAUCGAAAGAUGAAGCGAAACGUGCUGUACCUUGCUGCCGGCGGACGUGCAGGCGA
25 AAAAUCCAUGGGCAAAACCGCUGCAUCAGGUUCAGGCUGACCUGAAAUAA

SEQ ID NO:75

AUGUCAAGGCAACCGAACAAAACGACAAGCUUAAACGAGCGAUCAUCAUUUCAGUCGCGCUGCAC
AUCAUUCUGAUCGCGCUGCUGAUCUGGAGUUCGUUUGACGAGCAUCUGGAUGCCUCUGCCGGCGG
CGGCGGCGGAUCGUCGAUUGAUGCCGUAUGGUCGAUCCGGGGGCGGUGGUAAUAACUUAUACC
30 GUCAGCAACAGCAGCAGGCCAGCGCACGUCGCGCCGUGAACAGCGUGAAAAACAGGCGCAGCAG
CAGGCGGAAGAGUUACGUGAGAAACAGGCGGCGGAACAGGAACGGCUGAAACAGCUCGAACAGGA
GCGGCUGCAGGCGCAGGAAGCGGCGAAAGAAGCGAAGGAGCAGCAGAAGCAGGCUGAAGAAGCGG
CUGCCAAGGCCCGCCGCGGCGGCAAAAGCCAAAGCGGACGCACAGGCAAAAGAAGCGCAGGAAGCC
GCUGCCAAAGCGGCCCGCCGAGGCGAAAGCGAAGGCGGAUGCCAGGCGAAAGCGGCAGAACAGGC
35 GGCGGCCAAGGCGGCUGCUGACGCGAAAAAGCAGGCCGAAGCCGUGCAGCGAAAGCCGUGCCG
AGGCGAAGAAACAGGCGGAAGCUGAAGCGGCGAAAGCUGCGGCCGAGGCGCAGAAGAAAGCGGAA
GCGGCGGCUGCGAAGAAAGCGCAACAGGAAGCGGAGAAAAAAGCCCAGCAGGAAGCGGCUAAGCA

GGCGGCAGCUGAAAAAGCGGCUGCCGAAAAAGCCGCUGAGAAAGCCGCCGCGCAAAAAGCGGCCG
CUGAGAAGGCCGCCGCCGAGAAAGCCGCAGCCGCUGAAAAAGCGGCGGCAGCGAAAGCGGCUGCA
GCAGAGAAGGCUGCAGCUGAUAAAGCGGCCAAAGCGGCAGCAGCAAAAGCCGCGGCGGCGAAGAA
AGCGGCGGCUGCGAAAGAAGCGGACGGCGUUGACAACCUUGCUCGGCGAUCUGAGUUCUGGUAAGA
5 AUGCGCCUAAAACAGGCGGUGGGGCCAAAGGAAACAUGCCUCCGCUGCCGGGAGUGGUAUACU
AAAAACAGUGCCUCAGGGGCUGAUUAACAACUAUGCCGGACAGAUAAAAUCGGCGAUUGAAAGU
AAGUUUUAUGACGCAUCGUCCUAUGCGGGCAAAACAUGUACCUUGCGUAUCAAACUUGCUCUGA
CGGCCUGUUGUAAAUAUACAGUCCGAAGGUGGUGAUCCUGCUCUGUGCCAGGCCGCUCUUGCCG
CAGCCCGACAGGCUAAGUUUCCGAAACCACCUAGCCAGGCAGUAUAUGAAGUCUCAA AAAAUGCGC
10 CACUGGACUUCAACCUCAGUGA

SEQ ID NO:76

AUGUUUUUUUAAGUAUUUUUACAUGGAGAUGACAAAAGUGAAAUUAAGCGCUCUGUUUAUUGC
CCUGAUUCCUCUACUGGGCUCGCCGGUUAUUAUGCAGAAACUACUGCUGCGCCGGUUCUGGAAA
AUCGCGCUGCGCAGGGAGAUUAUACCCACUCCUGGCGGCGCGCUGCGUUUAACAGGCGAUCAAACC
15 GAAGCGCUGCGCGCCUCGUUAAUUAAGCCAGCUAAAAACGUUUAUUUUGCUGAUUGGCGAUGG
CAUGGGUGAUUCGGAAAUUACCGCUGCGCGAAACUAUGCCGAGGGGGCGGGCGGUUCUUUAAA
GGAUUUGAUGCUCUGCCGUUAACCGGGCAGUACACGAUUAUUCGUGGAUAAAAAACCGGGAA
ACCGGACUACGUGACCGACUCGGCGGCCUCCGCCACCGCCUGGACCACCGGCGUGAAGACUUAUA
ACGGCGCGCUGGGCGUCGAUUAUUAUGAGAAUGCGCAUCAGACCAUCCUCGAGCUGGCGAAAGCG
20 GCGGGGCUGGCCACCGGCAACGUUCCACCGCCGAGCUGCAGGACGCCACCCCGCGGCGUUGGU
AGCGCAUGUGACAUCGCGUAAAUGCUACGGCCGACGGUCACCAGCGAAAAAUGCCCCAGCAAUGC
GCUGGAAAAAGGGGGCAAAGGCUCCAUAACCGAACAGCUGCUGAACGCCCGACCGGAUGUCACCU
UGGGCGGCGGCGCGAAGACCUUUACCGAAACGGCGACGGCGGGCGAGUGGCAGGGGCAAAACCCU
GCGCGAGCAGGCGCAAGCGCGCGGCUACCAGAUUGUGACCGACGCGGCUUCUCUUGCCGCCGCGA
25 CGGAAGCCAGUCAGGAUAAACCGCUGCUGGGACUCUUUGCCGAUGGCAAUUAUGCCGGUACGCUGG
GAAGGGCCGAAGGCGUCUUAUACGUAUAUUCGAUAAGCCGCCGUGACCUGUACGCCAAACCC
GAAGCGUGACGCCUCGGUGCCGACGCUGGCGCAGAUGACGGAGAAAGCGAUUGACCUGCUCAGUC
GCAACGAGAAAGGUUUCUCCUGCAAGUCGAAGGCGCUUCCAUCGAUAAGCAGGACCAUGCGGCG
AAUCCGUGCGGCCAGAUCCGCGAAACGGUUGAUUCUUGACGAAGCGGUGCAGAAGGCGCUGGAAUU
30 CGCGCGAAAAGACGGUAAUACCCUGGUGAUCGUCACCGCCGACCAUGCGCAUGCCAGCCAGAUCA
UCCCGGCGGAUAGCAAAGCCCCGGGGCUGACCCAGGCUCUGAACACGCACGAUGGCGCGGUGAUG
GUGAUGAGCUACGGCAACUCUGAGGAAGAGUCGAUGGAGCACACCGGCACCCAACUGCGCAUUGC
GGCCUACGGUCCGAUGCGGCUAACGUCGUAGGCCUGACCGAUCAGACCGACCUGUUCACGACCA
UGAAAGCUGCCCUGAGUCUCAAUAA

35 SEQ ID NO:77

AUGUCACUGCCGUUCAACCCCCAUUAUUCGCCUGCUCUGUAGCGCUGGCUUACUCGCGGCGGC
AGGAACACUCUAUGUGCAAAGCCGAACCCAGCGACGAUCGCUGAACCGCCUGCGCAGCAAGCGCC

AGCGCCCGCAGCGUCGACGACACAGCCGGUGGCCGCCACUACACCCAGGCGCAAAUUGAUCAGU
GGGUCGCCCCUAUCGCGCUCUACCCGGACAGCCUGCUGUCGAGGUGUUGAUGGCCUCCACUUAU
CCCGACAACGUCCUGCAGGCGGUCCAGUGGUCCCAGGAUAACCCCGCGAUGAAAGGGGAUGCGGC
CGUGCAGGCGGUUGCCAGCCAGCCGUGGGACCCUAGCGUCAAUUCUCUUGUCGCUUUUCCUGCCCC
5 UGCUGGCGAUGAUGGGCGAGAAUCCGCCUGGGUGGAAAUCUUGGCAAUGCGUUUUUGGCCCA
GCCGCAUGAUGUGAUGGAUUCAGUGCAGCGCCUGCGCGCCAUUGCCCAACAAACCGGGACGCUGA
AAUCCACACCGCAGCAGAAAGUGAUUUGUACCCCUGCCGACCGGUUUCAGCCAGCAGCAGCACGG
CAGCAACCGCAACCGCCACACAGCGGCGCCUGCGCCACGCAGGUCAUUAUUAGAGCCGACCA
AUCCACAGGUGGUCUAUGUUCCAGCUAUAACCCUCCACCGUCUAUGGUACCUGGCCGAACAGC
10 GCCUAUCCGCCGGUCUAUCUGCCGCCCCUCCCGGGGAGCAGUUUACCGAUAGCUUCGUCAAAGG
CUUCGGGUACAGCCUCGGCGUGGCCACCACCGUGGGCGCUGUUCAGCAGUAUCGACUGGGAUGAUG
AUGACCAUCACCAUCACGAUGACGACUACCACCACGGCGAUUACUCGCAUAAUGGCGAUAAUCA
AUUUAAUGUAAAUAAUUAUCAAUCAUAUAACAGGAGAAAACCGGCCGGAACACGUUAACUGGC
AGCACAUAUCCUGCCUAUCGCGGACACACACCGUAUCCCGAUAAUACGGUAGCUCAGCGCUUCCAUC
15 AGACCAACGUUUCGGCGGACUGAGCGCGACCCAACAUGCGCCAGUCGAUCGCGAAGCGCAGCGC
CAGGCAGCGAUGACCCAGCUGCAGCAUAACGUACCGACGGCCACAGCGGGCAACCGUGGCGGCAAA
CAACGCCUCACGCGACGCCCAGCGUCAGGCGGCCUCGGCGCAGCUGAAGCAAGCCACCCAACGCA
GUAAUUACCGCGGUUACGACAGUACGCCGACCCAACAGCAGCGUCGCGAGGCGGCAAAAACGCAG
CUGAAAAACCCACGCCGACGCAACAGCAGCGUCGAGAAGCCGCCAGGAGCCACGAGCAGAACCGC
20 ACACCUCAGCAGCAGCAGCGCCGGCAGCAGUUCAGUCCGCCACGCCAGCCAGCGUCAGCAGACG
CUCAGCCAUCUGCGCGCCAACGCCCUUAGCGGCAACGAAAGCCGCGCCCCUCCUGGCAAGCGCAG
CAGGAACGAGGACUGCAGAGCCGCCAGUUUUCGGCGUAAACCGCGAGUUAACGCGAUGGCACCAG
AGAACGUCUUUCCGAACACCAUGAACUGCGUCGCCGCUAA

SEQ ID NO:78

25 AUGUUUAAGUUUAAGGCUUCUUAUGUCGCACUGGCGGCAGUAUUAACCUCGUCGGUAGUUUAUGC
CGACCCCAACAAGCUAUACGCACUCUCCGGCGCCACGGUUAUCGAUAUUGAAAAGCCGAACGCCGC
CGGUGUCUCCCAUAACCUGUACCGCGACUUAACGUCGGCGCCAUGGCACCAUCCUCAAUAACAG
CGGCGAUGAUGUCAGCCACAGCACAUAUUGGCAUAUCGCCCCGCAACAUAUUCUGACCGCCGCGCAG
CGCUUCGGUGAUUUUGAACGAGGUGACCUCCAAAAACGCCAGUAGCCUGAAGGGCUUUUAUCGAAG
30 UCAACGGUCAGAAAGCGGAUGUGGUAAUCGCCAACCCGAACGGCAUCACCUGUUCGGCGUGUAGC
UUUGUUAUAACCAACAAGGCUAUCCUGACCACCGGCAAGGUUAUAUGACCGACGAUGGCGCUAUC
GGCAGCUAUACCGUAACGGGCGGCACCCUACCAUCGGCGAAAAUGGCAUGAACGCCGCCAACGG
CUAUGCGGUUCUGCUCGCCGACGCGAUCAAUAUCAACGGUAAAGUGCAGGCCAACACGCCCUUGG
UCAGCGCGGGCAACUUCACCAUGGAUAACAGCUCUGGCUCGGUGACCUCGCGUGUAAAAAGGCC
35 ACCUGAUCCAGAUGACGGUUAACCCGCAGUACAGCAUCGACGUCAGCAGCCUUGGCGGCAUUGA
GGCCAACAGCAUCAGCAUGGUCGGCAUAACAUCGGCUUUGGCGUACGUAAUAAAGGCUCUAUCG
UCGCGAAUAGUUCGUGCAGCUCACCAGCAACGGUAAUCUGCUGAACAAAGGCACGAUCAAAGCA
ACGGUCUGCUGAGUCAGGUCGCCACCGCCUCGGGCAUACCAUAGACGGUAGCAUCGCCGGCGCC

U AUU AUU UAAUGCUCUCCAGUGGCGAUU AUUAUCGUU AACACCGGUUCUCUCUCCGGCGGCCAGCU
GAUUGCCACCGCUAACGGCAACAUCACCAACGGCGACUCAGGCACGAUGACCGGCACCAGUGGAU
AAGCCUGACCAGCGGCGGGAAAAUCCGCAACGAAGAAAAAGCCUCCUGCUGUCAAUAACCAGAU
UGCCGCCACGGCAAUCGGUGAUUUCCUCAUGAAGGCCAAAAUCAGCGCCAAACACACCAGCCUGAC
5 GUUUGUCGGCGACAGCUUUAAAAACACUGGCAAU AUUAACUCUACUGGCCAAACCACCAUUCAGUC
GCUUAAACAGGACGGCAGCGCCAAUACGGGCGAGAU CUUAACCUCGGCAAUAUCACCGGCGAAAA
UAUCAUUCUGCAGACCAAUGGCAGCUGGGCGAAAGCAGCAGUGGUCGU AUUUGAGGCAACCAACG
CCAUUACCGCCCACAGCUACUGGCUGAACCAAAAUGGUU AUUAUGA AUGCCGCCGAUAUCACCACCG
AUCACGGCGUAGUGAAU AUUAUGGCAAU AUUACUGCCAAAAAU AUUCAAUCACGACCUACUCAG
10 AUUAUCACCAACGAAGGGCAGAU CAGCAGCACCGGCGACCUGACCUU AAAUACCAAAAAU AAAGGCG
CGAUCUACAAU AUUCAACCCUCAGCGCGGGCGGCAACAUGACGU UAACCGCCACCAAAGUGGUCA
AUGGUGGU AAAAGUUGCGGCAUACUGGGCCUGGCGAAAUGCGGCGUCGGGACGU UAACUGCUGA
CAAGCUGGUACUGAACUCAUCGCAGAAU AUGUUAUGCGACAUGGGUGGAAAACAGUAU UUCAAGA
GCACCGAAGUCAACACGGUGAAAUAA

15 SEQ ID NO:79

AUGAUGGACAACCUACGCACGGCCGCAACAGCGUCGUGCUCAAGAUU AUUUUCGGUAUCAUUAU
CGUCUCGUUCAUUUUGACCGGGGUGAGUGGUU ACCUGAUUUGCGGUGGCAAAACUAUGCCGCAA
AAGUGAAUGGCCAGGAGAUUGGCCGUGGGCAGUUUGAAAACGCCGUCGCCAGCGAACGUAACCGU
AUGCAGCAGCAGCUUGGCGAUCAAUUCUCCGAGCUGGCGGCGAACGAAAACUACAUGAAAACCAU
20 GCGCCAGCAGGUGCUGAACCGCCUGAU CGAUGAGUCGCUUCUGGAUCAGUAUGCCCGCGAGCUGG
GCCUCAGCAUCAGCGAUAGAGCAGGUGAAGCAGGCGAUCU UCCAGACCCAGGCGU UCCAGACGAAC
GGUAAGUUCGACAACCAGCGUUUCAGUGGU AUUUGUCGCCCAGAUUGGGGAUGACCACCGAUCAGUA
CGCCCAGGCGCUGCGUAACCAGCUGACCACGCAGCAGCUGAU UAACGCCAUUGCGGGUACCGACU
UCAUGCUGCCGGGCGAGUCCGAUCAGCUGGCGGCGCUGGU AUUCAACAGCGGGUGGUCCGCGA
25 AGCGACCAUCAACGUAAAUGCCCUGGCGGCAAAACAGACCGCCAGCGAUAGAGGAAAUCAACGCCU
CUGGCAGCAGAAUCAGGCCCGUUUUAUGGCGCCGGAGCAGU UCCGCGUCAGCUACA UCAAAAUGG
AUGCCGCCAGCAUGCAGGAGAGCGCCUCUGACGAAGAGAUUCAGUCAUGGUACGACCAGCACAAG
GAUCAGUUCACUCAGCCGAGCGCAACCGCUACAGCGUGAUUCAGACCAAAACUGAAGCCGAUGCG
AAAGCGGUACUGGCCGAGCUGCAAAAAGGAGCGGACUUCGCCACGCUGGCGAAAGAAAAAU CGAC
30 CGAU AUUAUCUCUGCCCGCAACGGUGGCGAU AUGGGGUGGAUGGAAGAUGCCUCUACCGUGCCUG
AGCUGAAAAGAUGCCGGGCGUAAAGAGAAAGGCCAGCUGUCUGGCGUGAUCAAUCCUCGGUUGGC
UCCUGGUAGCUCGUCUGGACGACGUCCAGCCGGCGCAGGUGAAGCCGCUGGCUGACGUGCGUA
AUGACAUUGCGGCGAAAGUGAAGCAGGAAAAAGCGUUGGAUGCUUACUACGCGCUGCAGCAGAAG
GUGAGCGAUGCGGCCAGCAACGAUAAUGAUCGUGGCGAGCGCAGCGCAGGUCGCCGGGCUGAA
35 GGUCGUAGAAACCGGCUGGUUUGGCCGCGAU AACCGCCGAGGAGCUGAACUUUAAACCGGUCG
CUGACGCUAUUUUCAACGGCGGUCUGGUGGGUGAGAACGGCGCGCCGGGCAGCAACUCCGAUAUC
AUUACCGUUGACGGCGAUCGCGCUUUUGUUCUGCGCAUUAAGCGAACACAAAGCCGAGGCGGUGAA
GCCGCGUGGCCGAAGUGAAGGCACAGGUUAGCGAU AUUCGUUAAGCACAAUAAAGCGGAACAGCAGG

CGAAACUGGAGGCCGACAAGCUGCUGGCGGCGCUGAAAGACGGCAAAGGCGAUGAAGCGAUGAAG
GCGGCUGGCCUGAGCUUUGGCGCGCCGACGCUUUCUGUACCGGCCAGGAUCCGCUGAGCCA
GCUGGCAUUUACCCUGCCGCUGCCGCAGCAGGGUAAACCGGUCUACGGCGUGGGCAGCAUAUGC
AAGGCGAUGUGGUGCUGGUAGCGCUGGAUGAGGUGAAAGCCGGCAGCAUGCCGGAAGAGCAGAA
5 GAAGGCCAUGGUUCAGGGGAUACCCAGAACAAUGCCCAAUCGCUUUCGAAGCGCUGAUGAGCA
ACCUGCGCAAGGCGGCGAAAAUUAAGCUCGGCGACAGCAUCGACCAGCAGCAGUAA

SEQ ID NO:80

AUGUUCAGGUUAAACCCUUUUAUCCGGGCGGGAUUGUCUGCGUCCGUCGUAUCGUUGGCGUUUCC
GGCUCUGGCCGAUGUGAAUGAAGAAACGCUGGUGGUGACCGCCUCGGCCACUGAACAGAAUGUCA
10 AAGACGCGCCGGCGAGCAUCAGCGUCAUCACCCAACAGGAUUUACAACGCAAGCCUGUUCAGAAC
UGAAAGACGUGCUGCGCGAUGUGCCUGGGGUCCAGCUCACCAACGAAGGGGAUAACCGCAAGGGC
GUUAGCAUCCGCGGUCUGAGCAGCAGCUAUACCCUGAUCCUGGUCGACGGCAAGCGCGUUAACUC
GCGGAACGCCGUCUUCGCCACAAUGACUUCGACCUUAACUGGAUCCCGGUGGAUGCUAUUGAGC
GUAUCGAAGUGGUGCGCGGCCCGAUGUCCUCCUCUACGGCUCCGAUGCGCUCGGUGGGGUGGU
15 CAACAUUAUUACCAAAAAAUCGGCCAGAAUGGACCGGGACGCUGAGUGCUGAUACCACUAUUA
GGAGCACCGCGAUCGCGGGGAUACCUUGGAACGGCCAGUUCUUCACCAGCGGCCCGCUGAUCGACG
GCGUACUUGGAAUGAAGGCCUACGGCAGCCUGGCAAAACGCGCCAAGGACGAUCCGCAGUCAUCC
AGUAAUGCCACCGGCGAGACGCCGCGCAUCGAGGGCUUCACCAGCCGCGAUGGCAAUGUUGAAUU
CGCCUGGACGCCGAACGAAAACCACGAUUUUAACCGCAGGCUACGGCUUUGACCGUCAGGAUCGCG
20 AUUCCGAUUCUUUGACCGCAACCGCCUUGAGCGGGAGAACUACUCUCUGAGCCAUAACGGCCGC
UGGGGAUAUCGGCAAUAGCGAGCUCAAGUUCUACGGCGAAAAGGUGGAUAACAAAAUCCAGGGCA
GAGCGGGACUAUUACCUCGGAAAGCAAUGCCAUCGACGGCAAGUAUGUCCUGCCGCUGGGCAUGA
UUAACCAGCUGGUGACCUUCGGCGGGCGAAUGGGCGCCACGACAAACUUAAGAUCGGGUCAACCUG
AGCAGCGGGCGGCCAGUCAACGUCGGCCAGCCAGUACGCCCUUUUAUCGAAGACGAAUGGCGCAU
25 CAUCGAGCCGCUGGCGCUGACCACCGCAUUCGUUUGGACGACCAUCAGACCUAUGGCGAUCACU
GGAGCCCGCGCGCCUAUCUGGUGUAUAACGCCACCGAUACCGUACCGUCAAGGCGGCGUGGGCG
ACGGCGUUUAAAGCCCCGUCGUCUGCAGCUUAACCCCGACUGGACCACCAACUCCUGCCGCGG
CUCGUGCAGCAUCGUCGGUAACCCGGAUCUGAAACCGGAAACAGCGAAAGCUUCGAGCUCGGUC
UCUACUACCGCGGGGAAGAGGGCUGGCUUGAAAAUGUCGAAGGCAGCAUCACCACCUUCCAGAAU
30 AAUGUCGACGACAUGAUCGACGUUCUGCGCACCUCCAGCGCCAGCGAAGCGCCGGGCUACCCGAA
CUUUGUCGGCUGGAAAACUGUCAACGGCAAGCGCGUGCCGAUCUCCGCUAUUUCAACGUCAACA
AAGCCCGCAUCAAGGGGUGGAGACGGAGGUGAAGAUCCCGUUUGGCGAUGAGUGGAAGCUGAC
GGUGAACUACACCUACAACGAUGGUCGCGAUCUGAGCAAUGGCGGCGACAAACCGCUGCAGACGC
UGCCGUUCCAUAACGCCAACGGCACGCUCGACUGGAAACCGCUGGACGACUGGUCCUUCUACGUG
35 ACGGCCAACUAUAACGGCCAGCAGCGCGCGGUGAGCGCCACCGGCAAAACGCCGGGCGGCUACAC
CCUGUUUGACGUUGGCGCGGCAUGGCAGGUGACCAAAAACGUGAAACUGCGCUCCGGGGUGCAGA
ACGUGGGUGAUAAAGAUCUGAGCCGGGACGACUACAGCUAUACCGAAGAAGGCCGUCGCUACUUU
AUGGCGGUGGAUUAUCGCUUCUGA

SEQ ID NO:81

AUGAACAGAGCCGCCACGCUGACCCUCAACGCGCCCCUGCUGAUGCUCGUCGCUGCGCUGGGCGCU
UUCAACCCCUUUCACCGCCGGCGCCGCGCCGGCCUUUCUUGAUUACGCCAACAGCAAACCCAGCA
AUCUCAGGGCGCAAGAAAAAACGAUGCCGCAAGCGCAAAACAAACACAAGAAAGCCGCCAGAGCGC
5 AGAUAAUAAAAAACCGGUACCAGCACCUCACAAUUACAAAAAGAAUACACCAGCCAGCAGGCGGC
GAUUGCACAAAAAGAUAAAGCUUAUACAGCAAUUAAAAAACAGCUUGCCGCUACGCCGCAAACGGA
UACUGCCGGAGCGAAUGAGCAAGCGGCGUUGAAUAAGAGAAUUAUGAAUUACAGGUCGCCUUA
GCGCCGCUACUGCAGAAAAAGAGGCAUUAUAAAAAAGCAGGCGUUGUGCAGAAUAAUAAUCUAC
AGCAAAGCCAGGCCGCGGCGGCGUCAGCAGAUCCAGCAAUUACGACGCAGAUUCAGCAAGCCGAA
10 GCUGAAAAUAAACGCCUCAGCGCCAGCUUUACCACGCUUAAUAAAGAUAAACACGCGCUAAUGACC
CAACUGGCCGCAACGGAAAAAGAGAAACAGGCGCUCUUGAGCAGGUCAAAGCGCUUAAACGUGAC
AAACAGCCGCGUGACGACCCGGCUGGGCCGCGCGGAAAAAGAGAAACAGGCCGUCCUCGAGCAGGU
UAAGGCCCCUUAACGCCGAUAAACAGUCGCUGACUAUUCGCCUCGCCGUGCGGAGAAAGCGCAGC
AGGCCGCGUUGUAGCCAGGCUAAAGCGCUUAAACGUGACAAACAGCCGUGGCUACCCGACUGGCC
15 GCCGCGGAAAAAGAGAAACAGGCCGUCCUCGAGCAGGUUAAGGCCCCUAGCGCCGAUAAGCAGUC
GCUGACUAUUCGCCUCGCCGUGCGGAGAAGGCGCAGCAGGCCGCUUUGACCAGGCUAAAGCGC
UUAACGUGACAAACAGCCGUGGCGACCCGGCUGGCCGCCGCGGAAAAAGAGAAACAGGCCGUC
CUCGAGCAGGUUAAAGCCCUUAAACGCCGAUAAGCAGUCGCUGACUAUUCGCCUCGCCGUGCGGA
AAAGACGCAGCAGGCUGCCUCGAUCAGGUCAAAGCCCUUAAACGCCGAUAAACAUCGUGUCCAC
20 CCGGCGUGGCCGCCGCGGAUAAAGCGCCGAUGGCCCGCUAACGACGCCGUGCGCCAAAAAUG
AGCCACCAGAGAUGGCGGCCAUAGUGGCAGCCUAUCGCCUGCAGGCGGAUAAAGACAACGCCAG
CUACGGAUGAAAGAAGAUGAAAUCGAACUGCUGAGAACGCAGCUUUCUGUACAGUCCAAACGCGC
AGCGGCGAGAGCGCCGCCGCCAAACUCAGCGCAUCGGGAGAACAGCAGGCUUAUGCGAUCGGCGC
CUCGAUGGGAAGCGAGGCGCUAACGUCCUUACCACCCGUCGUACUCAGGGAGUUACCGUCGACG
25 CAGGCCUGGUGCUGCAGGGCAUCGAAGAUGCCUUUCGCGGCCAGCUUCGUCUCGGAGAGCAGGAA
CGUAACAAGGCGCUGUUUGAUGUGUCGCAGCAGGUUUUUCAGAACCUGAAUAAAAUAGAGCAGAA
AAACAUCAGUGCCGCAAGAAAUUACAGCAGGCGUUUGCGCGCAAAAAAGAUUGGUCUUUAAAG
AGGGCGUCUACAGCCGCGUCGAUUACCGGGUAAAGGAAAAUAAAGCGGUAAUGACCGGUUACC
GUGGUGAUCAAAGAGAUGCUGACGGACGGGACGGUGAUCAACGAUAUGGAAGCGAAAGAUCAGGC
30 GCUUACGCAAAAGCUGGAUGCCUAUCCCCCGUGUUUCGCGAACC CGUGAAGCGUCUACAGAACC
ACGGCUCCGUGACGCUCGUCGUCCCGCCUGAAAAGGCCUAUGGCAGUAAAGGAUUACCGCCAAA
AUCCCGCCAGGCGCCACCAUGGUUUUUAUCCGUGCGGAUAGAUAGCCAACCCGAGCCGGCAAA
AUAG

SEQ ID NO:82

35 AUGAAAAUCCUGUCCGUGCGUCACGCCGCCUCCCGGCCUGCUCUUGCCGCUCAUUGCGGCAGC
CCAGGCCGCGUGAUGAACAAACCAUGGUGGUGACCGCCGCGCAACCACGGUUUCUGAACUGGAUA
CCCCCGCCGCCGUCAGCGUGGUGAAUGGGGAUGAGAUGCGCCAGGCCGCGCCGCGCGUCAUUC
UCUGAAUCGUGGGCGCCGUGCCGGGCCUGCAGGUGCAGAACC GGCAAAACUAUGCCCAGGAUCU

GCAGCUGUCGAUUCGCGGCUUUGGCUCGCGCUCAACCUAUGGCGUGCGCGGACUGCGCAUCUAUG
UGGAUGGCAUUCGCGCCACCAUGCCCGACGCGCAGGGGAGACCUCAAAUAUUGAUUACGGCAGC
GUUGACACCAUUGAGGUGCUGCGCGGCCCCUUCUCUGCCCUGUACGGUAACUCGUCCGGCGGGG
UGAUCAACGUCACCAGCCAGACCGGCACCCAGCCGCCACCGUGGAAGCCAGCAGCUACUAUGGCA
5 GCUUCGGCACCUGGCACUACGGGAUGAAAGCCACUGGCGCCGUUGGCGACGGCAGCCACGCAGGC
GAUGUGGAUUACACGGUCUCAACCAUUCGCUUACCCACCCAUGGCUAUCGCGAUCACAGCGGCGC
GCGCAAAAAUCUGGCGAACGCCCGGCUGGGGGUGCGCAUCAACGACGUCAGUAAGCUGACUCUGC
UGCUGAAUAGCGUGGAUAUCAAAGCCAAUGACGCCGGUGGCCUGACCGCCGAUGAAUGGCGCGAU
AACCCGCGCCAGUCGCCGCGCGGCGACCAGUAUAAUACCCGCAAGAAUACCCGACAGACCCAGGCC
10 GGCCUGCGCUAUGAGCGCCAGCUCAGUGCCCAGGACGAUCUCAGCGUUAUGAUGUACGCUGGAGA
ACGUGAAACCACUCAGUUCAGUCGAUCCCGCGCGCGCCGAGCUGAAGCCGAGCCAUGCCGGCG
GGGUGAUCGACCUUACCCGUCACUACCAGGGGAUCGAUACCCGGCUGACCCAUCGCGGAGAGCUG
CUGGUGCCCUCACGCUCACCGCCGGUCUCGACUACGAAAAUAGAGCGAGCGGCGCAAAGGGUA
UGAAACUUGUGAUGGUCAACGGCGCGCCGAGUAUGGCGAACAGGGCGCGCUGCGCCGUAACG
15 AACGCAACCUGAUGUGGAACGUCGACCCCUACCUGCAGACCCAGUGGCAGCUCACUGACAAACUCU
CGCUCGAUGCCGGGGUUCGCUACAGCUCGGUAUGGUUCGACUCGAACGACUACUACAUCACCCCA
GGCAAUGGCGAUGACAGCGGUGAUGCCAGCUAUCACAAAUGGCUGCCCGCGGGCUCGCUGAAUA
UGCCUGACCGACGCGUGGAACGUCUAUCUUCGCCGCGCCGCGGCUUCGAGACGCCAACCAUUA
ACGAACUCUCCUACCGCUCCGAUAACCAGAGCGGCCUCAACUUCGGCCUGAAACCCUCCACCAACG
20 ACACGGUGGAGAUCCGCGAGCAAGACGCGGAUCGGCAAUGGGCUGUUCACCGCCGCCUGUUCAG
ACCAUACCGAUAAUGAGAUUGUGGUCGACAGCAGCAGCGGCGGGCGCACCAUUAUAAAAACGC
CGGCAAGACCCGCCGUCAGGGGAUGGAGCUGGGGCUUGGAUCAGCAGUUGGCGAGAGCUGGCGU
CUGAAGGCGGCCUGGACCGGCUUGGACGCGACCUAUCGCACUAACGUCUGCGACGACGCCAGCUG
CAAUGGCAAUCGCAUUCGGGGAUUCGCGCGCAAUAUGGGCUACGCCUCCUUGGCUAUCAGCCGG
25 AGCAAGGUUGGUACGCCGGGAGCGAUUAUUCGCUAUAUGAGCGAUUAUGGCCAAUGACGAAAAC
ACCGCCAAAGCGCCCUCCUGGACGGUGGUUGGCCUGACGACUGGCUAUAUAAUGGAGCUACGGCAG
GAUGGAUAUGGAUCUGUUCGGUCGCAUCGACAACCUGUUCGACCGGGAGUACGUCGGGUCUGUCA
UCGUUAACGAGUCUAACGGACGUUACUACGAGCCUGCCCCGGGACGUAACUACGGCAUCGGCCUG
AACCUCGCCUGGCGCUUCGAAUAA

30 SEQ ID NO:83
AUGAAAUACAGCUCUCACUUCGCCUGGGGAUCGUCAUUCUCUGCUCGCCUGUAGCGUGCCGCU
GCAGGCGGCAGAGAACAUGACCGAACAAUCGACGCCUGACGAGAGCGCCGCCACUGCCGAAAAUCA
CGAGGAGACGAUGGUCAUAACCGCCGCCAGGCAGAACCUGCAGGCGCCGGGCGUGUCGACCAUCA
CCGCAGAAGAGAUCCGCAAACAUCSCCGCCGCGGAUGUGUCGGAGUUAUUCGUACGCAGCCC
35 GGGGUAAACCUGACCGGCAACUCCACCAGCGGGCAGCGCGGCAACAACCGGCAAAUUGAUUCCG
UGGCAUGGGGCCCCGAGAAUACGCUGGUGCUGGUCGAUGGUAAACCGGUGACCAGCCGUAACUCG
GUGCGGUUUGGCUUGGCGCGGCGAUCGUGACUCCCGCGGCGAUACCAGUUGGGUGCCAGCGGAGA
UGAUCGAUCAUAUCGAUGUGAUCGCGGCCCGGCGGCGCGCUAUGGUAAUGGCGCGAUGGG

CGGGGUCGUCAACAUCGUGACCAAACCGACCACGCGAGAAUGGCACGGGUCGUGGAAUACCUAUA
UGAAUGCUCGCCGACGACCCGUAAGAAGGGGCGACGAAACGUACUAACUUUAGCCUCAUUGGUCCG
CUGUCGGACAGUGUCAGCUUCAUCUCUGGGGUAUUCUGAGUAAAACCCAGGCCGAUGCACAGGA
UUAUAACGCCGGGCAUGAAGCGGAACGUACCGGUUCCUACGCCGGUUCUUAUCCCGCCGGACGUG
5 AAGGGGUGGUGAACAAAGAUUUCACAGUAAGCUGCGCUGGGAGUUUGCCCCGAUGCAGGCCUG
GAGUUUGAGGCCGGUUACAGCCGCCAGGGUAAUCUCUAUGCCGGCGACACACAAAACACCAAUACC
AGUACGCUGGUGAAGAGUAUGUACGGGAAAGAGACCAACCGUCUCUACCGGCAAACUUACGGCGU
ACAUGGACCGGCGGCUGGGAUAAUGGCGUGACCAGCAACAGCUAUGCCCAGUACGAACACACCC
GUAACUCGCGAAUGGAUGAAGGGCUGGCGGGCGGUACGGAAGGGAUCUUCUCCAGUAGCGAGUU
10 UUCAGAUUUCGAUCUGGCCGAUGUCCUGCUACAUAUGAAGUGAAUAUCCGUUUACGCUGGGGG
UCGAUCAGAAUCUGACGCUGGGGGCAGAAUGGAAUCAGCAGCGGAUGAAAGAUGGCGUAUCGACA
ACCCAGGCGCUCUCUUAUGGCACUAUCGAUGGCGUAUCGGCUACCGGUCGUAGCCCGUACUCCAG
UGCCGAGAUUCUUCUCGUGUUUACCGAAGAUAAUAUGGCGCUAACGGACAGCACCAUGCUGACAC
CCGCUCUGCGCUUCGAUACCCACAGCAUCGUCGGCAAUAACUGGAGCCCCUCACUGAACCUUGUCUC
15 AGGAGCUGACGGACGACUGGACGCUGAAGCUGGGCAUUGCCCGUGCUUACAAGGCGCCUAACCUC
UACCAGUUGAACCCGAACUAUAUUCUCUACAGCAACGGUCAAGGCUGUUACGCCAGUAGUCCGCC
UGCUAUCUGAUGGGGAAUAGCGAUCUGAAAGCGGAGACCAGCGUUAUAAAGAGAUUGGUCUUGA
GUACAAGCAUGAUGGCUAUCAGGCGGGGAUACCUUGGUUCCGUAACGACUAUCACAAUAAGAUUG
AGUCAGGGUAUGCGGCGGUGGGUACCGCCAGCAACGGCACCAACAAUAUCUAUCAGUGGGAAAAC
20 GUACCAAAGGCGUUAUGUGGAAGGCCUGGAAGGAACGCUGAAUCUGCCGGUGGGGGAGGCGGUUA
ACUGGAGCAAUAACCUAGACCUUGGAUGCUGCAGAGCAAGAAUAAGACGACCGGCGACCGGCUGUCA
GUGAUCCCGCAGUUUACCCUGAACUCGACUUUGAGCUGGCAGGUUCGUGAAGAUCUCUCCUGCA
GAGCACCUUUACCUUGUAUGGCCGACAGAAACCAAAACGCUUCAAUUAUAGGGGCGAGGCGGUCA
GCGGCAGCGAACUAAACGAAGUCAGCCCAUACAGCAUUGUCGGCCUCAGUGCGACCUGGGAUGUG
25 AACAAAAAUCUGAGCUUACCCAGCGGGAUAGAUAAACCUUUUGAUUUCGCCACUACCGGGCAGG
GAAUGCGCAAACGACCGGCAACGCGACGACGGGAGCUUAUCUGUAUGGCGCGGGUGCCGAGACCU
AUAACGAAUCGGGGCGGACCUUCUUUAUGAGCGUUAUACUCAUUUCUGA

SEQ ID NO:84

AUGGAAAAAACGCUUCUCUGCCUUUCGGCAGUUUCAACUCAUUGGCAUUGUUUACAGGUCUGUG
30 UCUGGGAGCCUCGCCGGCAGCAGGCAUCGCAGCGGAAAAUUCGGUCAAAAAUAGUGAAGAGACGC
UGGUAGUGGAAGCCGCUCCGCCUUCACUCUACUCCCCGGCGCUUCCGCCGAUCCCAAGUUCAAU
AAACCGCUGGUCGAUACCAACCCGCACCAUACCGUGAUCCCGGAACAGGUGAUUAAAGAUACAGGGC
GUCACCAACCUAGACUGACGCCCUCAAAACGUUCCCGGCGUCGGGGCGUUUUAUGCCGGGGAGAA
UGGCAGCUCAACCACCGGGGAUGCCAUCUUUAUGCGCGGCGUGGAUACCUCUACAGCAUCUAUG
35 UGGACGGCAUUCGCGACAUCGGUAGCGUGACGCGCGAUACCUCAAUACCCAGCAGGUGGAAGUC
AUCAAAGGGCCCGCCGGCACGGACUAUGGCCGCGAGCGCGCCUCCGGCUCGAUCAUAUGAUCAG
CAAGCAGCCGCGCCUUGACUCCGGGAUCGACGGCUCGGCCAGCAUCGGCAGCGCCUGGUCGCGCC
GGGGCACUCUCGACCUGAACAGGCGUUUAGCGACAACGCUGCGUCCGUCUGAACCUGAUGGGG

GAAAAACGCAUGACGCUGGUCGGGACCGCAUUGAAAACGAACGCUAUGGCAUCGCACCGUCGCU
GGCCUUCGGCCUUGAUACCCCAACUCGUCUGUAUCUGAACUAUCUGCACGUCCGGCAGAACAACAC
CCCGGAUGGCGGGAUCCCCUACCGUCGGCCUGCCGGGCUAUUCGGCGCCUUCGCCGAAGUAUGCCG
CACUCAACUCCGCCGGGAAGGUCGAUACCAGCAAUUUCUAUGGCACCGACUCCGAUUACGAUAAAU
5 CUACUACCGACAGCGGUACCCUGCGCUUCGAACACGAUCUGACGGAGAAUACCACCGUGCGCAAUA
CCACCCGCUGGUCGCGAGUGAAACAGGAGUAUCUUUUGACCGCGGUGAUGGGCGGCGCGAACAUA
AUCACCGCCCCCGAUUAUGACGUAACACCUGGAGCUGGUCGCGUCUGGUUAAUACCAAAGAU
GUCAGCAACCGUAUUCUGACCAACCAGACCAUAUACCCUCGACUUUCAUACUGGCUCGAUAGGC
CAUGACGUCAGCGCCGGCGUGGAGUUUACCCGGGAAAACCAGACCAACUAUGGCGUUAACGCCAG
10 GACCGCGCCGGCGGUGAAUCUCUACCAUCCGGUGAGCAACCUGUCGAUUGGCGGGCUGGACAGAA
ACGGGGCGAACGCCAACGGCCAGACCGAUACCUUCGGGAUUUAUGCCUUUGAUACGCUGACGCUG
ACCGAGCGGAUUGAGAUCAACGGCGGGCUGCGUCUCGACAAUUAACAUACCAAAUAUGACAGCGC
CACCGCCUGCGGCGGCAGCGGACGCGGGGCUAUCGCCUGCCCCGCCCGGACAGUCGACCGGCAGCC
CGGUCACCACUGUCGAUACCGCUAAAUCCGGCAAUCUGGUUAAUCUGGAAAGCCGGGGCGCUGUAC
15 CGCUUAACCGAGCAGGGCAAUGUCUACGUCAACUACGCCAUCUCACAGCAGCCGCCGGGAGGCAG
CAGCUUCGCCUGGCCGCCAGCGGCAGCGGCAACAGCGCUAACCGGACCGACUUUAAGCCACAGA
AGGCGAAAUCCAGCGAGCUGGGCACCAAGUGGCAAUCUUCGACAACCGUCUGCUGCUCAGCGCG
GCGUUAUUCGCAACCGAUUAUGAAAACGAAGUGGCCGCCAACGAUGACGGAACCUUGGUCGAGUA
CGGCAAAAAGCGCGUGGAGGGGUAGAACUCUCCGCGACCGGAAACCUGACCCCGGACUGGACGA
20 UUAUCGCCGGCUACACUCAGCAGCAUGCGACAGUGACGGAGGGACAGAACGUUGCACAGGAUGGA
UCUUCGCCCCUGGCCUACACCCCGAAACAUGCCUUUACGCUGUGGACGCAGUAUCAGGCCACCAGC
GAUCUGUCCGUCGGCGGCGGUGUGCGCUAUGUCGGAAGCCUGCGCCGGGGCAGCGAUGGUGCAG
UCGGUACCCCGGAUCACACCGAGGGCUACUGGGUUGCCGACGCCAAACUGGGCUAUCGGGUCAAC
AGCAACCUCGAUCUGCAGCUCAAUAUGUAUAACCUGUUUGAUACCGAUUACGUGGCCUCCAUAAC
25 AAGAGCGGCUAUCGCUAUCAUCCGGGCGAACCCCGGACCUUUAUGCUGACGGCGAACGUCCAUUU
CUGA

SEQ ID NO:85

AUGGCGACUAUGUACAAUUCGACUCCGUCAGCAGCAUGGUGUAAAAACGCCUGCUGGUGACCUC
UUUGUUUGCAGCAAUUUAUCAGACUUCUGCCAUCGCAGCAGAUACUUCGCCGCUAGCGGCGAGG
30 CGGUGGAUGACACCUCGGAACAAUUGACCGUACCGCCCCCGCGCCGGUGCAGAAAGCCGGUAGC
GAACACAGCAUCAGCGCCCGGGAGCUGGAGAAUAAAGGCGCUAACGAUUUCGGCUCAAUCAUGCG
CUAUGAGCCGCUCAUCAGCGCCACCGGGGCCAGCGGCGGCUCCGGCAACGGCAAAAGCGGCUUCG
ACCGCGGAGGUUACACCGGCUACAACAUAUCGCGUAUGGAGAGCAACCGCGUAGGCAUCGACGUG
GACGGUAUCGCGCAACCCAACGCCACCGGCCGCGGCUACGUCGGCCGCGCCGGGCUAACACCUU
35 CGGCAUCGGCCGCGAUUAUAUCGACCCGUAUAUGUACGGCAGCGUUGAUUAUCCAGUCCGGCGCCA
CCUCGACGGAAACGGCCAACAGCGCUAUCGGGGGGAUGUCUCCUUCGCCCGAAUACAGCGGAU
GAUUACCUGCGCCCGGGCAAGACCAGCGCCUUCGGCUACCGCAGCGGUUACGACUCUGCGGAUCG
CAGCUGGCACAACGGGGUGACCGUCGCCGGCGGCGAUGAGUCCUGCGCGGGAUUUUGGUCUAU

AGCCGCCGUGACGGCCAGGAAACUGAAAAACAACAGCGGCACCGUCGACGCCUACCCGGCGAACUG
GCACUCCGAUGCUUUUCUGGCCUCCGGGAUCUGGCAGCCUAACGAUGAGCACAAGCUGACCAGCA
CCUUCGACUAAUACCAUAAAACCAACCACACCCACUACGAUACCUGGGACUCCAGCGGCAACAGCA
CCAUCGGCACCCGCCAACCAGACCAGCCAGACCCGGCGCUGGGGGCCUGAGCCUGAAGGAUGACUGG
5 ACGCCGAUGAACGACUACCUCGACAGCGUCUCCACAAAAUUCUACUACCAGCAUACCGAAGCCCAU
GACUGGACUUAUAUGCCGGACAGCGUCACCCGCAAAUUGCAGACGGUGAACUCUAACUACGAUACC
GACACCUGGGGGCCUGCAGACCCGCGCUGGGCGAAAACCCUGGGCCGCCACGAUCUGAGCGCCGGUUU
CAACGCCAGCACCAGCAAAACCCAGCGGCCGUUCAGCCAGUCGCCGAUCCCCAGCGUUUACAGCGA
GAUCAUGCAGCCGGAGGCAGACAGCCGCAGCUACACCCUCGGCGGCCUUUGUCCAGGAUAAGAUA
10 ACUUCGAUCUCGACAGCCACAACUUCGCCGUUAUUCGGCGUGCGCGUGGUGCAUCAAUCGACU
AAGCCGGAUUUUCUGUCCGAUCUCGCCGCCAACAGCAGCGUGCUGAGCGAAUCGUCGGUGGGCGAA
UCUGUACGGCAAAAACAGCGAUACCCAGGUUCGCCGUCGUUGACCUUCCAGUACGACCUCACCCC
GCGCCUGAUGACCUACCUGCAGUACCAGCGCGGGGCGCAGUUCCCCAACGCCAGCCAGCUGUAUG
GCUCCUGGAACCUCGGCUCCAGCUACGCCGGCAGCCAGCAGUAUGCCCUGAUCGGCAAUACCGAU
15 CUGAAGACGGAACCAGCGAUAAUCUCGAGUGGGGGCUGAAAGGGGAAGUUACCGAAGGCAUCAC
CCUGCGCACGGCGCUGUUCUACAACAGCUAUAAGAACUUUAUCGCCUAUACCCGCUAUACCCGCGC
CAACAAUCCGGGCCAGUUCACGAAUGUGCCGUCGAACAUCUACACCAUUUAUCAGGCGGAAAACCG
CGAUAAGCCUAUAUCUACGGCGGUGAGAUUAGCACCAAAUUUAACUUUGGCACCUGGUUUUGAGC
AGGUGGACGGCCUGAGCGCCACCCUCGCCUCGGCUAUAGCGAAGGGAAAUCGAAAUCCAGCUAC
20 AGCGGCGAUAAAUACGUCGACCUCGACAGCGUGGCGCCAAUGAAAGCCAUCGUCGGCGUGGGCGUG
GGACGAUCCGGCGAAACGCUACGGCACCCGCCUGACGGCGACCUUUGUCAAGGGAAACAGGCGA
CCGCCACCAACCGCGAAAGCUACAGCAACAGCGGAUCCGCCAUACCCGAUGCCAGCAGCGACUAUA
UGCGCGUGCCGGGCUACGGCAUGCUGGACUGGACCGCGUACUGGCAGGUGGCGAAAAACGUGCG
CCUCAUUGGCGGGGUCUACAACCUCACCGAUUCGUAAAUACUGGGAUUACCUGAGCAGCCGCAUA
25 UCGAGACCGGCACCAACCAGGACGCCAACGAUAAAGCGCUGGCGGUGAUGCCGGGGCCGACCUUG
CAGCUGGGCGUCAACGUCGACUUCUGA

SEQ ID NO:86

AUGGCGAUGAAAAAGUUGCUCUAUAGCGUCGCUGCUGUUUAGCAGCGCGACUGUAUACGGUGCUGA
AGGGUUCGUGGUGAAGGACAUUCAUUUCGAAGGCUUGCAGCGUGUCGCUGUUGGUGCGGCCUC
30 CUCAGUAUGCCAGUGCGUCCUGGCGAUACGGUGACCGACGAUGAUUAUCAGUAACACUAUUCGCGC
GCUGUUUGCCACUGGCAACUUCGAGGACGUCCGCGUCCUGCGCGAUGGUGAUACCCUGCUGGUUC
AGGUGAAAGAGCGUCCGACGAUCGCCAGCAUCACUUUCUCCGGCAACAAGUCGGUGAAAGAUGAC
AUGCUCAGCAGAACCUUGAGGGCCUCAGGCGUUCGGGUGGGCGAGUCGUUGACCGCACGACCAU
CGCGGAUAUCGAGAAGGGUCUUGAAGACUUCUACUACAGCGUCGGUAAAUACAGCGCCAGCGUCA
35 AAGCAGUCGUUACGCCGUGCCGCGUAACCGUGUCGAUUUGAAGCUGGUCUUCAGGAAGGCGUC
UCCGCAAAAAUUAACAGAUCAACAUCGUCGGCAACCAUGCGUUUUCGACCGAUGAGCUGAUCUCC
CACUCCAGCUGCGCGAUGAGGUGCCGUGGUGGAACGUGGUCGGCGACCGUAAAUACCAGAAGCA
GAAGCUAGCGGGCGACCUUGAAACCCUGCGCAGCUACUACCUGGAUCGCGGCUAUGCCCGUUUCA

ACAUCGAUUCUACCCAGGUCAGCCUGACGCCGGAUAAGAAAGGGAUCUACAUCACCGUCAACAUCA
CCGAAGGCGAUCAGUACAAGUUUCCGGAGUGCAGGUGACGGGCAACCUCGCUUGGCCAUUCCGCG
GAAAUCGAAGCGCUGACUAAAGUUGAGCCAGGCGAACUGUACAACGGCGCGAAAGUGACCAAGAU
GGAACGACAUACAAGAAACUGUUGGGUCGUUAUGGUUACGCCUAUCCGCGCGUGCAGUCGCAGC
5 CGGAGAUCAACGACAGCGAUAAAACCGUUAAGCUGCACGUUAACGUCGACGCAGGCAACCGUUAUU
ACGUGCGUAAAAUUCGCUUCGAAGGCAACGACACCUCUAAAGAUGCCGUACUGCGCCGCGAAUUG
CGCCAGAUUGAAGGCGCAUGGCUGGGCAGCGACCUCGUCGAUCAGGGUAAAGACCGUCUCAUUCG
UUUAGGUUUUCUUUGAAACGGUGGAUACUGAUACCCAGCGCGUGCCGGGCAGCCCGGACCAGGUCG
ACGUUGUCUACAAGGUGAAAGAGCGUAACACCGGUAGCUUCAACUUCGGUAUCGGCUACGGCACCC
10 GAGAGCGGCGUCAGCUUCCAGGCGGGCGUUCAGCAGGAUAACUGGUUAGGUACUGGCUAUGCUG
UCGGGAUCAACGGUACCAAAAACGACUACCAGACCUAUACCGAGCUGUCGGUGACCAACCCGUACU
UCACCGUAGACGGUGUAAGCCUCGGCGGUCGUGUCUUCUAUAUGACUUUGAUGCGAACGAUGCG
GAUCUGUCUGACUUAACCAACAAAAGCUAUGGUACAGACAUUACGCUGGGCUUCCCGGUCAACGAA
UACAACACGCUGCGCGCCGGCGUCGGUUAUGUGCAUAACUCCUGUCCAUAUAGCAGCCGCAGGU
15 GGCAAUGUGGCGUUAACCUAACUCGAUGGGCCAGUAUCCGGACAACACCAACGACCGGAACUCGU
UCAGUGCGAAUGACUUCACCUUAACUACGGUUGGACCUAUAACAAGCUUGACCGCGGCUUCUUC
CCAACGGAAGGUUCGCGCGUCAACCUGAACGGUAAGGUGACCAUUCGGGCUCAGACAACGAGUA
CUACAAAGCGACGCUGGAUACCGCGACCUACGUGCCGAUCGACAACGAUCAUCAGUGGGUAGUAC
UGGGUCGUACGCGCUUUGGUUAUGGCGAUGGUUACGGCGGCAAAGAGAUGCCGUUCUAUGAGAA
20 CUUCUAUGCCGGUGGUUCCAGCACCGUGCGUGGCUUCCAGUCGAACACCAUUGGUCCGAAGGCGG
UGUACUUCCCGGCAAGCAGUCGUCAUGAUGACGAUAGUUACGAUAAUGAAUGUAAGAGCACCC
GAAUCCGCACCGUGUAAAUCCGAUGAUGCGGUGGGCGGUAACGCGAUGGCGGUGGGCAGCCUUG
AGCUGAUUACCCCGACGCCGUUUAUUAUGUGACAAUAUGCGAACUCGGUCCGUACUUCGUCUUC
UGGGAUUUGGGUACCGUAUGGGAUACUCACUGGGAUUCGAGCGCGUACGCUGGUUAUCCGGAUU
25 ACAGCGAUCCGAGCAACAUCCGUUUGUCUGCGGGUAUUGCCGUGCAGUGGAUGUCGCCGUUGGG
GCCGUUGGUCUUCUCCUACGCCCAACCGUUCAAAAAGUACGAUGGAGACAAAGCCGAACAGUCCA
GUUUAACAUUGGUAAAACCGGUAA

SEQ ID NO:87

AUGACAGAUGUGACUUAUAAAGCGCUGGCCUCAGAGAUUCAGACCUCUGUGGAUCGCCUGAUACA
30 GCAAUUUGCUGACGCAGGCAUCCGCAAAUCGGCUGAUGAUUUCUGUGACCUCGCAAGAGAAACAAA
CUUUGUUGACGCACCUGAACCGUGAACACGGCUCGCGCCAGACAAGCUGACGUUACAGCGUAAG
ACGCGCAGUACGUUAAUUAUCCAGGUACCGGUGGAAAGAGUAAAUCGGUACAAAUCGAAGUCCG
CAAGAAACGCACCUUUGUGAAACGCGAUCCGCAAGAGGCUGAACGCCUGGCCGCGGAAGAGCAGG
CGCAGCGUGAAGCGGAAGAGCAGGCCCCGUCGUGAAGCUGAAGAAGCAGCGAAACGCGAGGCGCAA
35 UUAAAAGCUGAACGUGAGGCCGCGAGAACAAGCUAAACGUGAAGUCGCUGAUAAAGCGAAACGUGAA
GCUGCGGAAAAAGACAAAGUGAGCAAUCAACAUACCGACGAAAUGACCAAAACCGCCCAGGCUGAA
AAGAUCGUCGCGAGAACGAAGCCGCGGAUUUGAAGCGCAAAUCGGAAGAAGAAGCACGCCGCAAA
CUUGAAGAAGAAGCGCGCCGUGUAGCGGAAGAAGCACGCCGUUUGGCUGAAGAAAACGAAAAAA

UUGGUCUGAAACCUCAGACAGCCCGGAAGAUAGCAGCGACUAUCACGUCACCACAUCACAGCAUGC
UCGUCAGGCUGAAGAUGAUAAACGAUCGUGAAGUCGAAGGCGGUCGCGGCCGUAGCCGUAGCAGCA
AAGCGGCUCGUCCGGCGAAGAAAGGCAACAAACACGCUGAAUCGAAAGCUGAUCGUGAAGAAGCC
CGCGCGGCCGUGCGCGGCGGUAAAGGCGGUAAGCACCGUAAAGGUUCCGCUCUGCAGCAGGGCU
5 UCCAGAAGCCAGCGCAGGCCGUAACCGUGACGUCGUAUUCGGCGAAACCAUACCGUUGGCGAA
CUGGCUAACAAGAUGGCGGUGAAAGGUUCUCAGGUAUCAAAGCGAUGAUGAAGCUGGGCGCCAU
GGCGACCAUCAACCAGGUCAUCGACCAGGAAACCGCACAGCUGGUUGCCGAAGAGAUGGGCCACA
AAGUUAUCCUGCGUCGUGAAAACGAACUGGAAGAAGCCGUAAUGAGCGACCGUGACACCGGCGCG
GCGGCUGAACC GCGCGCACCGGUCGUGACCAUUAUGGGUACGUAUGACCACGGUAAAACCU CGCU
10 GCUGGACUACAUUCGUUCUACCAAGGUUGCCUCCGGCGAAGCGGGUGGUUUACCCAGCACAU CG
GUGCUUACCACGUCGAAACCGACAACGGCAUGAUCACCUUCCUGGAUACCCCGGGCCACGCCGCG
UUUACCUC CAUGCGUGCUCGUGGGCGCGCAGGCGACGGAUAUCGUGGUUCUGGUGGUGGCGGCAG
ACGACGGCGUGAUGCCGCGAGACUAUCGAAGCUAUCCAGCACGCUAAAGCGGCGCAGGUACCGGUG
GUAGUGGCGGUGAACAAGAU CGAUAAAGCCAGAAGCCGAUCCGGAUCGCGUGAAGAACGAACUGUC
15 CCAGUACGGCAUCCUGCCGGAAGAGUGGGGCGGCGAGAGCCAGUUCGUCCACGUUUCGCGAAAG
CGGGUACCGGCAUCGACGACCUGCUGGACGCGAUCCUGCUGCAGGCUGAAGUUCUUGAGCUGAAA
GCGGUCCGCAACGGUAUGGCGAGCGGCGCGGUCAUCGAAUCCUCCUUGAUAAAGGUCGUGGUCC
GGUAGCUACCGUUCUGGUUCGCGAAGGUACUCUGCACAAGGGCGACAUUGUUCUGUGCGGCUUC
GAAUAUGGCCGUGUGCGCGCGAUGCGUGACGAACUGGGUCGCGAAGUGCUGGAAGCGGGUCCGU
20 CCAUUC CGGUGGAAAUCCUCGGCCUGUCCGGUGUGCCGGCUGCCGGUGAUGAAGUGACCGUAGU
GCGUGACGAGAAAAAAGCGCGUGAAGUGGCGCUGUAUCGUCAGGGCAAUUCGUGAAGUUAAGC
UGGCGCGUCAGCAGAAAUCUAAACUGGAAAACAUGUUCGCUAACAUGACCGAAGGCGAAGUUCAC
GAAGUGAACAU CGUACUGAAAGCGGACGUACAGGGUUCUGUCGAAGCGAUUUCGGAUCCUUAUCU
GAAACUGUCUACCGACGAAGUGAAAGUGAAGAUCAUCGGUUC CGGCGUAGGUGGUUAUCACCGAAA
25 CCGACGCUACCCUGGCAGCAGCAUCCAACGCGAUUCUGGUUGGCUUAACGUUCGUGCCGAUGCC
UCUGCGCGUAAAGUUAUCGAAGCGGAAAGCCUGGAUCUGCGUUAUCUACUCCGUCAUCUAUAACCU
GAUCGACGAAGUGAAAGCGGCGAUGAGCGGCAUGCUGUCUCCGGAACUGAAACAGCAGAUCAUCG
GUCUGGCUGAAGUGCGUGAUGUCUUAACUCCGAAAUUCGGCGCAUCGCGGGCUGUAUGGU
UACCGAAGGGACGAUCAAACGUCACAACCCAAUCCGCGUUCUGCGUGACAACGUGGUUAUCUAUGA
30 AGGCGAGCUGGAAUCCUGCGCCGCUUCAAAGAUGACGUUAACGAAGUCCGUAACGGCAUGGAAU
GUGGUUAUCGGCGUGAAGAACUACAACGACGUUCGCGUUGGCGAUUGAUCGAAGUGUUCGAAAUC
AUCGAAAUCCAGCGUAGCAUCGAUUAA

SEQ ID NO:88

AUGAAAAGAAUGUUAUUAACGCAACUCAGCAGGAAGAGUUGCGCGUCGCCCUGUUGAUGGGCA
35 GCGCCUGUACGACCUGGAUAUCGAAAGCCCCGGGCACGAACAGAAAAAAGCGAACAUCUACAAAG
CAAAUACCCGCAUUGAACCCAGCCUUGAAGCCGCGUUUGUUGAUUACGGCGCCGAGCGUCAUG
GUUUCUCCCCCUCAAAGAAU CGCCCGCGAAUACUUC CCGGCAACUACAAUGCGCAUGGUCGUC
CUAAUAUCAAGACGUACUGCGGGAAGGUCAGGAAGUUAUCGUGCAGAUUGAUAAAGAAGACGC

GGCAACAAAGGCGCUGCGCUCACCACCUUUAUCAGCCUCGCGGGCAGCUAUCUGGUACUGAUGCC
GAACAACCCGCGCGCCGGGGAAUUUCCCGCCGUAUCGAGGGCGACGACCGUACCGAACUGAAAG
AAGCGCUGGGCGAGCCUGGAGCUUCCGGACGGCAUGGGCCUGAUCGUUUCGACCCGUGGGCUGCGG
CAAUCCGCCGAAGCCCUGCAGUGGGACCUGAGCUUCCGCCUGAAGCACUGGGAAGCGAUUCAGA
5 AAGCCGCGGAAAGCCGUCCGGCGCCGUUCCUGAUCCACCAGGAAAGCAACGUCAUUGUCCGCGCC
UUCCGUGACUACCUUGCGCCAGGACAUCGGCGAAAUCCUGAUCGAUAACCCGAAAGUGCUUUGAGCU
GGCGCGCCAGCAUAUCGCCGCGCUGGGUGCUGCCGAUUUCAGCAGCAAAUAAAACUGUACACCG
GUGAAAUCCCGCUGUUCAGCCAUAUUCAGAUCGAAUCGCAAAUUGAGUCCGCCUUCAGCGCGAA
GUGCGCCUGCCUUCGGCGGGUCUAUCGUUAUCGAUAGCACCGAAGCGCUGACCGCGAUUCGAUUA
10 CAACUCCGCCCGCGCCACCCGCGGCGCGGAUAUCGAAGAGACAGCCUUCAAUACCAACCUCGAAGC
GGCUGACGAAAUUGCCCGCCAGCUGCGUCUGCGCGACCUCGGCGGCCUGAUCGUUAUCGACUUA
UCGAUAUGACCCCGGUUCGCCACCAGCGCGCCGUGGAGAAUCGUCUGCGCGAAGCCGUCGUCAG
GACCGUGCGCGCAUUCAGAUACGCAUAUUUCGCGCUUCGGCCUGCUGGAGAUUGCCCGUCAGCG
CCUGAGCCCGUCGCUUGGGCGAGUCCAGCCACCACGUCUGCCCGCGCUGCUCGGGCACCGGCACCG
15 UGCGUGAUAAACGAAUCGCUUGCGCUCUCUAUUUCUGCGUCUGAUCGAAGAAGAAGCGCUGAAAGAG
AAUACCAAAGAAGUCCACGCCAUUGUUCGGUACCGAUUCGCCUCCUAUCUGCUGAACGAAAAACGU
GCCGCAGUGAGCGCUAUCGAAUCCCGUCAGGGCGAUGUGCGCGUUAUUUUCGUGCCAAACGACGA
AAUGCAAACGCCGCACUACUCCGUCCUGCGCGUGCGCAAAGGUGAAGAAACCUCAACGCUGAGCUA
UCUGCUGCCGAAGCUGCAUGAAGAAGAAAUGGCGCUGCCAGGCGACGAUGAGCCGGCGGAGCGGA
20 AACGUCCGGAACAGCCGGCCUUGGCCGCUUUUGUCAUGCCAGAUGCGCGCCGACCCCGAUGCUC
GAAGAGCCUGCCGCCGCGCCUGUCGCCGCAGCGGCACCGUUCGCGGCCGCCGACCGGCGCAGCC
UGGCCUGCUCUCACGCUUUCUUCAGCGCGCUGAAGAAUAUCUUCUCUGGGCGCCGAAGAGGCCAAAC
CGGCUGAAGUUCAGGUCGAGAAGAAAGCGGAAGAAAAACCGGAGCGUCAGCAGGAGCGUCGUAAA
CCGCGCGCCAACAACCGCCGCGACCGCAACGACCGCCGUGAUAAACCGCGACAAUCGUGACAACCGC
25 GAUAACCGUGACAAUCGCGACACCCGUGCGGACAAUGCCGAGGGCCGUGAACCGCGCGAAUCGCG
UGAAGAGAACCGUCGCAACCGUCGCGAGAAGCCGUCGCGAGAACGUGGAAGCCCGUGAUGUUCGCC
AAACCUCAGGCGACGACGCGGAGAAAGCGAAAUCCCGUGACGAGCAGCAGCCGCGCCGCGAACGC
ACCCGCCGCCGCGAGUGACGACAAACGUCAGGCGCAGCAGGAAGCCAAAGCGCAGACUCGCGAAGA
GCCGGUUGUGCAGGAGACGGAGCAGGAAGAGCGUGUACAAACUCUGCCGCGUCGUAAACCGCGCC
30 AGCUGGCACAGAAAGUGCGCGUUGAGUCCGCUUGCUGCUGAGCCAGUUGCCGAGAUUCGUGCCAGAA
GCCGUAGUGGCUGAAGUUAUCGCUCCGCACAGCGAGCCGGUGAAAGCCGAGCUGCCGGCAGGGG
UGGAGAGCGUGGCGGACCAGGACGAAAAUGGCGAAUCCCGUGAAGCGAACGGUAUGCCGCGUCGC
UCACGUCGCUCCCCGCGUCACCUUGCGCGUCAGCGGUCAGCGUCGUCGUCGCUAUCGUGACGAACG
CUAUCCGACCCAGUCGCCUAUGCCGCGUACCGUAGCCUGCGCAUCGCCGAGAUUGGCUUCCGGUA
35 AAGUCUGGAUCCGCUACCCGGUGGUUCGUCCGCAGGAUCAGCAGCCGGAAGAGGUUCAGGUUCAG
GACGCCAGCGUCGCGAAACUGUCGAGGCCGUAGCGGCCCGGUCGCCGUCGUUGAAACCGUUAAC
CGCUGCGCCGGUCACCGUCGAGCCGGCUACCAUGGAACAGUAACCGCUGAGCCGGUAGUCGUCG
AGCCGGUAGCGGCCGCCGAGCCGCUUGGUCGUUGAUGCUGCGGAAGUUGUCGCGCCAGCAGCCGU
CGAGCCAGCGCCUCAGGAGCCGGUCACCGAAGCACCGGCUGUCGAAGCGCCUCAGGCUAUCGCGC

CAGUGACGCUCGACGCCGAGCCGGUGGUGGUAGAACCUGAAGCGGUGGAAACGACGCCUGUCGUU
GCAGCGCCAGUGGAAACUAUCGCCCCGGUCGCAGAAACCGUGGAGCAAGCGCCAGUGACCGAAGC
GGCCCCUGCCGAACCGGUCAAAGCCGAGCCCCGGUGAGCAAGCCGGUCGUAGUGGCGGGUCAUC
GCCAUGCCACCGCGCCAAUGACCCGUGCGCCAGCUCCGGACUAUGUCCCGGAAGCACCGCGUCAU
5 AGCACCUGGGUGCGCCCGCCGUUCGCCUUUGAAGGUAAAAGGCGCCGCCGGUGGUCAUAGCGCGAC
CCAUAAGCCACCGCUGAACCGACUCGCCCACAGCCCGUCGAGUAA

SEQ ID NO:89

AUGCGCAAGCUCUCACUAAGUUUACUCACGCUGUCCUCGGCGUUGCGCUGCUGCCGUUAGCGCA
GGCGGCGACGACGCCUGCCCAGGAGCAUCUGCUGGAGCAGGUCCGCCUCGGCGAGGCCAGCAAUC
10 GUGAAGACCUGGUGCGCCAGUCGCUGUACCGUCUGGAGCUGAUUGAUCCCAACAACCCGGAGCUG
AUUGCCGCGCGGAUGCGCUAUCUGCUGCGUCAGGGGGAUGCCGCCGGGGCGCAAAAAGAGCUGG
AACGACUGACGAAGCAGGCGCCGGACUCCCCGGAGCUGAAGGCGUCGCGCAAUGAGAUGAAAAGC
AACACCGGCGAGGGCCGCCAGGCGCUGCAGCAGGCGCGACUCUGGGGCGUGGCCGGGAAGGUCG
AUGAAGCCAUCGCCGCCUAUGAAAAACUGUACGGCGGGGUGCCGGAUGACGUUUGACGUCGCCAUU
15 GAGUACUGGACGCUGGUGGCGCGCCUGCCGGCCCCGCAUAGCGAAGGCGUCAGCCAGUUGAAAAA
ACUGAACGCCAGCGCGCCGGGCAACGUCAGCCUGCUGACUUCGCUGGCCGAAGCAGAUGUUCGCCG
AUAACAAACCGCAGGAGGGGUUCGCCUAUCUGGCGGAGAUGGCCCGAUCGGCCUCGGGACGCGGU
AUCGCCGCCGAUAUGUGGUUCAGUGAGGUGAAAAGCAUGCCGGUGAGUAAGGCCAGCGUGCAGGC
GUUGCAGCAAUUUCUUCUGCAGUUUCCACCGGCUCGGUGGCGGCGAACGCCCGGUUCUGCUCG
20 ACCAACAGCAGGCGCAGCUGCAGGAUCCGACUUUCCGCGCCCGCUCGGAAGGGCUGGCCGGCGGUC
AAGUCCGGGAUACCACGCAGGCGGUCGCGGAUCUGCAGAAAGCCGUUCAGGCCGACAGCCGCGA
CAGCGACGCGGUGGGCGCUCUCGGCCAGGCCUAUUCCAGCGCGGCGACCGCGCGCGGGCAGUG
GCGCAGCUCAGUAAAAGCGAUUGCUAUGGACCCUGACAGCCCGAACCGCGGCAAGUGGGACAGCCU
GCUGCAAACUAACCGCUACUGGCGUCUGAUAAAGCAGGGGGAUAACGCCCGUAAAGCCGGCCAGC
25 UUUCGCAGGCGCAGAACUAUUAUGCCCAGGCGCAGCGGGUCGAUCGCACCGACAGCUAUGCCGUG
CUGGGGCGUGGGGACGUCGCGGCGGCGCGCAAAGAGGCGGCGGCGGAGCGCUAUUACCAGC
AGGCGUUGCGCCUGGAUCGCGGCAAUAACCGGCGGUGCGCGGCCUGGCCAACCUUAUCGCGCC
GAAUCGCCGGAGAAAGCCAGCGCCUGGAUCGCCGGCCUCCUCCCGCUCAGCGGCGGAGCAUCGA
UGAUAUUGAGCGCAGCCUGACUAACGACCGGCUGGAGAAACAGGCGCAGGCUCUGGAGAGCCAGG
30 GCAACUGGGCGCAGGCGGCGGAAGUUCAGCGUCGGCGCCUGGCGCUGGAUCCGGACAGCGUCUG
GAUAACCUACCGUCUGGCGCGGGAUCUGGUCAGCGCCGGCGAACGCCAGGAGGCCGACGCGCUGA
UGCGGACGAUGGUCAACCGCCAGCCGCAGGACGCCGAACGGGUCUACGCCUCGGGACUCUACCUG
UCGGGGAACGACCAGGACGAUCUGGCUUCUGGCGCAAUUCGCCGCUUGCCGCGCAGCGCGUGGAC
GGAUAACAUUCGUGAGCUCGAAGCGCGUUUGCAAAGCGACCGGGUGCUGCGCCAGGCCAACAGC
35 UGCGCGACAGCGGUAACGAAGCGCAGGCGAUCGCCCUUAUCCGACAGCAGCCCGCCUCGGUGCGC
UAUGACCUAGCGCUCGCCGACUGGGCGCAGCAGCGCGGCGACAGCCAGACGGCGAUUGCCAACUA
UCAGCGGGUGCUGCGCCAGGAGGCCGACAACGGCGGAUGCGCGCCUCGGCCUUGCGGAAGUCUACC
UGGCCGAGGGCGAUAAACCGGCCCGCCGGGCGCAGGUCAUGCAGCUGAAAGGCGCAGAGACCGAA

UCCAUGAACAU GCAGCGGCGGGUGGCGCUGGCGCGAGCUGGCCUUGGCGAUACCGCUGACGCGC
AACGGAUUUUUAAUCAGAUUGUGCCGAGGCGAAGGCGCAGCCGCCUCGAUGGAGAGCGCGCUG
GUGCUGCGCGAUGCCGCGCGCUUUGCCACCCAGAGCGGGGCGCCGAGCAGGCGCUGACGCACUA
CCGGGAAGCUAUGGUGGCCUCCGGCAUUACCCCGCGCAGCCGAGGAUAACGAUACUUUUACGC
5 GGCUGACGCGCAACGACAGCCAUGAUGACUGGCUGAAGCGCGGGAUCCGAGCGAUGCCGCCGAC
CUUUAUUCGUCAGCAGGAUCUGAACGUCACCCUGGAACAUGACUUCUGGGGUUCCAGCGGCACCGG
CGGCUAUUCCGACCUGAAGGCGCAUACCACCAUGCUGCAGAUUGGAUGCUCCGUGGCGGAUGGCC
GGAUGUUCUUCGACCGACCGUUGUCAUAUGGAUGCCGGCAGCUUUUCCACCCACAGCGACGGG
AGCUACUCGCCCAGCUGGGGACCGUGCGGGGAGAUCCGUGUACCAGCGGCAGUAAAAUACAGAC
10 CGACAGCGGGGCCAGCGUGGCGGUCGGCUGGAAGAAUGACACCGGAGCGGGGAUAUCGGCACC
ACGCCGAUGGGGCUUCAUGUCGUCGAUGUGGUGGGGGGCGUGAGCUACAGCAGCGACGUCGGGC
CGGUGGGGUACACGGUCAACGUCCACCGGCGGCCUAUCUCCAGCUCGCUGCUCUCCUUUGGCGGG
CAGAAGGACAGCAGCAGCCAUAACCGGCGCCACCGUGGGGCGGCGUCCGCGCCGACGGCGGCGGCCU
GAGCCUGAGCUACGAUCGCGGGGAGGCUCACGGCAUCUGGUCCUCGCUGGGCGCCGACUCGCUG
15 ACCGGUAAAAACGUGGCGGAUAACUGGCGCGUGCGCUGGAUGACCGGGUACUACUACAAGGUCAU
CAACGAGAAUAUUCGUCGCGUCACCGUCGGCCUCAACAAUAUGAUCUGGCACUACGACAAAGAUUC
CAGCGGCUACACCCUCGGCCAGGGCGGCUAUUACAGCCCACAGGAGUAUCUCUCGUUCGCCGUGC
CGGUGACCUGGCGUCAGCGCACCGAGAACUGGUCCUGGGAGCUCGGCGGGUCGGUGUCAUGGUC
CCAUUCGCGCACCCAGACGCAAGCCCGCUAUCCGCGUCUGAACCUGAUCCCGUCCGACUACCGGCA
20 GCGCGCCAGCGAGCUGACGGAGGAGGGGAGCAGCAGCCAUGGAUUCGGUUACACCGCCAGAGCGC
UGGUGGAGCGGCGGGUGACCAGCAACUGGUUCGUCGGCGCCGCGGUCGAUAUUCAGCAGGCGAA
GGAUUACACCCGAGCCAUGCGCUGCUUUACGUCCGCUACUCGGCGGCGCGGCUGGCAGGGGGAUC
UGGAUAUGCCGCCCCAGCCGCUGGUGCCCUACGCCGACUGGUAG

SEQ ID NO:90

25 AUGAGCCAGGAUAACACCGAAGACAAAGAAGUCAAAACUAACCAAACUCAGCAGCGGGCGCCGACUC
CUUGAGGCGAUGCUCAUCCUUUGCUCCUCUUCGCCAUCUGGCUGAUGGCGGCACUACUGAGCUU
UAACCCUCGGAACCCAGCUGGUCGCAAACGGCAUGGCAUGAGCCUAUUCAUAAUUUAGGCGGCG
CCCCCGGCGCGUGGCUUGCCGAUACCCUCUUUUUUAUUUUUGGCGUCAUGGCCUACACCAUCCCG
GUGAUCAUCAUCGGCGGAUGCUGGUUUGCCUGGCGGCAUCAGGAAAACGACGAUAUUGAUUA
30 UUUUGCCGUUUCCCUUCGCCUCAUCGGUGCGUUAAGCCUGAUCCUGACCUCUGUGGUCUGGCGG
CGAUUAACGCCGAUGAUUUCUGGUACUUCGCCUCCGGCGGGGUGAUCGGCAGCCUGCUGAGCACC
ACGCUGCAACCCUCGUCGACAGCAGCGGCGGCACCAUCGCCUGUUGUGUAUCUGGGCGGCGCGG
GCUGACGCUGUUCACCGGCGUGGUCGUGGGUCAGCAUUGCGGAAAAGCUGGGCGGCGGCAUCCUG
UCCGUUCUCACCUUUGCCAGCAACCGUACCCGUCGGGAUGAUACCUGGGUCGAUGAAGGCGAAUA
35 UGAAGACGACGAGGAAGAGUACGACGACGAAGAGGCGGCCAGGCCGAGGAUUCGCGUCGCGCCC
GUAUCUUAACGACGCGCGCUGGCGCGGCGUAAGCGUCUGGCCGAGAAGUUUACCAACCCUAUGGGG
CGUAAAACCGACGCGCUGCGCUUUUCUCCGGCAAACGGAUGGAUGACGGCGAAGAGGUGGUGCAAUA
CAGCGCCAGCGGGGCGCCUGUUGCCGCCGACGAUGUACUGUUUCCGGCGCCAGCGCCGCGCGU

CCCGCAGAGGAUGAUGUGCUGUUCUCCGGCGCCAGCGCCGUGCGCCCGGGCGAUUUCGACCCUUA
CGAUCCGUUGUUGAAUUGGCCACAGUAUCGCUGAGCCGGUAAGCGCAGCGGCGGCGGUACAGCCG
CGCCGCAGGCGUGGGCAGAAUACCCGGUGGGCCAUCACGGCGCUGCGCCAGCUUAUCAGCCGGAA
GCCAGCUAUCCGCCGCAGCAGGCCUAUCAGCCUGAACCCGCUCCGUUCCAGCAGGCCUAUCAGCCU
5 GAACCCGCUCCGUUCCAGCAGGCGUCUUAUCAGCCGCCAGCGGGCAAACCGCACCGCAGGCGUA
UCAGCCUGAGCCAGCGCCGUAUCAACAGCCGGUUUACGAUCCGCGUGCCGGUCAACCGUGCGCCGC
AGGCCUAUCAGCCUGAGCCAGCGCCGUAUACAGCAGCCGGCUUACGAUCCGU AUGCCGGUCAACCU
GCGCCGCAGGCCUAUCAGCCUGAACCUGCGCCGUAUACAGCAGCCGGCUUACGAUCCGCAUGCCGG
UCAACCGCACCGCAGGCCUAUCAGCCUGAGCCAGCGCCGUAUACAGCAGCCGGCUUACGAUCCCUA
10 UGCCGGUCAACCGUGCGCCGCAGGCCUAUCAGCCGGAGCCAGCGCCGUAUACAGCAGCCAACUACG
AUCCCUAUGCCGGUCAGCCUGCGCCUCAGACCUAUCAGCAGCCGGCUUACGAUCCGAAUGCCGGU
CAGCCCCGCGCCGCAGCCGUAUACAGCCGGAGCCAGCGGCGUAUCAGCCGCAAAGCGCGCCAGUUC
CCCACCGGAGCCAGAGCCCGAGGUCGUGCAGGAGGAAGUGAAACGUCCGCCGCUUAUUAUUUCG
AGGAAGUGGAAGAGAAGCGGGCGCGCAACGCGAGCUGUUGGCCUCCUGGUUAUCAGCCAAUUCU
15 GAGCCGGAAGUCCGAUUGCCACUAAACCGCUGACGCCGCCGACCACUGCGUCCAAACCGCCAGUG
GAGACAACCGUAGUCUCUGCGGUAGCGGCUGGGGUGCAUCAGGCUACCGCCGCCAGCGGCGGCG
CGGCGGCAGCAACCUCGUCCACUGCCGCAUCCGCUGCGGCUACGCCAUUGUUCAGCCCGGCGUCC
AGCGGCCCAAGGGUUCAGGUGAAAGAGGGCAUCGGUCCAAAACUACCGCGGCCCAUUCGCGUGCG
UGUUCUACGCGUCGGGAACUGGCCUCCUACGGCAUCAAGCUACCGUCGCAGCGGGAGGCGGAAC
20 AGCGCGCGCGGCAGGCGGAGCGCGAUCCGCAUUAUGAUGAUGAGCUGCUCUGGAUGAGGAAGC
GGAUGCUAUGGAGCAGGAUGAACUGGCUCGCCAGUUCGCCGCCACCCAGCAGCAGCGCUACGGUC
AUCGCUUGGAAGACGAUAACGCGACUGAUGACGAUGAGGCCGACGCCGCGGCGGAAGCGGAGCUG
GCGCGUCAGUUUGCCGCUACCCAGCAGCAGCGGUACGCUACCGAGCAGCCGCCGGGCGCCAACCC
GUUCUCGCCGGCAGAUUAUGAAUUCUCGCCGAUGAAAACGUUGGUCAAUGACGGCCCGAGCGAAC
25 CGCUGUUUACGCCGACGCCGGAAGUCCAGCCGCAGCAGCCGGCCAGCGCUAUCAACAACCGGCG
GCCGCUCCGCAGCAGGGUUAUCAACCUGCGCAGCAUCAGCCGAUACACCAUCAGCCUGUGCCGCC
ACAGCCGCAGUCCUAUCCGACUGCGUCGCAGCCCGUACAGCCGCAACAACCGGUUGCCCCGCAGG
GGCAUCAGCCUGCCGCCCCUGCGCCGCAGGAGAGCCUGAUCCACCCGCUGCUGAUGCGCAAUGGC
GAUAGUCGACCGCUGCAAAAGCCGACCACGCCACUGCCGUCGCUUGGAUCUGCUUACCCCGCCGCC
30 GAGUGAAGUCGAGCCGGUGGAUACCUUUGCUCUCGAGCAGAUUGGCACGCCUGGUGGAAGCGCGA
CUCGCUGAUUUCGCAUUAAGCGGAUGUGGGUGAACUACUCACCGGGGGCCGGUGAUCACCCGCUU
CGAACUGAAUCUGGCGCCUGGCGUUAAGGCCGCACGGAUCUCUAACCGUACAGGGACCUUGGCGC
GAUCGCUGUCAACGGUCGCCGUGCGCGUGGUGGAGGUGAUCCCGGGCAAACCGUAUGUCGGGCU
UGAGCUGCCGAAUAAAAACGCCAGACCGUCUACCGUGGUGAAGUGCUGACAACGCCAAGUUCGG
35 UGAUAACCCAUCUCCGCUACCGUGGUGUUGGGUAAAGACAUCGCUUGGCGAUCCGGUAGUAGCCG
AUCUGGCGAAAAUGCCGCAUCUGCUGGUGGCCGGUACCACCGGUUCCGGUAAGUCUGUUGGCGUC
AACGCCAUGAUCCUCAGCAUGCUCUACAAGGCGCAGCCGGAAGAUGUGCGUUUCAUUAUGAUCGA
CCCGAAAAUGCUCGAGCUGUCGGUCUACGAAGGAUUCCGCACCUGCUGACGGAAGUGGUCACCG
ACAUGAAAGACGCCGCCAAUGCGCUGCGCUGGAGCGUCAUAGAUGGAGCGCCGCUACAAGCUG

AUGUCGGCGCUGGGCGUGCGUAACCUCGCGGGCUACAACGAGAAGAUCGCCGAAGCCGCGCGCAU
 GGGACGUCCGAUCCCGGAUCCGUACUGGAAGCCUGGCGACAGCAUGGACGCCGUACAUCCGGUGC
 UGGA AAAACUGCCGUACAUCGUGGUGCUGGUGGAUGAAUUCGCCGAUCUGAUGAUGACCGUCGGC
 AAAAAGGUGGAAGAGCUGAUCGCUCGCCUGGCGCAGAAAGCGCGCGCGGGGGAUCCACCUGGU
 5 GCUGGCGACACAGCGUCCGUCGGUAGAUGUUAUUACCGGCCUGAUUAAGGCCAACAUCCCGACGC
 GCAUCGCCUUUACCGUGUCGAGUAAAAUUGACUCACGUACCAUUCUCGAUCAGGGCGGCGCGGAA
 UCGCUGCUGGGUAUGGGGGGAUAUGCUUUACUCCGGGCCGAACUCUACCACGCCGGUGCGUGUCCA
 CGGGGCGUUUGUGCGCGACCAGGAAGUCCACGCCGUGGUUCAGGACUGGAAAGCCCGCGGUCGC
 CCGCAAUAUGUGGAUGGCAUUACCUCGACAGCGAAAGCGAAGGCGGCGGUGGCGGCUUCGACGG
 10 CGGGGAAGAGUUGGAUCCGUUGUUCGAUCAGGCAGUCAACUUUGUGACCGAGAAGCGCAAAGCGU
 CGAUUUCCGGGGUUCAGCGUCAGUUCGCAUCGGCUAUAACCGUGCCGCGCGUAUUUAUCGAACAG
 AUGGAAGCGCAGGGUAUCGUCAGCGAGCAGGGCCAUAACGGUAACCGCGAAGUGCUGGCGCCGCC
 GCCCUUGAAUGA

The polypeptides of the invention can also be designated as follows:

SEQ ID NO:	Designation	SEQ ID NO:	Designation
1	KP1_2999	18	KP1_1632
2	KP1_0355	19	KP1_1274
3	KP1_3995	20	KP1_3820
4	KP1_3023	21	KP1_0953
5	KP1_1709	22	KP1_2972
6	KP1_4823	23	KP1_0306
7	KP1_1443	24	KP1_2284
8	KP1_1444	25	KP1_4356
9	KP1_0026	26	KP1_1032
10	KP1_3952	27	KP1_4886
11	KP1_0090	28	KP1_2074
12	KP1_4374	29	KP1_5221
13	KP1_1620	30	KP1_1891
14	KP1_5089	91	KP1_1547
15	KP1_1701	92	KP1_1958
16	KP1_1186	93	KP1_4144
17	KP1_0947	94	KP1_4102

15 When designating a fragment of one of these proteins, this is done using the nomenclature
 KP1_XXXX-A-p1-p2, where XXXX is any of the 4 digit numbers following "KP1" in the table
 above, and p1 and p2 are the start and end amino acids relative to the entire sequence of

the protein. For instance KP1_1891-50-200 is the fragment of KP1_1891 that has the amino acid sequence defined by residues 50 to 200 of KP1_1891, i.e. a (poly)peptide having the amino acid sequence of SEQ ID NO: 30, residues 50-200.

EXAMPLE

5 *Challenge studies in mice*

1. CHALLENGE STUDY (Klebsiella pneumonia – intranasal (IN) Model):

Challenge strain: *Klebsiella pneumoniae* NTUH-K2044 (Wu KM et al. (2009), J. Bacteriol, **191**:4492-4501).

Mouse strain: BalbC/ByJ (inbred)

10 Dose: 25 µg in each immunization.

Immunization route: 3 x subcutaneous

Immunization interval: 14 days

Inoculation route: intranasal (IN)

End point: Lethal challenge

15 Adjuvant choice: Priming immunization used Alum + IFA (incomplete Freund's adjuvant); 1st and 2nd booster immunizations used alum only

Bleeds: Bleed mouse 4 days before challenge for subsequent ELISA test.

Trial type: Double blinded

No of mice per group: At most 16 mice (see tables 1-6 for details)

20 Monitoring period: 7 days

2. CHALLENGE STUDY (Klebsiella pneumonia – intraperitoneal (IP Model)):

Challenge strain: *Klebsiella pneumoniae* NTUH-K2044)

Mouse strain: NMRI (outbred)

Dose: 25 µg in each immunization.

Immunization route: 3 x subcutaneous

Immunization interval: 14 days

Inoculation route: intraperitoneal (IP)

5 End point: Lethal challenge

Adjuvant choice: Priming immunization used Alum + IFA (incomplete Freund's adjuvant); 1st and 2nd booster immunizations used alum only

Bleeds: Bleed mouse 4 days before challenge for subsequent ELISA test.

Trial type: Double blinded

10 No of mice per group: At most 16 mice (see tables 1-6 for details)

Monitoring period: 7 days

A total 6 experiments was carried out. Only experiment 2 utilised the IP model whereas the remaining experiments utilised the IN model.

15 A number of the tested proteins proved insoluble in saline. Instead they were solubilized in 4 M urea to avoid precipitation before adding aluminum hydroxide. After adding aluminum hydroxide the urea is removed completely. The remaining proteins are solubilized in physiological saline.

The protocol for immunization is described below.

1st immunization:

- 20 - 25 µg protein (per mice) are mixed with 100 µl aluminum hydroxide (Alhydrogel 2.0%, Brenntag) per 125 µg protein and incubated with end-over-end rotation for 1 hour.
- The compositions is centrifuged at 1000 rpm for 2 minutes and the supernatant is removed
 - The alu-beads are washed once (slowly) in 0.9% (0.15 M) NaCl to remove excess urea
 - Freund's incomplete adjuvant (Sigma) is added 1:1 (v/v) and the resulting mixture is
- 25 vortexed thoroughly for 1 hour.
- Subsequently the final composition is injected subcutaneously

2nd and 3rd immunization

- The mice receive booster immunization with 2 weeks interval, using the same amount of protein mixed with aluminum hydroxide and physiological saline solution.
- Subsequently the final composition is injected subcutaneously

- 5 The following table A lists the immunogens used in each of the immunization studies in 6 different experiments as well as the p-value for the survival in each group when compared to mice vaccinated with phosphate buffered saline alone.

The corresponding survival plots are shown in Figs. 1-6, which show the results for Experiments 1-6, respectively. The survival data are also indicated for each group of mice in
10 each experiment in Tables 1-6.

Table A: Kaplan-Meier survival curve overview				
Challenge:			P-value	
EXPERIMENT # 1 (IN model)	Immunization agent – Protein ID(s)		Log rank test	Fisher's exact test
Group 1 vs PBS	(KP1_1547-26-742; NCBI-ProteinID: BAH62300) SEQ ID NO: 91, residues 26-742 Positive control		0.2321	0.5000
Group 2 vs PBS	(KP1_1958-22-356, NCBI-ProteinID: BAH62679) SEQ ID NO: 92, residues 22-356 Positive control		0.9346	0.7419
Group 3 vs PBS	(KP1_4144-1-245, NCBI-ProteinID: BAH64685) SEQ ID NO: 93, residues 1-245 Positive control		0.0004	0.0030
Group 4 vs PBS	(KP1_1632-23-597 + KP1_1632-276-597 + KP1_1632-23-275) Mixture of 3 peptides: SEQ ID NO: 18, residues 23-597 + SEQ ID NO: 18 residues 276-597 + SEQ ID NO: 18, residues 23-275		< 0.0001	< 0.0001
EXPERIMENT # 2 (IP model)	Protein ID		Log rank test	Fisher's exact test
Group 1 vs PBS	(KP1_5089-121-428 + KP1_0947-1-535 + KP1_0947-21-535) Mixture of 3 peptides: SEQ ID NO: 14, residues 121-428 + SEQ ID NO: 17, residues 1-535 + SEQ ID NO: 17, residues 21-535		0.6869	0.32700
Group 2 vs PBS	(KP1_1620-1-382 + KP1_1620-21-382 + KP1_4374-27-376) Mixture of 3 peptides: SEQ ID NO: 13, residues 1-382 + SEQ ID NO: 13, residues 21-382 + SEQ ID NO: 12, residues 27-376		0.0249	0.02690

Table A: Kaplan-Meier survival curve overview

Challenge:		P-value	
		Log rank test	Fisher's exact test
Group 3 vs PBS	(KP1_0953-31-500 + KP_0953-31-675 + KP1_0355-22-117) Mixture of 3 peptides: SEQ ID NO: 21, residues 31-500 + SEQ ID NO: 21, residues 31-675 + SEQ ID NO: 2, residues 22-117.	0.0153	0.01170
Group 4 vs PBS	(KP1_4356-35-790 + KP1_4356-450-790 + KP1_4356-35-450 + KP1_0306-25-752 + KP1_0306-470-752 + KP1_0306-25-469) Mixture of 6 peptides: SEQ ID NO: 25, residues 35-790 + SEQ ID NO: 25, residues 450-790 + SEQ ID NO: 25, residues 35-450 + SEQ ID NO: 23, residues 25-752 + SEQ ID NO: 23, residues 470-752 + SEQ ID NO: 23, residues 25-4690	0.2216	0.02690
EXPERIMENT # 3 (IN model)	Protein ID		
Group 1 vs PBS	(KP1_5221-23-650 (NaCl) + KP1_5221-651-1159 (Urea)) Mixture of 2 peptides: SEQ ID NO. 29, residues 23-650 (in saline) + SEQ ID NO: 29, residues 651-1159 (in Urea)	0.0156	0.2759
Group 2 vs PBS	(KP1_1186-35-484 (NaCl)) 1 peptide: SEQ ID NO: 16, residues 25-484	0.3488	1.0000
Group 3 vs PBS	(KP1_3995-22-119 (NaCl) + KP1_3995-22-119 (Urea)) Mixture of 2 peptides: SEQ ID NO: 3, residues 22-119 (in saline) + SEQ ID NO: 3, residues 22-119 (in Urea)	0.8585	0.4839

Table A: Kaplan-Meier survival curve overview			
Challenge:		P-value	
Group 4 vs PBS	(KP1_1032-21-809 (Urea) + KP1_1032-451-809 (Urea) + KP1_1032-21-450 (NaCl)) Mixture of 3 peptides: SEQ ID NO: 26, residues 21-809 (in Urea) + SEQ ID NO: 26, residues 451-809 (in Urea) + SEQ ID NO: 26, residues 21-450 (in saline)	0.0576	0.1129
EXPERIMENT # 4 (IN model)	Protein ID	Log rank test	Fisher's exact test
Group 1 vs PBS	(KP1_1709-1-121 (NaCl)) 1 peptide: SEQ ID NO: 5, residues 1-121 (in saline)	0.2473	1.0000
Group 2 vs PBS	(KP1_2999-22-94 (NaCl)) 1 peptide: SEQ ID NO: 1, residues 22-94 (in saline)	0.7392	1.0000
Group 3 vs PBS	(KP1_1274-36-624 (NaCl)) 1 peptide: SEQ ID NO: 19, residues 36-624 (in saline)	0.5190	1.0000
Group 4 vs PBS	(KP1_0026-1-168 (NaCl)) 1 peptide: SEQ ID NO: 9, residues 1-168 (in saline)	0.3482	1.0000
EXPERIMENT # 5 (IN model)	Protein ID	Log rank test	Fisher's exact test
Group 1 vs PBS	(KP1_4102-582-1099 + KP1_4102-1100-1649, i.e. two fragments of NCBI-ProteinID: BAH64645) Mixture of 2 peptides: SEQ ID NO: 94, residues 582-1099 + SEQ ID NO: 94, residues 1100-1649 Positive control	0.0012	0.0217

Table A: Kaplan-Meier survival curve overview			
Challenge:		P-value	
Group 2 vs PBS	(KP1_3820-26-657 + KP1_3820-392-657 + KP1_3820-26-391 + KP1_3820-26-153 + KP1_0306-61-177) Mixture of 5 peptides: SEQ ID NO: 20, residues 26-657 + SEQ ID NO: 20, residues 392-657 + SEQ ID NO: 20, residues 26-391 + SEQ ID NO: 20, residues 26-153 + SEQ ID NO: 23, residues 61-177	< 0.0001	< 0.0001
Group 3 vs PBS	(KP1_2284-1-761 + KP1_2284-515-761 + KP1_2284-1-514 + KP1_2284-61-176) Mixture of 4 peptides: SEQ ID NO: 24, residues 1-761 + SEQ ID NO: 24, residues 515-761 + SEQ ID NO: 24, residues 1-514 + SEQ ID NO: 24, residues 61-176	0.0019	0.0217
Group 4 vs PBS	(KP1_2972-25-701 + KP1_2972-450-696 + KP1_2972-25-449 + KP1_2972-20-154) Mixture of 4 peptides: SEQ ID NO: 22, residues 25-701 + SEQ ID NO: 22, residues 450-696 + SEQ ID NO: 22, residues 25-449 + SEQ ID NO: 22, residues 20-154	< 0.0001	0.0088
EXPERIMENT # 6 (IN model)	Protein ID	Log rank test	Fisher's exact test
Group 1 vs PBS	(KP1_5089-121-428 + KP1_0947-1-535 + KP1_0947-21-535) Mixture of 3 peptides: SEQ D NO: 14, residues 121-428 + SEQ ID NO: 17, residues 1-535 + SEQ ID NO: 17, residues 21-535	0.0148	0.1129
Group 2 vs PBS	(KP1_1620-1-382 + KP1_1620-21-382 + KP1_4374-27-376) Mixture of 3 peptides: SEQ ID NO: 13, residues 1-382 + SEQ ID NO: 13, residues 21-382 + SEQ ID NO: 12, residues 27-376	0.0006	0.0506

Table A: Kaplan-Meier survival curve overview		
Challenge:		P-value
Group 3 vs PBS	(KP1_0953-31-500 + KP1_0953-31-675 + KP1_0355-22-117) Mixture of 3 peptides: SEQ ID NO: 21, residues 31-500 + SEQ ID NO: 21, residues 31-675 + SEQ ID NO: 2, residues 22-117	< 0.0001 0.0004
Group 4 vs PBS	(KP1_4356-35-790 + KP1_4356-450-790 + KP1_4356-35-450 + KP1_0306-25-752 + KP1_0306-470-752 + KP1_0306-25-469) Mixture of 6 peptides: SEQ ID NO: 25, residues 35-790 + SEQ ID NO: 25, residues 450-790 + SEQ ID NO: 25, residues 35-450 + SEQ ID NO: 23, residues 25-752 + SEQ ID NO: 23, residues 470-752 + SEQ ID NO: 23, residues 25-469	0.0012 0.0004

Table 1, survival in Experiment 1

Group	Survival	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
1	# Alive	16	16	16	16	7	0	0	0
	% Survival	100.0	100.0	100.0	100.0	43.8	0.0	0.0	0.0
2	# Alive	15	15	15	15	8	3	1	1
	% Survival	100.0	100.0	100.0	100.0	53.3	20.0	6.7	6.7
3	# Alive	16	16	16	16	14	12	11	9
	% Survival	100.0	100.0	100.0	100.0	87.5	75.0	68.8	56.3
4	# Alive	16	16	16	16	16	16	15	14
	% Survival	100.0	100.0	100.0	100.0	100.0	100.0	93.8	87.5
5	# Alive	16	16	16	16	7	4	1	1
	% Survival	100.0	100.0	100.0	100.0	43.8	25.0	6.3	6.3

Table 2, survival in Experiment 2

Group		Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
1	# Alive	16	13	4	4	4	4	4	4
	% Survival	100	81.3	25.0	25.0	25.0	25.0	25.0	25.0
2	# Alive	16	15	9	9	9	9	8	8
	% Survival	100	94	56	56	56	56	50	50
3	# Alive	16	15	9	9	9	9	9	9
	% Survival	100	94	56	56	56	56	56	56
4	# Alive	16	11	8	8	8	8	8	8
	% Survival	100	69	50	50	50	50	50	50
5	# Alive	16	14	2	2	2	2	2	2
	% Survival	100	87.5	12.5	12.5	12.5	12.5	12.5	12.5

Table 3, survival in Experiment 3

Group		Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
1	# Alive	16	16	16	16	10	5	3	1
	% Survival	100.0	100.0	100.0	100.0	62.5	31.3	18.8	6.3
2	# Alive	15	15	15	15	7	1	0	
	% Survival	100.0	100.0	100.0	100.0	46.7	6.7	0.0	
3	# Alive	15	15	15	15	3	1	1	1
	% Survival	100.0	100.0	100.0	100.0	20.0	6.7	6.7	6.7
4	# Alive	16	16	16	16	7	4	3	3
	% Survival	100.0	100.0	100.0	100.0	43.8	25.0	18.8	18.8
5	# Alive	16	16	16	16	4	1	0	0
	% Survival	100.0	100.0	100.0	100.0	25.0	6.3	0.0	0.0

Table 4, survival in Experiment 4

Group		Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
1	# Alive	10	10	10	10	1	0	0	0
	% Survival	100.0	100.0	100.0	100.0	10.0	0.0	0.0	0.0
2	# Alive	15	15	15	15	6	0	0	0
	% Suivival	93.8	93.8	93.8	93.8	37.5	0.0	0.0	0.0
3	# Alive	14	14	14	14	3	0	0	0
	% Survival	100.0	100.0	100.0	100.0	21.4	0.0	0.0	0.0
4	# Alive	15	15	14	14	3	0	0	0
	% Survival	100.0	100.0	93.3	93.3	20.0	0.0	0.0	0.0
5	# Alive	16	15	15	15	6	0	0	0
	% Survival	100.0	93.8	93.8	93.8	37.5	0.0	0.0	0.0

Table 5, survival in Experiment 5

Group		Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
1	# Alive	16	16	16	16	14	8	7	5
	% Survival	100.0	100.0	100.0	100.0	87.5	50.0	43.8	31.3
2	# Alive	16	16	16	16	15	14	13	12
	% Suivival	100.0	100.0	100.0	100.0	93.8	87.5	81.3	75.0
3	# Alive	16	16	16	16	14	8	6	5
	% Survival	100.0	100.0	100.0	100.0	87.5	50.0	37.5	31.3
4	# Alive	16	16	16	16	16	11	9	6
	% Survival	100.0	100.0	100.0	100.0	100.0	68.8	56.3	37.5
5	# Alive	16	16	16	16	8	2	0	
	% Survival	100.0	100.0	100.0	100.0	50.0	12.5	0.0	

Table 6, survival in Experiment 6

Group		Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
1	# Alive	16	16	16	15	10	7	5	3
	% Survival	100.0	100.0	100.0	93.8	62.5	43.8	31.3	18.8
2	# Alive	16	16	15	15	13	9	8	4
	% Suivival	100.0	100.0	93.8	93.8	81.3	56.3	50.0	25.0
3	# Alive	16	16	16	16	16	12	10	9
	% Survival	100.0	100.0	100.0	100.0	100.0	75.0	62.5	56.3
4	# Alive	16	15	15	14	13	9	9	9
	% Survival	100.0	93.8	93.8	87.5	81.3	56.3	56.3	56.3
5	# Alive	16	16	16	16	6	0		
	% Survival	100.0	100.0	100.0	100.0	37.5	0.0		

CLAIMS

1. A polypeptide comprising

a) an amino acid sequence selected from the group consisting of any one of SEQ ID NOs: 1-30, 93, and 94, or

5 b) an amino acid sequence consisting of at least or exactly or at most 5 contiguous amino acid residues from any one of SEQ ID NOs: 1-30, 93, and 94, or

c) an amino acid sequence having a sequence identity of at least 60% with the amino acid sequence of a),

10 d) an amino acid sequence having a sequence identity of at least 60% with the amino acid sequence of b), or

e) an assembly of amino acids derived from any one of SEQ ID NOs: 1-30, 93, and 94, which has essentially the same 3D conformation as in the protein from which said assembly is derived so as to constitute a B-cell epitope, said polypeptide being antigenic in a mammal.

15 2. The polypeptide according to claim 1, wherein the at least or exactly or at most 5 contiguous amino acid residues are at least or exactly 5, at least or exactly or at most 6, such as at least or exactly or at most 7, at least or exactly or at most 8, at least or exactly or at most 9, at least or exactly or at most 10, at least or exactly or at most 11, at least or exactly or at most 12, at least or exactly or at most 13, at least or exactly or at most 14, at
20 least or exactly or at most 15, at least or exactly or at most 16, at least or exactly or at most 17, at least or exactly or at most 18, at least or exactly or at most 19, at least or exactly or at most 20, at least or exactly or at most 21, at least or exactly or at most 22, at least or exactly or at most 23, at least or exactly or at most 24, at least or exactly or at most 25, at least or exactly or at most 26, at least or exactly or at most 27 at least or exactly or at most
25 28, at least or exactly or at most 29, at least or exactly or at most 30, at least or exactly or at most 31, at least or exactly or at most 32, at least or exactly or at most 33, at least or exactly or at most 34, and at least or exactly or at most 35 contiguous amino acid residues.

3. The polypeptide according to claim 1 or 2, wherein the sequence identity with the amino acid sequence of a) is at least 65%, such as at least 70%, at least 75%, at least 80%,
30 at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

4. The polypeptide according to claim 1 or 2, wherein the sequence identity with the amino acid sequence of b) is at least 60%, such as at least 65%, at least 70%, at least 75%,
35 at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

5. The polypeptide according to any one of the preceding claims, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, and 90 in any one of SEQ ID NOs: 1-30, 93, and 94.
6. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, and 113 in any one of SEQ ID NOs: 2-30, 93, and 94.
7. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 114 or 115 in any one of SEQ ID NOs: 3-30, 93, and 94.
8. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to amino acid residue 116 in any one of SEQ ID NOs: 4-30, 93, and 94.
9. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to amino acid residue 117 in any one of SEQ ID NOs: 5-30, 93, and 94.
10. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to amino acid residue 118 in any one of SEQ ID NOs: 6-30, 93, and 94.
11. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, and 137 in any one of SEQ ID NOs: 7-30, 93, and 94.
12. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue

corresponding to any one of amino acid residues 138, 139, 140, 141, 142, 143, 144, 145, 146, and 147 in any one of SEQ ID NOs: 8-30, 93, and 94.

13. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue
5 corresponding to any one of amino acid residues 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, and 164 in any one of SEQ ID NOs: 9-30, 93, and 94.

14. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue
10 corresponding to any one of amino acid residues 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, or 192 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, or 208 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, and 225 in any one of SEQ ID NOs: 10-30, 93, and 94.

15. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue
corresponding to any one of amino acid residues 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, and 241 in any one of SEQ ID NOs: 11-30, 93, and 94.

16. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue
20 corresponding to any one of amino acid residues 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 25 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, and 318 in any one of SEQ ID NOs: 11-30 and 94.

17. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue
corresponding to any one of amino acid residues 319, 320, 321, 322, 323, 324, 325, 326,
30 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, or 356 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, and 372 in any one of SEQ ID NOs: 12-30 and 94.

18. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 373, 374, 375, 376, 377, and 378 in any one of SEQ ID NOs: 13-30 and 94.

5 19. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 10 423, and 424 in any one of SEQ ID NOs: 14-30 and 94.

20. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, and 437 in any one of SEQ ID NOs: 15-30 and 94.

15 21. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, and 480 in 20 any one of SEQ ID NOs: 16-30 and 94.

22. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 25 507, 508 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, and 531 in any one of SEQ ID NOs: 17-30 and 94.

23. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 532, 533, 534, 535, 536, 537, 538, 539, 30 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, or 563, 427564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, and 593 in any one of SEQ ID NOs: 18-30 and 94.

24. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, and 620 in any one of SEQ ID NOs: 19-30 and 94.

25. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, and 653 in any one of SEQ ID NOs: 20-30 and 94.

26. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, and 671 in any one of SEQ ID NOs: 21-30 and 94.

27. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, and 697 in any one of SEQ ID NOs: 22-30 and 94.

28. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, and 748 in any one of SEQ ID NOs: 23-30 and 94.

29. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 749, 750, 751, 752, 753, 754, 755, 756 and 757 in any one of SEQ ID NOs: 24-30 and 94.

30. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 758, 759, 760, 761, 762, 763, 764, 765,

766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, and 786 in any one of SEQ ID NOs: 25-30 and 94.

31. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue

5 corresponding to any one of amino acid residues 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, and 805 in any one of SEQ ID NOs: 26-30 and 94.

32. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue

10 corresponding to any one of amino acid residues 806, 807, 808, 809, 810, 811, 812, 813, 815, 816, 817, 818, 819, 820, 821, 811, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886,
15 887, 888, 889, 890, 891, and 892 in any one of SEQ ID NOs: 27-30 and 94.

33. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue

corresponding to any one of amino acid residues 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918,
20 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006,
25 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, and 1073 in any one of SEQ
30 ID NOs: 28-30 and 94.

34. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue

corresponding to any one of amino acid residues 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094,
35 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108,

1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, and 1155 in any one of SEQ ID NOs: 29, 30 and 94.

- 5 35. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1190, 10 1191, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1200, 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1213, 1214, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226, 1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, 1254, 1255, 1256, 1257, 1258, 1259, 1260, 15 1261, 1262, 1263, 1264, 1265, 1266, 1267, 1268, 1269, 1270, 1271, 1272, 1273, 1274, 1275, 1276, 1277, 1278, 1279, 1280, 1281, 1282, 1283, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 20 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, 1360, 1361, 1362, 1363, 1364, 1365, 1366, 1367, 1368, 1369, 1370, 1371, 1372, 1373, 1374, 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1382, 1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394, 1395, 1396, 1397, 1398, 1399, 1400, 25 1401, 1402, 1403, 1404, 1405, 1406, and 1407 in SEQ ID NO: 30 and 94.

36. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 30 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453, 1454, 1455, 1456, 1457, 1458, 1459, 1460, 1461, 1462, 1463, 1464, 1465, 1466, 1467, 1468, 1469, 1470, 1471, 1472, 1473, 1474, 1475, 1476, 1477, 1478, 1479, 1480, 1481, 1482, 1483, 1484, 1485, 1486, 1487, 1488, 1489, 1490, 1491, 1492, 1493, 1494, 1495, 1496, 1497, 1498, 35 1499, 1500, 1501, 1502, 1503, 1504, 1505, 1506, 1507, 1508, 1509, 1510, 1511, 1512, 1513, 1514, 1515, 1516, 1517, 1518, 1519, 1520, 1521, 1522, 1523, 1524, 1525, 1526, 1527, 1528, 1529, 1530, 1531, 1532, 1533, 1534, 1535, 1536, 1537, 1538, 1539, 1540,

1541, 1542, 1543, 1544, 1545, 1546, 1547, 1548, 1549, 1550, 1551, 1552, 1553, 1554, 1555, 1556, 1557, 1558, 1559, 1560, 1561, 1562, 1563, 1564, 1565, 1566, 1567, 1568, 1569, 1570, 1571, 1572, 1573, 1574, 1575, 1576, 1577, 1578, 1579, 1580, 1581, 1582, 1583, 1584, 1585, 1586, 1587, 1588, 1589, 1590, 1591, 1592, 1593, 1594, 1595, 1596, 1597, 1598, 1599, 1600, 1601, 1602, 1603, 1604, 1605, 1606, 1607, 1608, 1609, 1610, 1611, 1612, 1613, 1614, 1615, 1616, 1617, 1618, 1619, 1620, 1621, 1622, 1623, 1624, 1625, 1626, 1627, 1628, 1629, 1630, 1631, 1632, 1633, 1634, 1635, 1636, 1637, 1638, 1639, 1640, 1641, 1642, 1643, 1644, and 1645 in SEQ ID NO: 94.

37. The polypeptide according to any one of the preceding claims, which is fused or conjugated to an immunogenic carrier molecule.

38. The polypeptide according to claim 37, wherein the immunogenic carrier molecule is a polypeptide that induces T-helper lymphocyte responses in a majority of humans, such as immunogenic carrier proteins selected from the group consisting of keyhole limpet hemocyanin or a fragment thereof, tetanus toxoid or a fragment thereof, diphtheria toxoid or a fragment thereof.

39. The polypeptide according to any one of the preceding claims, which is capable of inducing an adaptive immune response against the polypeptide in a mammal, in particular in a human being.

40. The polypeptide according to claim 39, which is capable of inducing, in the mammal, a protective adaptive immune response against infection with *K. pneumoniae*.

41. The polypeptide according to claim 39 or 40, which induces a humoral and/or a cellular immune response.

42. An isolated nucleic acid fragment, which comprises

i) a nucleotide sequence encoding a polypeptide according to any one of the preceding claims, or

ii) a nucleotide sequence consisting of the amino acid encoding part of any one of SEQ ID NOs: 31-90 and 95-102,

iii) a nucleotide sequence consisting of at least or exactly or at most 10 consecutive nucleotides in the amino acid encoding part of any one of SEQ ID NOs: 31-90 and 95-102,

iv) a nucleotide sequence having a sequence identity of at least 60% with the nucleotide sequence in i) or ii),

v) a nucleotide sequence having a sequence identity of at least 60% with the nucleotide sequence in iii),

vi) a nucleotide sequence complementary to the nucleotide sequence in i)-v), or
vii) a nucleotide sequence which hybridizes under stringent conditions with the nucleotide sequence in i)-vi).

43. The nucleic acid fragment according to claim 42, which is a DNA or an RNA fragment.

5 44. The nucleic acid fragment according to claim 42 or 43, wherein the nucleotide
sequence consists of at least or exactly 10, such as at least or exactly or at most 11, such as
at least or exactly or at most 12, at least or exactly or at most 13, at least or exactly or at
most 14, at least or exactly or at most 15, at least or exactly or at most 16, at least or
exactly or at most 17 at least or exactly or at most 18, at least or exactly or at most 19, at
10 least or exactly or at most 20, at least or exactly or at most 21, at least or exactly or at most
22, at least or exactly or at most 23, at least or exactly or at most 24, at least or exactly or
at most 25, at least or exactly or at most 26, at least or exactly or at most 27, at least or
exactly or at most 28, at least or exactly or at most 29, at least or exactly or at most 30, at
least or exactly or at most 31, at least or exactly or at most 32, at least or exactly or at most
15 33, at least or exactly or at most 34, at least or exactly or at most 35, at least or exactly or
at most 36, at least or exactly or at most 37, at least or exactly or at most 38, at least or
exactly or at most 39, at least or exactly or at most 40, at least or exactly or at most 41, at
least or exactly or at most 42, at least or exactly or at most 43, at least or exactly or at most
44, at least or exactly or at most 45, at least or exactly or at most 46, at least or exactly or
20 at most 47, at least or exactly or at most 48, at least or exactly or at most 49, at least or
exactly or at most 50, at least or exactly or at most 51, at least or exactly or at most 52, at
least or exactly or at most 53, at least or exactly or at most 54, at least or exactly or at most
55, at least or exactly or at most 56, at least or exactly or at most 57, at least or exactly or
at most 58, at least or exactly or at most 59, at least or exactly or at most 60, at least or
25 exactly or at most 61, at least or exactly or at most 62, at least or exactly or at most 63, at
least or exactly or at most 64, at least or exactly or at most 65, at least or exactly or at most
66, at least or exactly or at most 67, at least or exactly or at most 68, at least or exactly or
at most 69, at least or exactly or at most 70, at least or exactly or at most 71, at least or
exactly or at most 72, at least or exactly or at most 73, at least or exactly or at most 74, at
30 least or exactly or at most 75, at least or exactly or at most 76, at least or exactly or at most
77, at least or exactly or at most 78, at least or exactly or at most 79, at least or exactly or
at most 80, at least or exactly or at most 81, at least or exactly or at most 82, at least or
exactly or at most 83, at least or exactly or at most 84, at least or exactly or at most 85, at
least or exactly or at most 86, at least or exactly or at most 87, at least or exactly or at most
35 88, at least or exactly or at most 89, at least or exactly or at most 90, at least or exactly or
at most 91, at least or exactly or at most 92, at least or exactly or at most 93, at least or
exactly or at most 94, at least or exactly or at most 95, at least or exactly or at most 96, at

[illegible]

or exactly or at most 211, at least or exactly or at most 212, at least or exactly or at most 213, at least or exactly or at most 214, at least or exactly or at most 215, at least or exactly or at most 216, at least or exactly or at most 217, at least or exactly or at most 218, at least or exactly or at most 219, at least or exactly or at most 220, at least or exactly or at most 221, at least or exactly or at most 222, at least or exactly or at most 223, at least or exactly or at most 224, at least or exactly or at most 225, at least or exactly or at most 226, at least or exactly or at most 227, at least or exactly or at most 228, at least or exactly or at most 229, at least or exactly or at most 230, at least or exactly or at most 231, at least or exactly or at most 232, at least or exactly or at most 233, at least or exactly or at most 234, at least or exactly or at most 235, at least or exactly or at most 236, at least or exactly or at most 237, at least or exactly or at most 238, at least or exactly or at most 239, at least or exactly or at most 240, at least or exactly or at most 241, at least or exactly or at most 242, at least or exactly or at most 243, at least or exactly or at most 244, at least or exactly or at most 245, at least or exactly or at most 246, at least or exactly or at most 247, at least or exactly or at most 248, at least or exactly or at most 249, at least or exactly or at most 250, at least or exactly or at most 251, at least or exactly or at most 252, at least or exactly or at most 253, at least or exactly or at most 254, at least or exactly or at most 255, at least or exactly or at most 256, at least or exactly or at most 257, at least or exactly or at most 258, at least or exactly or at most 259, at least or exactly or at most 260, at least or exactly or at most 271, at least or exactly or at most 272, at least or exactly or at most 273, at least or exactly or at most 274, at least or exactly or at most 275, at least or exactly or at most 276, at least or exactly or at most 277, at least or exactly or at most 278, at least or exactly or at most 279, at least or exactly or at most 280, at least or exactly or at most 281, at least or exactly or at most 282, at least or exactly or at most 283, at least or exactly or at most 284, and at least or exactly or at most 285 consecutive nucleotides in the amino acid encoding part of any one of SEQ ID NOs: 31-90.

45. The nucleic acid fragment according to any one of claims 42-44, wherein the sequence identity with the nucleotide sequence in i) or ii) is at least 65%, such as at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

46. The nucleic acid fragment according to any one of claims 42-44, wherein the sequence identity with the nucleotide sequence in iii) is at least 65%, such as at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

47. A vector comprising the nucleic acid according to any one of claims 42-46, such as a cloning vector or an expression vector.

48. The vector according to claim 47, which comprises in operable linkage and in the 5'-3' direction, an expression control region comprising an enhancer/promoter for driving
5 expression of the nucleic acid fragment defined in claim 29-i), optionally a signal peptide coding sequence, a nucleotide sequence defined in claim 29-i), and optionally a terminator.

49. The vector according to claim 47 or 48, wherein the expression control region drives expression in prokaryotic cell such as a bacterium, e.g. in *E. coli*.

50. The vector according to claim any one of claims 47-49, which is capable of
10 autonomous replication.

51. The vector according to any one of claims 47-50, which is capable of being integrated into the genome of a host cell.

52. The vector according to any one of claims 47-51, which is incapable of being integrated into the genome of a mammalian host cell.

53. The vector according to any one of claims 47-52, which is selected from the group consisting of a virus, such as a attenuated virus, a bacteriophage, a plasmid, a minichromosome, and a cosmid.
15

54. A cell which is transformed so as to carry the vector according to any one of claims 47-53.

55. The transformed cell according to claim 54, which is capable of replicating the nucleic acid fragment defined in claim 42-i).
20

56. The transformed cell according to claim 54 or 55 which is capable of expressing the nucleic acid fragment defined in claim 42-i).

57. The transformed cell according to any one of claims 54-56, which is selected from a
25 prokaryotic cell and a eukaryotic cell.

58. The transformed cell according to any one of claims 54-57, which is a bacterial cell selected from the group consisting of Escherichia (such as E. coli), Bacillus (e.g. Bacillus subtilis), Salmonella, and Mycobacterium, preferably non-pathogenic, e.g. M. bovis BCG.

59. The transformed cell according to any one of claims 54-58, which is stably transformed by having the nucleic acid defined in claim 42-i) stably integrated into its genome.

60. The transformed cell according to any one of claims 54-59 which secretes or carries on its surface the polypeptide according to any one of claims 1-41.

61. The transformed cell according to claim 60, wherein the cell is a bacterium and secretion is into the periplasmic space.

62. A cell line derived from a transformed cell according to any one of claims 54-61.

63. A pharmaceutical composition comprising a polypeptide according to any one of claims 1-41, a nucleic acid fragment according to any one of claims 42-46, a vector according to any one of claims 47-53, or a cell according to any one of claims 54-59 and a pharmaceutically acceptable carrier, vehicle or diluent.

64. The pharmaceutical composition according to claim 63, which further comprises an immunological adjuvant.

65. The pharmaceutical composition according to claim 64, wherein the adjuvant is an aluminium based adjuvant.

66. A method for inducing immunity in an animal by administering at least once an immunogenically effective amount of a polypeptide according to any one of claims 1-41, a nucleic acid fragment according to any one of claims 42-46, a vector according to any one of claims 47-53, a cell according to any one of claims 54-59, or a pharmaceutical composition according to any one of claims 63-65 so as to induce adaptive immunity against *K. pneumoniae* in the animal.

67. The method according to claim 6, wherein, when the polypeptide according to any one of claim 1-28 or a composition comprising said polypeptide is administered, the animal receives between 0.5 and 5,000 µg of the polypeptide according to any one of claims 1-41 per administration.

68. The method according to claim 67 or 68, wherein the animal receives a priming administration and one or more booster administrations.

69. The method according to any one of claims 67-69, wherein the animal is a human being.

5 70. The method according to any one of claims 67-70, wherein the administration is for the purpose of inducing protective immunity against *K. pneumoniae*.

71. The method according to claim 70, wherein the protective immunity is effective in reducing the risk of attracting infection with *K. pneumoniae* or is effective in treating or ameliorating infection with *K. pneumoniae*.

10 72. The method according to any one of claims 66-68, wherein the administration is for the purpose of inducing antibodies specific for *K. pneumoniae* and wherein said antibodies or B-lymphocytes producing said antibodies are subsequently recovered from the animal.

15 73. The method according to any one of claims 66-68, wherein the administration is for the purpose of inducing antibodies specific for *K. pneumoniae* and wherein B-lymphocytes producing said antibodies are subsequently recovered from the animal and used for preparation of monoclonal antibodies.

74. A polyclonal antibody in which the antibodies specifically bind to at least one polypeptide according to any one of claims 1-41, and which is essentially free from antibodies binding specifically to other *K. pneumoniae* polypeptides.

20 75. An isolated monoclonal antibody or antibody analogue which binds specifically to a polypeptide according to any one of claims 1-41.

25 76. The isolated monoclonal antibody or antibody analogue according to claim 76, which is a monoclonal antibody selected from a multi-domain antibody such as a murine antibody, a chimeric antibody such as a humanized antibody, a fully human antibody, and single-domain antibody of a llama or a camel, or which is an antibody analogue selected from a fragment of an antibody such as an Fab or an F(ab')₂, and an scFV.

77. A pharmaceutical composition comprising an antibody according to any one of claims 74-76 and a pharmaceutically acceptable carrier, vehicle or diluent.

78. A method for prophylaxis, treatment or amelioration of infection with *K. pneumoniae*, in particular infection with multi-resistant *K. pneumoniae*, comprising administering a therapeutically effective amount of an antibody according to any one of claims 74-76 or a pharmaceutical composition according to claim 77 to an individual in need thereof.

5 79. A method for determining, quantitatively or qualitatively, the presence of *K. pneumoniae*, in particular the presence of multi-resistant *K. pneumoniae*, in a sample, the method comprising contacting the sample with an antibody according to any one of claims 74-76 and detecting the presence of antibody bound to material in the sample.

10 80. A method for determining, quantitatively or qualitatively, the presence of antibodies specific for *K. pneumoniae*, in particular the presence of antibodies specific for multi-resistant *K. pneumoniae*, in a sample, the method comprising contacting the sample with a polypeptide according to any one of claims 1-41 and detecting the presence of antibody said polypeptide.

15 81. A method for determining, quantitatively or qualitatively, the presence of a nucleic acid characteristic of *K. pneumoniae*, in particular the presence of a nucleic acid characteristic of multi-resistant *K. pneumoniae*, in a sample, the method comprising contacting the sample with a nucleic acid fragment according to any one of claims 42-46 and detecting the presence of nucleic acid in the sample that hybridized to said nucleic acid fragment.

20 82. The method according to claim 81, which includes at least one step of molecular amplification of the nucleic acid which is to be detected in the sample, for instance a step of PCR amplification.

83. A method for the preparation of the polypeptide according to any one of claims 1-41, comprising
- culturing a transformed cell according to claim 54 and any one of claims 55-59 insofar as
25 these depend on claim 54 under conditions that facilitate that the transformed cell expresses the nucleic acid fragment according to claim 42-i) and any one of claims 43-46 insofar as these depend on claim 42-i) and subsequently recovering said polypeptide, or
- preparing said polypeptide by means of solid or liquid phase peptide synthesis.

30 84. A method for determining whether a substance, such as an antibody, is potentially useful for treating infection with *K. pneumoniae*, the method comprising contacting the polypeptide according to any one of claims 1-41 with the substance and subsequently establishing whether the substance has at least one of the following characteristics:
1) the ability to bind specifically to said polypeptide,

- 2) the ability to compete with said polypeptide for specific binding to a ligand/receptor,
- 3) the ability to specifically inactivate said polypeptide.

85. A method for determining whether a substance, such as a nucleic acid, is potentially useful for treating infection with *K. pneumoniae*, the method comprising contacting the substance with the nucleic acid fragment of any one of claims 42-46 and subsequently establishing whether the substance has either the ability to

- 1) bind specifically to the nucleic acid fragment, or
- 2) bind specifically to a nucleic acid that hybridizes specifically with the nucleic acid fragment.

86. The polypeptide according to any one of claims 1-41 for use as a pharmaceutical.

87. The polypeptide according to any one of claims 1-41 for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *K. pneumoniae*.

88. The nucleic acid fragment according to any one of claims 42-46 or the vector according to any one of claims 47-53 for use as a pharmaceutical.

89. The nucleic acid fragment according to any one of claims 42-46 or the vector according to any one of claims 47-53 for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *K. pneumoniae*.

90. The cell according to any one of claims 54-61 for use as a pharmaceutical.

91. The cell according to any one of claims 54-61 for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *K. pneumoniae*.

92. The antibody, antibody fragment or antibody analogue according to any one of claims 74-76 for use as a pharmaceutical.

93. The antibody, antibody fragment or antibody analogue according to any one of claims 74-76 for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *K. pneumoniae*.




Fig. 1




Fig. 2

2/3




Fig. 3




Fig. 4

3/3




Fig. 5




Fig. 6